WO2008129058A1 - Duck embryonic derived stem cell lines for the production of viral vaccines - Google Patents

Duck embryonic derived stem cell lines for the production of viral vaccines Download PDF

Info

Publication number
WO2008129058A1
WO2008129058A1 PCT/EP2008/054912 EP2008054912W WO2008129058A1 WO 2008129058 A1 WO2008129058 A1 WO 2008129058A1 EP 2008054912 W EP2008054912 W EP 2008054912W WO 2008129058 A1 WO2008129058 A1 WO 2008129058A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
virus
duck
cell
medium
Prior art date
Application number
PCT/EP2008/054912
Other languages
French (fr)
Inventor
Fabienne Guehenneux
Karine Moreau
Magali Esnault
Majid Mehtali
Original Assignee
Vivalis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0809842A priority Critical patent/BRPI0809842B8/en
Priority to ES08736491.5T priority patent/ES2442009T3/en
Application filed by Vivalis filed Critical Vivalis
Priority to PL08736491T priority patent/PL2150275T3/en
Priority to NZ581321A priority patent/NZ581321A/en
Priority to EA200970996A priority patent/EA021064B1/en
Priority to CA2684845A priority patent/CA2684845C/en
Priority to SI200831121T priority patent/SI2150275T1/en
Priority to EP08736491.5A priority patent/EP2150275B1/en
Priority to KR1020157005296A priority patent/KR20150036788A/en
Priority to AU2008240708A priority patent/AU2008240708B2/en
Priority to CN200880013257.3A priority patent/CN101668539B/en
Priority to US12/597,486 priority patent/US20100062489A1/en
Priority to MX2009011505A priority patent/MX343247B/en
Priority to DK08736491.5T priority patent/DK2150275T3/en
Priority to JP2010504672A priority patent/JP5539185B2/en
Publication of WO2008129058A1 publication Critical patent/WO2008129058A1/en
Priority to IL201679A priority patent/IL201679A/en
Priority to HK10107529.3A priority patent/HK1140964A1/en
Priority to US14/069,423 priority patent/US9260694B2/en
Priority to HRP20131203AT priority patent/HRP20131203T1/en
Priority to US15/013,079 priority patent/US9822345B2/en
Priority to US15/785,530 priority patent/US20180135026A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18451—Methods of production or purification of viral material

Definitions

  • the present invention relates to the development and manufacturing of viral vaccines.
  • the invention relates to the field of industrial production of viral vectors and vaccines, more specifically to the use of duck cell lines derived from embryonic stem cells that are free of avian endogenous retrovirus, for the production of viral vectors and viruses.
  • the invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
  • Vaccines effectively reduce and prevent death and disease from many viral infections such as for example flu, measles, mumps, smallpox, yellow fever.
  • Both ALV-E and EAV are members of endogenous retrovirus families present in the chicken germ line.
  • ALV-E are expressed from ev loci, which are inheritable proviral elements. Based on their envelope sequences, ALV-E are differentiated from ALV subgroups A to D and J which are exogenously acquired infections. While exogenous ALVs cause several neoplastic diseases, such as myocarditis and osteopetrosis in infected chickens, ALV-E are not known to be pathogenic to chickens. The lack of oncogenic potential with ALV-E infections may be attributed to the absence of both a viral oncogene and enhancer activity in the endogenous long terminal repeat (LTR).
  • LTR long terminal repeat
  • Ev loci More than 20 different ev loci have been identified in White Leghorn chickens (ev- 1 to ev-22). Ev loci designations are assigned in the order discovered and are phenotypically categorized with regard to the gene products they express and their capacity to generate infectious particles. ALV-E phenotypes conferred by ev loci range from structurally and enzymatically complete infectious particles to structurally or enzymatically (RT-) defective to no detectable viral protein expression. Most ev loci are structurally incomplete and therefore do not encode all sequences necessary for production of infectious virus particles. Chicken strain, named ev-0, has been obtained by breeding to be resistant to ALV-E.
  • Line-0 chickens are lacking ev loci (i.e ev-0) but EAV proviral sequences are present in the genome line 0 chickens (Dunwiddie and Faras, 1985, Proc Natl. Acad. Sci USA, 82: 5097-5101 ).
  • EAV EAV-like virus
  • ALV ALV-like virus
  • EAV EAV-like virus
  • none of the known EAV sequences represents full-length and intact retroviral genomes and no infectious EAV isolates have been yet identified.
  • EAV have been shown to be highly expressed in embryonic cells derived from the avian genus, gallus. Weissmahr et al. (1997, J. Virol 71 :3005- 3012) have shown that particles from the EAV endogenous retrovirus family are most likely responsible for a large portion of the particles-associated RT activity found in the supernatants of cultured chick embryo fibroblasts.
  • cell lines for the production of viral vaccines are MDCK (cells derived from the kidney of Madin-Darby dog), PerC6 (cells derived from human embryonic retinal cells genetically modified by inserting the E1 genes from the human adenovirus type 5) developed by CRUCELL (Netherland)), VERO (cells derived from epithelial cells of kidney from African green monkey (Cercopithecus aethiops) isolate at the Chiba University in Chiba, Japan), BHK21 (Cells immortalized from baby hamster kidney cells). None of the cell lines available fulfil all the medical, regulatory and industrial requirements.
  • the inventor has taken advantage of its expertise in avian biology and in avian embryonic stem (ES) cells to undertake the development of novel stable duck cell lines that enables the efficient replication of a large group of human and veterinarian vaccines and vaccine candidates.
  • ES avian embryonic stem
  • the inventor was able to generate a series of well characterized and documented duck cell lines (i.e the dEBx® cells) that are derived from duck ES cells, with no steps of genetic, chemical or viral immortalization and that do not produce replication-competent retroviruses in culture.
  • the instant invention provides a process for obtaining continuous diploid avian cell lines, named EBx, derived from avian embryonic stem cells (ES), wherein said avian cell lines do not produce replication-competent endogenous retrovirus particles.
  • the cell lines of the invention are "continuous" because they have the characteristics to be cultured in vitro over an extended period of time.
  • the cells of the invention are capable of proliferating for at least 50 generations, at least 75 generations, at least 100 generations, at least 125 generations, at least 150 generations, at least 175 generations, at least 200 generations, at least 250 generations.
  • the 250 generations do not constitute a time limit because the cells obtained are still alive and can still be passaged for additional passages.
  • the cells of the invention can be cultured "continuously” as long as telomerase is expressed by the cells. Indeed, it is assumed that the high level of telomerase expression of avian cells of the invention is responsible for genetic stability (i.e avian cells of the invention are diploid) and the continuous cell growth.
  • passage it is meant the transfer of transplantation of cells, with or without dilution, from one culture vessel to another. It is understood that any time cells are transferred from one vessel to another, a certain portion of the cells may be lost and therefore, dilution of cells, whether deliberate or not, may occur.
  • This term is synonymous with the term 'subculture'.
  • the passage number is the number of times the cells in the culture, that grow either in suspension or in adherence, have been sub-cultured or passed in a new vessel. This term is not synonymous with population doubling or generation which is the time needed by a cell population to replicate one time; that is to say, roughly the time for each cells of a population to replicate.
  • Avian ES cells of step a) of the invention have a population doubling time (PDT) of around > 40 hours.
  • the avian EBx cells of the invention have a PDT of around ⁇ 30 hours; usually for EBx® cells, there is one passage every 3 generations.
  • diploid it is mean that cells of the invention have two copies (2n) of each chromosome, usually one from the mother and one from the father.
  • avian EBx® cell lines of the invention are continuous and diploid (i.e genetically stable) constitutes a remarkable and unique feature because these terms are usually antagonist.
  • cancer cells and/or immortalized cells obtained by chemical, physical (U.V irradiation, X-ray or g-irradiation, ...) or genetic modification (virus transformation, oncogenes overexpression, ...) are continuous cells because they are able to replicate indefinitely into culture, but they are not genetically stable because they display polyploid karyotypes.
  • primary cells such as chicken embryonic fibroblasts, MRC5, WI38 which are non- transformed cells, are not continuous because they have a finite life-span after few generation, but they are genetically stable (i.e diploid) cells.
  • the terms "cell line” and "cells” will be used indistinctly.
  • Anseriformes i.e duck, goose, swan and allies.
  • the order Anseriformes contains about 150 species of birds in three families: the Anhimidae (the screamers), Anseranatidae (the Magpie- goose), and the Anatidae, which includes over 140 species of waterfowl, among them the ducks, geese, and swans. All species in the order are highly adapted for an aquatic existence at the water surface. All are web-footed for efficient swimming (although some have subsequently become mainly terrestrial).
  • Galliformes i.e chicken, quails, turkey, pheasant and allies.
  • the Galliformes is an order of birds containing the chicken, turkeys, quails and pheasants. About 256 species are found worldwide.
  • Columbiformes i.e Pigeon and allies.
  • the bird order Columbiformes includes the very widespread doves and pigeons.
  • endogenous retroviral particle or "endogenous retrovirus particle”
  • retroviral particle encoded by and/or expressed from ALV-E or EAV proviral sequences present in some avian cell genomes.
  • ALV-E proviral sequences are known to be present in the genome of domestic chicken (except Line-0 chicken), red jungle fowl and Ringneck Pheasant.
  • ALV-E proviral sequences are known to be present in the genome of domestic chicken (except Line-0 chicken), red jungle fowl and Ringneck Pheasant.
  • ALV-E proviral sequences are known to be present in the genome of domestic chicken (except Line-0 chicken), red jungle fowl and Ringneck Pheasant.
  • EAV proviral sequences are known to be present in all genus gallus that includes domestic chicken, Line-0 chicken, red jungle fowl, green jungle fowl, grey jungle fowl, Ceylonese jungle fowl and allies) (see Resnick et al., 1990, J. Virol., 64:4640-4653).
  • the bird of the invention are selected among the birds that does not comprises ALV-E and EAV proviral sequences in its genome.
  • a man skilled in the art is able to determine whether ALV-E and EAV sequences are present in a bird genome (Johnson and Heneine, 2001 ; Weissmahr et al., 1996).
  • the bird is selected in the group comprising Anseriformes (i.e duck, goose, swan), turkeys, quails, Japanese quail, Guinea fowl, Pea Fowl. Therefore, cells derived from such bird do not produce replication-competent endogenous ALV-E and/or EAV particles.
  • the bird of the present invention is selected among the group comprising ducks, geese, swans, turkeys, quails and Japanese quails, Guinea Fowls and Pea Fowls.
  • the bird is a duck, more preferably a Pekin or Muscovy ducks.
  • the bird is a Pekin duck. Therefore, the instant invention provides a process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles.
  • ES embryonic stem cells
  • the bird of the invention are selected among the birds that does not comprises complete ALV-E proviral sequences in its genome but eventually EAV proviral sequences.
  • a man skilled in the art is able to determine whether partial or complete ALV-E and EAV sequences are present in a bird genome (Johnson and Heneine, 2001 ).
  • Several chicken strains have been selected by breeding that do not contain complete ALV-E proviral sequences (i.e: ev-0 strain) and therefore do not produce infectious ALV-E retroparticles, such as: - Line 0 domestic chicken of East Lansing USDA poultry stock (ELL-O strain).
  • the bird is an ev-0 domestic chicken (Gallus Gallus subspecies domesticus), preferably selected among ELL-O, DE and PE11.
  • the instant invention provides a process for obtaining continuous diploid chicken cell lines derived from embryonic stem cells (ES) of ev-0 chicken strains, wherein said ev-0 chicken cell lines do not produce replication-competent endogenous retrovirus particles.
  • ES embryonic stem cells
  • the bird of the invention are selected among the birds that comprise complete and/or incomplete ALV-E and EAV proviral sequences in its genome but that are unable to produce replication competent ALV-E and EAV retroparticles.
  • a man skilled in the art is able to determine whether ALV-E and/or EAV infectious and/or non-infectious retroparticles are produced from a bird cells (Johnson and Heneine, 2001 ; Weissmahr et al., 1996).
  • the bird is selected in the group comprising specific pathogen free (SPF) chicken, preferably from VaIo strain (Lohman) or Line 22 (SPAFAS).
  • SPPF specific pathogen free
  • SPAFAS Line 22
  • retroviral particles are infectious, that is to say that such retroviral particules are able to infect and to replicate in avian cells of the invention.
  • the process of establishment of continuous diploid avian cell lines, named EBx®, of the invention comprises two steps: a) isolation, culture and expansion of embryonic stem cells from birds that do not contain complete endogenous proviral sequences, or a fragment thereof, susceptible to produce replication competent endogenous retroviral particles, more specifically EAV and/or ALV-E proviral sequences or a fragment thereof, in a complete culture medium containing all the factors allowing their growth and in presence of a feeder layer and supplemented with animal serum; optionally, said complete culture medium may comprise additives, such as additional amino-acids (i.e glutamine, non essential amino acids...), sodium pyruvate, beta-mercaptoethanol, vitamins, protein hydrolyzate of non- animal origin (i.e yeastolate, plant hydrolyzates (soy, wheat, ...); b) passage by modifying the culture medium so as to obtain a total withdrawal of said factors, said feeder layer and said serum, and optionally said additives, and further obtaining adherent or
  • the modification of the culture medium of step b) of the process of establishment EBx® cell lines, so as to obtain progressive or total withdrawal of growth factors, serum and feeder layer, can be made simultaneously, successively or separately.
  • the sequence of the weaning of the culture medium may be chosen among: feeder layer / serum / growth factors; feeder layer / growth factors / serum; serum / growth factors / feeder layer; serum / feeder layer / growth factors; - growth factors / serum / feeder layer; growth factors / feeder layer / serum.
  • the sequence of the weaning is growth factors / feeder layer / serum.
  • the withdrawal of additives such as sodium pyruvate, non essential amino acids (NNEA), vitamins, yeastolate are performed after the weaning of feeder layer and before the weaning of serum.
  • the withdrawal of yeastolate is performed after the withdrawal of sodium pyruvate, NNEA and vitamins.
  • the avian embryonic stem cells according to step a) of the invention are collected from avian embryo at oviposition, that is to say when the egg is laid.
  • oviposition corresponds to the following development stages according to Eyal-Giladi's classification (EYAL-G I LAD I 's classification: EYAL-GILADI and KOCHAN, 1976, « From cleavage to primitive streack formation : a complementary normal table and a new look at the first stages of the development in the chick Erasmus "General Morphology" Dev. Biol. 49:321-337):
  • Muscovy duck also called Barbari duck
  • stage VII-VIII Guinea fowl: stage VII - VIII - Turkey: stage VII-VIII
  • stage Xl Japanese Quail: stage Xl
  • the duck embryonic stem (ES) cells of step a) are obtained by dissociating Pekin duck embryo(s) at around stage VIII (oviposition) of Eyal-Giladi's classification. If the laid egg collected at oviposition is not enough developed to collect embryonic stem cells, the laid egg may be further incubated between several hours (overnight) to one to two days to mature the embryo.
  • the duck embryonic stem (ES) cells of step a) is from a Muscovy duck. At oviposition, Muscovy duck is not enough mature because it is around stage VII, therefore, the egg is incubated overnight to mature the egg up to stage VIII to X of Eyal-Giladi's classification.
  • the chicken embryonic stem (ES) cells preferably from ev-0 chicken strain, of step a) is obtained by dissociating embryo(s) at around stage X (oviposition) of Eyal-Giladi's classification.
  • the avian embryonic stem cells according to step a) of the invention are collected from embryo before oviposition.
  • the main limitations encountered before oviposition is the fact that the egg has to be surgically removed from hens and that the amount of ES cells per embryo is less important.
  • ES cells are not well individualized rendering difficult in vitro culture of ES cells. A man skilled in the Art will be able to define the timeframe prior egg laying that allows to collect avian ES cells.
  • the avian embryonic stem cells according to step a) of the invention may be collected from avian embryo after oviposition up to hatching.
  • avian embryonic stem cells will progressively enter into differentiation to generate differentiated tissues; therefore, it is preferred to collect avian ES not to long after the lay.
  • a man skilled in the Art will be able to define the timeframe after egg laying that allows to collect avian embryonic stem cells.
  • the cells of step a) are a population of embryonic stem cells enriched in primordial germ cells (PGC). More preferably, the avian ES cells of step a) are purified PGCs.
  • PGC primordial germ cells
  • Primordial Germ Cells arise from the central region of the blastoderm (Ginsburg and Eyal-Giladi, 1987 Development 101(2):209-19; Karagenc et al, 1996 Dev Genet 19(4):290-301 ; Petitte et al, 1997 Poultry Sci. 76(8): 1084-92). Then they move to an anterior, extra-embryonic site, the germinal crescent until collected by the vasculature between 2.5 and 5 days of embryonic development to reach the germinal ridge.
  • PGCs are collected from embryonic blood collected from the dorsal aorta of a chicken embryo at stage 12-14 of Hamburger & Hamilton's classification (Hamburger & Hamilton 1951 A series of normal stages in the development of chick embryo. J. Morphol. 88: 49-92).
  • PGCs were collected from the germinal crescent by mechanical dissection of chicken embryo or from the gonads.
  • others methods for isolating PGCs are known and can alternatively be used.
  • avian embryonic stem cells are characterized by a slow doubling time comprises between 48 to 72 hours in culture at 39 0 C.
  • the defined cell culture conditions of avian ES cells followed by the progressive weaning in grow factors, feeder layer, additives and serum allow to adapt and select cells that maintain most of the desirable feature of ES cells (stability of karyotype, indefinite proliferation, expression of ES markers) but in addition display industrial-friendly characteristics like growth in suspension up to high cell densities in serum-free medium.
  • Telomerase constitutes one of the most important ES markers. Due to the sustained and maintained telomerase expression over the cell passages, EBx® cell are continuous (i.e immortal) but in addition are genetically stable (i.e diploid).
  • the present invention provides a process for obtaining continuous diploid avian cell lines derived from ES cells, wherein said avian cell lines do not produce replication competent endogenous retroviral particles, said process comprising the following steps of: a) isolating bird embryo(s), preferably from duck or from ev-0 chicken, at a developmental stage comprises from around stage Vl of Eyal-Giladi's classification
  • IGF-1 Insulin Growth factor 1
  • CNTF Ciliary Neurotrophic factor
  • IL-6 interleukin 6
  • IL-6R interleukin 6 receptor
  • SCF Stem cell Factor
  • FGF Fibroblast Growth Factor
  • the withdrawing of all the growth factors selected from the group comprising IL-6, IL-6R, SCF, FGF from the culture medium is performed simultaneously over one passage.
  • the withdrawing of IL- 6, IL-6R, SCF, FGF is performed at around passage 10 to 15; e) withdrawing IGF-1 and CNTF from the culture medium and further culturing the avian ES cells for at least one passage.
  • the withdrawing of the growth factors selected from the group comprising IGF-1 and CNTF from the culture medium is performed simultaneously, over one passage.
  • the withdrawing of IGF-1 and CNTF is performed at around passage N 0 15 to N 0 25.
  • the withdrawing of IGF-1 and CNTF is performed by progressive decreasing over several passages (at least 2 passages and approximately up to 15 passages); f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of additives in the culture medium so as to obtain a total withdrawal of additives after at least one passage; and, h) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and, i) obtaining adherent avian cell lines, named EBx®, derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum and additives, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; j) optionally, further adapting said adherent avian EBx® cell lines
  • the step of adaptation of cell culture to suspension can take place all along the process of establishment of EBx® cells.
  • EBx® cells derived from Muscovy embryonic stem cells
  • the cells were adapted to the growth in suspension prior feeder layer withdrawal.
  • duck EB® cells EB24, EB26, EB66
  • the cells were adapted to the growth in suspension prior animal serum withdrawal.
  • k Optionally further subcloning said avian EBx® cells, for example by limit dilution.
  • the present invention relates to a process for obtaining continuous diploid avian cell lines, named EBx®, derived from avian embryonic stem cells (ES), wherein said avian cell lines do not produce replication-competent endogenous retrovirus particles, and said process comprising the steps of: a) isolating bird embryo(s) at a developmental stage around oviposition, wherein the genome of said bird does not contain endogenous proviral sequences susceptible to produce replication competent endogenous retroviral particles ; b) suspending avian embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with at least:
  • IGF-1 Insulin Growth factor 1
  • CNTF Ciliary Neurotrophic factor
  • - mammalian serum such as foetal bovine serum
  • Step j) of adapting adherent avian EBx® cell lines to suspension culture conditions, when carried out, can be effected in another preferred embodiment before the step g) of progressively decreasing the concentration of mammalian serum in the culture medium.
  • the basal culture medium in step b) of the process for obtaining continuous diploid avian cell lines according to the present invention is further supplemented with a growth factor selected in the group comprising interleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF), and the said prcess further comprises a step d) of: d) optionally withdrawing all the growth factors selected from the group comprising IL- 6, IL-6R, SCF, FGF from the culture medium and further culturing the ES cells for at least one passage.
  • IL-6 interleukin 6
  • IL-6R interleukin 6 receptor
  • SCF Stem cell Factor
  • FGF Fibroblast Growth Factor
  • step e) of withdrawing IGF-1 and CNTF from the culture medium is effected after the step d) of withdrawing all the growth factors selected from the group comprising IL-6, IL-6R, SCF, FGF from the culture medium.
  • basal culture medium meant a culture medium with a classical media formulation that allows, by itself, at least cells survival, and even better, cell growth.
  • basal media are BME (basal Eagle Medium), MEM (minimum Eagle Medium), medium 199, DMEM (Dulbecco's modified Eagle Medium), GMEM (Glasgow modified Eagle medium), DMEM-HamF12, Ham-F12 and Ham-F10, Iscove's Modified Dulbecco's medium, MacCoy's 5A medium, RPMI 1640, GTM3.
  • Basal medium comprises inorganic salts (for examples: CaCI 2 , KCI, NaCI, NaHCO 3 , NaH 2 PO 4 , MgSO 4 , ...), amino-acids, vitamins (thiamine, riboflavin, folic acid, D-Ca panthothenate, ...) and others components such as glucose, beta- mercapto-ethanol, sodium pyruvate.
  • Basal medium is a synthetic medium. Table 1 gives the composition of DMEM / HAM F12:
  • basal medium of the invention may be complemented with additives selected in the following group:
  • non-essential amino-acids preferably around 1 % non-essential amino- acids
  • vitamins preferably around 1 % vitamins
  • beta-mercapto-ethanol preferably around 0.16 mM beta-mercapto- ethanol
  • the basal medium is preferably complemented with protein hydrolyzate of non-animal origin.
  • Protein hydrolyzates of non-animal origin are selected from the group consisting bacteria tryptone, yeast tryptone, plant hydrolyzates, such as soy hydrolyzates, or a mixture thereof.
  • the protein hydrolyzates of non-animal origin is yeast hydrolyzate.
  • the term "hydrolyzate" includes an enzymatic digest of soy peptone or yeast extract.
  • the hydrolysate can be obtained from a plurality of soy peptone or yeast extract preparations, respectively, which can be further enzymatically digested (for example, by papain), and/or formed by autolysis, thermolysis and/or plasmolysis.
  • Hydrolysates also may be obtained commercially, such as Yeastolate, Hy-Soy, Hy- Yeast 412 and Hi-Yeast 444, from sources such as SAFC BioSciences (formerly JRH) (Lenaxa, KA), Quest International (Norwich, N. Y.), OrganoTechnie S.A. (France) or Deutsche Hefewerke GmbH (Germany). Sources of yeast extracts also are disclosed in WO 98/15614.
  • Sources of yeast extracts and soy hydrolysates also are disclosed in WO00/03000.
  • the hydrolysates used in media of the invention are preferably purified from a crude fraction, because impurities which could interfere with efficient cultivation are preferably eliminated during this purification, thereby improving the consistency of the hydrolysate.
  • Purification can be by ultrafiltration or Sephadex chromatography (for example, with Sephadex G25 or Sephadex G10 or equivalent materials), ion-exchange chromatography, affinity chromatography, size exclusion chromatography or "reversed-phase" chromatography.
  • purification is performed by ultrafiltration utilizing a 1OkDa cut-off filter. These processes are known in the field.
  • fractions can be selected which contain soy or yeast hydrolysate of defined molecular weight.
  • the average molecular weights of the soy and yeast hydrolysates are preferably between about 220 and 375 daltons.
  • yeast hydrolyzate is present in the cell culture medium.
  • Yeast hydrolyzate 5OX (around 200 g/l) obtained for example from SAFC-BIOSCIENCES (Ref 58902C) is present in the cell culture medium at a final concentration comprises between around 0.1X to 2X, preferably around 0.5X to around 1X into the culture medium. Soy hydrolyzate may also be added to the cell culture medium.
  • Soy hydrolyzate 5OX obtained for example from SAFC-BIOSCIENCES (Ref 58903C) is added at a final concentration comprises between around 0.1X to 2X, preferably around 1X into the culture medium.
  • soy hydrolyzate and yeast hydrolyzate may be added to the cell culture medium as described in US2004/0077086.
  • a preferred basal medium of the invention is DMEM-HamF12 that are complemented with 2 mM L-glutamin, 1 mM sodium pyruvate, 1 % non-essential amino-acids, vitamins 1 %, 0.16 mM beta-mercapto-ethanol, and optionally with 1X yeast hydrolyzate.
  • complete culture medium it is meant a basal culture medium complemented or not, preferably a basal synthetic medium, supplemented with at least one growth factor and animal serum.
  • complete culture medium is described in WO 03/076601 , WO 05/007840, EP 787180, US 6,114,168, US 5,340,740, US 6,656,479, US 5,830,510 and in Pain et a/. (1996, Development 122:2339-2348).
  • the complete culture medium may a conditioned medium, preferably BRL conditioned medium.
  • BRL conditioned media is prepared according to art-recognized techniques, such as described by Smith and Hooper (1987, Dev. Biol. 121 :1-9). BRL cells are available from ATCC accession number CRL-1442. Conditioned medium may be supplemented with exogenous growth factors and animal serum as described below.
  • growth factors as used herein meant growth factor necessary for the survival and the growth of the undifferentiated avian ES cells in culture in a basal culture medium. It is possible to schematically distinguish two families of growth factors: the cytokines and the trophic factors.
  • the cytokines are mainly cytokines whose action is through a receptor which is associated with the gp130 protein.
  • leukemia inhibitory factor interleukin 11
  • interleukin 6 receptor interleukin 6 receptor
  • Ciliary Neurotrophic factor (CNTF) oncostatin and cardiotrophin
  • SCF Stem cell Factor
  • IGF-1 Insulin Growth factor 1
  • FGF Fibroblast Growth Factor
  • bFGF basic FGF
  • hFGF human FGF
  • the complete culture medium according to the invention comprises basal culture medium, preferably basal synthetic medium, and at least one cytokine whose action is through a receptor which is associated with the gp130 protein and/or at least one trophic factors.
  • the complete culture medium according to the invention comprises basal medium and at least one growth factor selected in the group consisting of Leukemia Inhibitory factor (LIF), oncostatin, cardiotrophin, Insulin Growth factor 1 (IGF-1 ), Ciliary Neurotrophic factor (CNTF), lnterleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF), Fibroblast Growth Factor (FGF), interleukin 11 (IL-11 ).
  • LIF Leukemia Inhibitory factor
  • IGF-1 Insulin Growth factor 1
  • CNTF Ciliary Neurotrophic factor
  • IL-6 lnterleukin 6
  • IL-6R interleukin 6 receptor
  • SCF Stem cell Factor
  • FGF Fibroblast Growth
  • the complete culture medium is basal medium supplemented with animal serum and with at least IGF-1 and CNTF.
  • the complete culture medium is basal medium supplemented with animal serum and at least IGF-1 , CNTF, IL-6 and IL-6R.
  • the complete culture medium is basal medium supplemented with animal serum and at least IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF.
  • the complete culture medium is a conditioned culture medium comprising growth factors (i.e expressed by BRL or STO cells for example) and optionally supplemented with at least one exogenous growth factors selected in the group comprising: LIF, IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF, IL-11.
  • the concentration of growth factors IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF, IL-11 in the basal medium or in the conditioned culture medium is comprised between about 0.01 to 10 ng/ml, preferably, 0.1 to 5 ng/ml, and more preferably about 1 ng/ml.
  • the culture medium of the invention may also comprise in addition antibiotics, such as for example, gentamicine, penicilline and streptomycine, to prevent bacterial contamination.
  • antibiotics such as for example, gentamicine, penicilline and streptomycine, to prevent bacterial contamination.
  • Antibiotics may be added to the culture medium at the early passages of ES cells culture. For example, gentamycin at a final concentration of 10 ng/ml, penicillin at a final concentration of 100 U/ml and streptomycin at a final concentration of 100 ⁇ g/ml may be added to the culture medium.
  • no antibiotics is added to the culture medium during the late steps of process of establishment of continuous diploid avian cell lines of the invention.
  • feeder cells are animal cells or cell lines cultured for the purpose of culturing avian ES cells.
  • the feeder cells can be substituted with extra-cellular matrix plus bound growth factors.
  • Feeder matrix will thereafter refers to either feeder cells or extra-cellular matrix.
  • a feeder matrix as used herein is constructed in accordance with procedures known in the art. As noted above, it is preferred that the feeder matrix be preconditioned. By the term “preconditioned” it is meant that the feeder matrix is cultured in the presence of media for a period of time prior to the depositing of cells originating from the blastoderm disk fertilized avian eggs in contact with the feeder matrix, e.g.
  • a feeder matrix is preconditioned by culturing the feeder matrix by itself for one to two days prior to the depositing of cells originating from the blastoderm disk fertilized avian eggs in contact with the feeder matrix.
  • the feeder cells preferably comprises mouse fibroblast cells. STO fibroblasts are preferred, but primary fibroblasts are also suitable. Also while the present invention has been described with respect to the use of mouse cell feeder matrices, it is contemplated that feeder matrices comprising cells from other murine species (e.g. rat); other mammalian species (e.g; ungulate, bovine, porcine species); or avian species (e.g.
  • feeder cells of the invention may be transfected with expression vector(s) allowing for example the constitutive expression of growth factors such as avian SCF in STO cells.
  • this "feeder" produces the factor in a form which is soluble and/or attached in the plasma membrane of the cells.
  • the culturing process of the present invention may optionally comprise establishing a monolayer of feeder cells.
  • Feeder cells are mitotically inactivated using standard techniques.
  • the feeder cells may be exposed to X or gamma radiation (e.g. 4000 Rads of gamma radiation) or may be treated with Mitomycin C (e.g.
  • Mono-layers may optionally be cultured to about 80 % confluency, preferably to about 90 % confluency, and more preferably about 100 % confluency. While configuration of the feeder cells as a monolayer is the preferred configuration for the culture, any suitable configuration is contemplated to be within the scope of the present invention. Thus, for example, layers, mono-layers, clusters, aggregates or other associations or groupings of feeder cells are contemplated to fall within the scope of the present invention and are particularly contemplated to fall with the meaning of the term "matrix”.
  • the culture medium of the invention is supplemented with animal serum.
  • the animal serum preferably used is fetal animal serum. Fetal bovine serum is preferred. Also while the present invention has been described with respect to the use of fetal bovine serum, it is contemplated that animal serum comprising serum from other animal species (e.g. chicken, horse, porcine, ungulate, etc.) may also be used.
  • the final concentration of animal serum in the culture medium is comprises between approximately 1 to 25 %, preferably between 5 % to 20 %, more preferably between 8% and 12 %. In the preferred embodiment, the final concentration of animal serum in the culture medium is approximately 10 %. According to a preferred embodiment, the culture medium comprises approximately 10 % of fetal calf serum.
  • the bird of the present invention is selected in the Order of
  • the instant invention provides a first process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles, and said process is comprising the steps of: a) isolating duck embryo(s) at oviposition (i.e egg laying), or slightly prior or after oviposition.
  • the egg may be incubated, usually overnight, to mature (i.e
  • ES duck embryonic stem cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with Insulin Growth factor 1 (IGF-1 ), Ciliary Neurotrophic factor (CNTF), interleukin 6 (IL-6), interleukin 6 receptor (IL-6R),
  • IGF-1 Insulin Growth factor 1
  • CNTF Ciliary Neurotrophic factor
  • IL-6 interleukin 6
  • IL-6R interleukin 6 receptor
  • SCF Stem cell Factor
  • FGF Fibroblast Growth Factor
  • the animal serum concentration at step b) is preferably of 5 to 10 %.
  • the concentration of with Insulin Growth factor 1 (IGF-1 ), Ciliary Neurotrophic factor (CNTF), interleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF) are preferably of about 1 ng/ml.
  • the instant invention also provides a second process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles, and said process is comprising the steps of: a) isolating duck embryo(s) at oviposition (i.e egg laying), or slightly prior or after oviposition.
  • oviposition i.e egg laying
  • the egg may be incubated, usually overnight, to mature (i.e Muscovy duck); b) suspending duck embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 , CNTF, IL-6, IL-6R, SCF and FGF and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the duck ES cells for at least 1 passage; d) withdrawing all the growth factors selected from the group comprising IL-6, IL-6R,
  • the animal serum concentration at step b) is preferably of 5 to 10 %.
  • the concentration of IGF- 1 , CNTF, IL-6, IL-6R, SCF and FGF are preferably of about 1 ng/ml.
  • the instant invention also provides a third process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles, and said process is comprising the steps of: a) isolating duck embryo(s) at oviposition (i.e egg laying), or slightly prior or after oviposition.
  • oviposition i.e egg laying
  • the egg may be incubated, usually overnight, to mature (i.e Muscovy duck); b) suspending duck embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with Insulin Growth factor 1 (IGF-1 ), and Ciliary Neurotrophic factor (CNTF) and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the duck ES cells for at least 1 passage; d) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the duck ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 25 passages, and further culturing the cells; Removal of additives?
  • IGF-1 Insulin Growth factor 1
  • g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and, h) obtaining adherent duck cell lines derived from ES cells, named duck EBx®, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent duck EBx® cell lines to suspension culture conditions. Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
  • the animal serum concentration at step b) is preferably of 5 to 10 %.
  • the concentration of with IGF-1 and CNTF are preferably of about 1 ng/ml.
  • the process of the invention may also comprises the additional step of adapting, duck EBx® cells to the growth in cell culture medium without protein hydrolyzate of non-animal origin, such as yeast hydrolyzates.
  • duck EBx® cell lines of the invention do not display reverse transcriptase activity by Q-PERT analysis. Moreover, no replication-competent endogenous retrovirus particles is produced by duck EBx® cells as demonstrated by co-culture experiments of duck EBx® cells of the invention with ALV replication competent cells, such as quail QT6 cells or chicken DF1 cells. In addition, transmission electronic microscopy (TEM) analysis also demonstrate the absence of replication-competent endogenous retrovirus particles in duck EBx® cells.
  • the duck EBx® cell line of the invention is selected among duck EB24, duck EB26 and duck EB66 as described hereinafter.
  • the bird of the present invention is selected in the Order of Galliformes and more preferably is a chicken, preferably an a ev-0 domestic chicken (Gallus Gallus subspecies domesticus). Therefore, the instant invention provides a process for obtaining continuous diploid ev-0 domestic chicken cell lines derived from embryonic stem cells (ES), wherein said ev-0 domestic chicken cell lines do not produce replication-competent endogenous ALV-E retrovirus particles, and said process is comprising the steps of: a) isolating ev-0 domestic chicken embryo(s) at oviposition (i.e egg laying) or slightly prior or after oviposition; b) suspending ev-0 domestic chicken embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 , CNTF, IL-6, IL-6R, SCF and FGF and animal serum; c) seeding the suspension of ES cells obtained in step
  • Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
  • the animal serum concentration at step b) is preferably of 5 to 10 %.
  • the concentration of IGF- 1 , CNTF, IL-6, IL-6R, SCF and FGF are preferably of about 1 ng/ml.
  • the instant invention also provides a second process for obtaining continuous diploid ev-0 domestic chicken cell lines derived from embryonic stem cells (ES), wherein said ev-0 domestic chicken cell lines do not produce replication-competent endogenous ALV-E retrovirus particles, and said process is comprising the steps of: a) isolating ev-0 domestic chicken embryo(s) at oviposition (i.e egg laying) or slightly prior or after oviposition; b) suspending ev-0 domestic chicken embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 ,
  • CNTF, IL-6, IL-6R, SCF and FGF and animal serum c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ev-0 domestic chicken ES cells for at least 1 passage; d) withdrawing all the growth factors selected from the group comprising IL-6, IL-6R, SCF, FGF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the chicken ES cells for at least one passage; e) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the ev-0 domestic chicken ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 45 passages, and further culturing the cells; g) optional
  • Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
  • the animal serum concentration at step b) is preferably of 5 to 10 %.
  • the concentration of with IGF-1 , CNTF, IL-6, IL-6R, SCF and FGF are preferably of about 1 ng/ml.
  • the instant invention also provides a third process for obtaining continuous diploid ev-0 domestic chicken cell lines derived from embryonic stem cells (ES), wherein said ev-0 domestic chicken cell lines do not produce replication-competent endogenous ALV-E retrovirus particles, and said process is comprising the steps of: a) isolating ev-0 domestic chicken embryo(s) at oviposition (i.e egg laying) or slightly prior or after oviposition; b) suspending ev-0 domestic chicken embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 and CNTF and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ev-0 domestic chicken ES cells for at least 1 passage; d) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage,
  • the animal serum concentration at step b) is preferably of 5 to 10 %.
  • the concentration of with IGF-1 and CNTF are preferably of about 1 ng/ml.
  • the bird of the present invention is a domestic chicken (Gallus Gallus subspecies domesticus) obtained from a specific-pathogen-free (SPF) flock. More preferably, the chicken strain is White-Leghorn.
  • SPF chicken eggs has been screened for the absence of known chicken bacterial pathogens and viruses, including the reticuloendotheliosis virus (REV) and the avian exogenous leucosis virus (ALV-A, ALV-B, ALV-C, ALV-D, ALV-J).
  • the SPF egg of the invention may VALO eggs from LOHMANN (Cuxhaven, Germany) or L22 eggs from CHARLES RIVER (Spafas).
  • the instant invention also provides processes for obtaining continuous diploid chicken cell lines derived from embryonic stem cells (ES) obtained from SPF chicken eggs, like described with ev-0 chicken eggs.
  • ES embryonic stem cells
  • the chicken EBx® cell line obtained from SPF eggs is EBv13.
  • Chicken EBx® cell lines of the invention may display reverse transcriptase activity by Q-PERT analysis, but without producing replication-competent endogenous retrovirus particles.
  • the absence of replication-competent endogenous retrovirus particles may be demonstrated by co- culture experiments of chicken EBx® ev-0 cells of the invention with ALV replication competent cells, such as quail QT6 cells or chicken DF1 cells.
  • ALV replication competent cells such as quail QT6 cells or chicken DF1 cells.
  • the absence of endogenous retrovirus particles in chicken EBx® ev-0 cells may be also demonstrate by TEM.
  • the processes of the invention may also comprise the additional step of decreasing the cell culture temperature to 37 0 C in order to adapt the avian cell lines of the invention to grow at 37 0 C.
  • the temperature adaptation is performed after feeder depletion and prior serum depletion.
  • the temperature adaptation is performed after the serum depletion step or after the step of adapting the cell lines to suspension culture.
  • the established lines EBx® of the invention have the characteristic to grow either as adherent cells or as suspension cells in a culture medium free of exogenous growth factors and animal serum and without feeder cells. Different techniques can be used alone or in combination to adapt cells to suspension culture, among them:
  • Adherent cells are seeded at high cell density, slightly above cell confluence to force the cells to go into suspension;
  • Adherent cells are seeded in a cell culture medium with a low animal serum concentration
  • Adherent cells are seeded onto cell culture vessels made of plastic that do not allow cell adhesion or a weak cell adhesion, such as bacterial dishes and plates and ultra-low attachment plates developed by companies like Corning (tissue culture dishes & plates Ref. 3262, 3473, 3471 , 3474; Flasks Ref. 3814%) or Sarstedt (Flask ref 831810502...); - Adherent cells are seeded on vessel and cultured under agitation (Approx. 50 rpm) .
  • the EBx® cells preferably duck EBx® and chicken EBx® ev-0, can be in vitro cultured over a considerable period of time.
  • the adherent or anchorage-independent (i.e "suspension) EBx® cells obtained by the process of the invention are capable to proliferate for at least 50 generation, at least 75 generation, at least 100 generation, at least 125 generation, at least 150 generation, at least 175 generation, at least 200 generation, at least 250 generation.
  • the expression "line” is understood to mean any population of cells capable of proliferating indefinitely in culture in vitro while retaining to a greater or lesser degree the same morphological and phenotypic characteristics.
  • Clones may be obtained, for example by limit dilution, from EBx® cells of the invention. These clones are cells which are genetically identical to the cell from which they are derived by division.
  • the present invention also relates to the continuous diploid avian cell lines, named EBx®, obtainable by the process of the invention, said EBx® being small, round (i;e diameter around 10 urn), individualized cells with a doubling time of around 30 hours or less at 37 0 C or 39 0 C.
  • the avian EBx® cells preferably the duck EBx® or chicken EBx® ev-0, express an embryonic stem cell phenotype with the following characteristics: a high nucleo-cytoplasmic ratio, - an endogenous telomerase activity, optionally, they may express one or more additional ES markers such as alkaline phosphatase, SSEA-1 , EMA-1 , ENS1 markers.
  • Said cells do not produce replication competent endogenous retrovirus particles.
  • the avian EBx® cell lines of the invention are capable of proliferating indefinitely in a basal medium, in particular in a medium such as SAFC Excell media, DMEM, GMEM, DMEM- HamF12 or McCoy, free of exogenous growth factors, serum and/or inactivated feeder layer, optionally complemented with various additives commonly used by persons skilled in the art.
  • a medium such as SAFC Excell media, DMEM, GMEM, DMEM- HamF12 or McCoy
  • additives are non-essential amino acids, vitamins, sodium pyruvate and antibiotics.
  • Duck EBx® cells of the invention have the remarkable feature to grow in a basal culture medium that is not complemented with glutamine.
  • the present invention also relates to a cell culture medium to maintain pluri-or multipotent avian embryonic stem cells, preferably pluri-or multipotent duck embryonic stem (ES) cells, into culture in an undifferentiated state.
  • the present invention relates to cell culture medium for duck embryonic stem cells comprising a basal culture medium, supplemented with animal serum and supplemented with at least IGF-1 and CNTF.
  • the present invention relates to cell culture medium for duck embryonic stem cells comprising a basal culture medium supplemented with animal serum and supplemented with at least IGF-1 , CNTF, II-6, II-6R.
  • the present invention relates to a cell culture medium for duck embryonic stem cells
  • a cell culture medium for duck embryonic stem cells comprising a basal culture medium supplemented with animal serum and supplemented with at least IGF-1 , CNTF, II-6, II-6R, SCF and FGF.
  • Said media are sufficient for the maintenance of said duck ES cells into culture for at least 7 days, preferably for at least 20 days, preferably for at least 100 days in an undifferentiated state.
  • Said culture media of the invention may further comprise optionally at least one compound selected in the group comprising lnterleukin-11 , cardiotrophin, oncostatin and leukaemia inhibitory factor (LIF).
  • said culture media further comprise protein hydrolyzate of non-animal origin as previously described; more preferably it is yeast hydrolyzate at 1X concentration.
  • the culture medium of avian (preferably duck) ES cells of the invention may further comprise a layer of feeder cells.
  • the instant invention also provide a sustained duck ES cell culture consisting essentially of undifferentiated duck ES cells expressing stem cell phenotype with the following characteristics: a high nucleo-cytoplasmic ratio, an endogenous telomerase activity, - optionally, duck ES cells may express one or more additional ES markers such as alkaline phosphatase, SSEA-1 , EMA-1 , ENS1 markers.
  • Said undifferentiated duck cells according to the invention are capable of maintaining said stem cell phenotype when grown on feeder cells in a cell culture medium for duck embryonic stem cells as previously described. Said undifferentiated duck cells are useful to produce chimeric or transgenic ducks.
  • the present invention also relates to a method of obtaining chimeric duck, said method comprising the steps of: a) introducing a sustained duck ES cell culture as described above into the sub- germinal cavity of a recipient duck embryo; and b) incubating the embryo obtained in step a) to hatch as a duckling; c) selecting said chimeric duckling comprising heterologous cells having colonized said duckling.
  • the present invention also relates to a method of obtaining genetically modified chimeric duck, comprising the steps of: a) introducing a genetically modified duck ES cells as described above into the sub- germinal cavity of a recipient duck embryo; and b) incubating the embryo obtained in step a) to hatch as a duckling; c) selecting said chimeric duckling comprising genetically modified heterologous cells having colonized said duckling.
  • the present invention also relates to a method of obtaining a progeny of said chimeric duckling wherein said method comprises the following steps: a) allowing the selected chimeric duckling obtained at steps c) to mature as an adult bird; b) breeding said adult bird having heterologous cells herein, thereby producing a bird progeny; c) selecting the birds of interest in the progeny.
  • the invention may comprise the additional step of expressing an heterologous polypeptide encoded by an expression vector comprised in said genetically modified duck ES cells.
  • the heterologous polypeptide is delivered into biological fluid of duck, such as blood, sperm, urine, or the white of a developing avian egg produced by a female of the genetically modified duck.
  • the EBx® cells of the invention have all the above mentioned characteristics and are useful for the production of biologies such as viral vaccines and recombinant peptides and proteins.
  • the instant invention also provide a process of replicating a virus in the continuous diploid avian EBx® cell lines of the invention. More preferably, the invention provides a process of replicating a virus in the continuous diploid avian EBx® cell lines of the invention, preferably duck or chicken EBx® cell lines, that comprise the steps of: infecting an avian EBx® cell culture with a virus of interest; said avian EBx® cells being preferably cultured in animal serum free medium; culture of infected avian EBx® cells in order to replicate said virus; harvest the virus in cell culture supernatant and/or inside said cells.
  • said process comprises the steps of: a) proliferating said avian EBx® in a cultivation vessel, in suspension, in a serum-free medium N°1 ; b) infecting said cells with the selected virus when the cell density is of at least 1.5 million cells/ml; c) optionally, shortly before infection, simultaneously to infection, or shortly after infection adding to the cell culture serum-free medium N 0 2; and d) further culturing said infected cells in order to allow virus replication; and e) optionally, harvesting said virus.
  • Said process of the invention may comprise the additional step of adding proteolytic enzyme in the culture medium in conditions that allow virus propagation.
  • the proteolytic enzyme is selected from the group consisting of trypsin, chymotrypsine, thermolysine, pepsine, pancreatine, papa ⁇ ne, pronase, subtilisine A, elastase, furine and carboxypeptidase.
  • the enzyme is trypsin.
  • the proteolytic enzyme is a recombinant protein produced on a procaryotic host or on plants (i.e: trypzean).
  • the proteolytic enzyme may added before, during and/or after the virus infection.
  • the addition of proteolytic enzyme is performed after virus infection.
  • the addition of proteolytic enzyme in the culture medium may be performed one time per day, more than one time per day, or less than one time per day until the virus harvest.
  • virus includes not only naturally occurring viruses but also attenuated viruses, reassortant viruses, vaccine strains, as well as recombinant viruses and viral vectors derived thereof.
  • the virus of the invention are preferably selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnavriruses and retroviruses.
  • the viruses, the related viral vectors, viral particles and viral vaccines belong to the family of poxviridae, and more preferably to the chordopoxviridae.
  • the virus or the related viral vectors, viral particles and viral vaccines are a poxvirus, preferably an avipoxvirus selected among fowlpox virus (i.e TROVAC), canarypox virus (i.e ALVAC), juncopox virus, mynahpox virus, pigeonpox virus, psittacinepox virus, quailpoxvirus, sparrowpoxvirus, starling poxvirus, turkeypox virus.
  • fowlpox virus i.e TROVAC
  • canarypox virus i.e ALVAC
  • juncopox virus mynahpox virus
  • pigeonpox virus psittacinepox virus
  • quailpoxvirus sparrowpoxvirus
  • the virus is a vaccinia virus selected among Lister-Elstree vaccinia virus strain, modified vaccinia virus such as Modified Vaccinia virus Ankara (MVA) which can be obtained from ATCC (ATCC Number VR-1508), NYVAC (Tartaglia et al., 1992, Virology, 188:217-232), LC16m8 (Sugimoto et Yamanouchi, 1994, Vaccine, 12:675-681 ), CVI78 (Kempe et al., 1968, Pediatrics 42:980-985) and other recombinant or non-recombinant vaccinia virus.
  • MVA Modified Vaccinia virus Ankara
  • influenza virus belongs to the family of ortho-myxoviridae, in particular influenza virus.
  • the influenza virus is selected from the group consisting of human influenza virus, avian influenza virus, equine influenza virus, swine influenza virus, feline influenza virus.
  • Influenza virus is preferably selected in strains A, B and C. Among strains A, one can recite viruses with different subtypes of haemagglutinin and neuraminidase, such as without limitation H1 N1 , H2N2, H3N2, H4N2, H4N6, H5N1 , H5N2, H7N7 et H9N2.
  • H1 N1 strains one can recite A/Porto Rico/8/34, A/New Caledonia/20/99, A/Beijing/262/95, A/Johannesburg/282/96, A/Texas/36/91 , A/Singapore, A/Solomon lslands/03/2006.
  • strains H3N2 one can recite A/Panama/2007/99, A/Moscow/10/99, A/Johannesburg/33/94, A/Wisconsin/10/04.
  • influenza Virus of the invention is selected among wild type virus, primary viral isolate obtained from infected individual, recombinant virus, attenuated virus, temperature sensitive virus, low-temperature adapted virus, reassortant virus, reverse genetic engineered virus.
  • the process of the invention comprises the additional step of adding proteolytic enzyme in the culture medium in conditions that allow virus propagation.
  • the enzyme is trypsin.
  • the final concentration of trypsin in cell culture medium is comprises between around 0.01 ⁇ g/ml up to 10 ⁇ g/ml. More preferably, the final concentration of trypsin in cell culture medium is comprised between 0.01 to 10 usp/ml (usp: US pharmacopea unit) preferably around between 0.05 to 2 usp/ml, more preferably around between 0.3 to 1 usp/ml and more preferably around 0.75 usp/ml.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of paramyxoviridae.
  • the virus is a naturally occuring paramyxovirus or a recombinant paramyxovirus selected in the group comprising measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human parainfluenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, duck para-influenza virus.
  • the virus is measles virus or a recombinant measles virus.
  • the virus is Newcastle Disease virus (NDV) or a recombinant NDV.
  • Example of NDV strain is LaSota strain.
  • the process of the invention comprises preferably the additional step of adding proteolytic enzyme in the culture medium in conditions that allow virus propagation.
  • the enzyme is trypsin.
  • the final concentration of trypsin in cell culture medium is comprises between around 0.01 ⁇ g/ml up to 10 ⁇ g/ml. More preferably, the final concentration of trypsin in cell culture medium is comprised between 0.01 to 10 usp/ml (usp: US pharmacopea unit) preferably around between 0.3 to 1 usp/ml, more preferably around between 0.4 to 0.75 usp/ml.
  • the EBx® cell lines of the invention that may grow in adherence are useful to perform virus titration, and preferably NDV titration, on a plaque assay.
  • virus growth in EBx® cells leads to the formation of characteristic giant cells.
  • NDV viral particles may be determined by haemagglutination assay. Therefore, the invention also pertain to the use of EBx® cells of the invention for the titration of virus, such as NDV virus.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of togaviridae.
  • the virus is a naturally occurring alphavirus or a recombinant alphavirus selected in the group comprising Sinbis virus, Semliki forest virus, O'nyong'nyong virus, Chikungunya virus, Mayaro virus, Ross river virus, Eastern equine encephalitis virus, Western Equine encephalitis virus, Venezuelan Equine encephalitis virus.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of herpesviridae.
  • the virus is a naturally occuring Marek Disease virus or a recombinant Marek Disease virus.
  • the Marek Disease virus (MDV) is preferably selected among the license vaccine strains of MDV such as : FC126 (HTV), SB-1 , 301 B/1 , CVI988 Clone C, CV1988/C/R6, CVI988/Rispens, R2/23 (Md 11/75).
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of hepadnaviridae.
  • the virus is a naturally occuring naturally occuring hepadnavirus or a recombinant hepadnavirus, preferably selected among avian and human hepadnavirus.
  • the avian hepadnavirus is preferably selected among the group consisting of duck hepatitis B virus (DHBV), heron hepatitis B virus (HHBV) and snow goose (SGHBV).
  • viruses, the related viral vectors, the viral particles and vaccines belong to the family of birnaviridae, in particular Infectious Bursal Disease virus.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of flaviviridae, in particular Dengue virus, Japanese encephalitis virus and West Nile virus.
  • viruses, the related viral vectors, the viral particles and vaccines belong to the family of coronaviridae, in particular Infectious Bronchitis virus.
  • viruses, the related viral vectors, the viral particles and vaccines belong to the family of circoviridae, in particular Chicken Anemia virus.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of retroviridae.
  • the virus is a naturally occurring retrovirus selected among reticulo-endotheliosis virus, duck infectious anemia virus, suck spleen necrosis virus, or a recombinant retrovirus thereof.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of parvoviridae.
  • the virus is a naturally occurring parvovirus such as duck parvovirus or a recombinant parvovirus thereof.
  • the viruses, the related viral vectors, the viral particles and vaccines belong to the family of adenoviridae.
  • the virus is a naturally occurring adenovirus preferably selected among fowl adenovirus, goose adenovirus, duck adenovirus and pigeon adenovirus or a recombinant adenovirus thereof.
  • Fowl adenovirus examples include Fowl adenovirus 1 (CELO), Fowl adenovirus 5 (340), Fowl adenovirus 4 (KR95), Fowl adenovirus 10 (CFA20), Fowl adenovirus 2 (P7-A), Fowl adenovirus 3 (75), Fowl adenovirus 9 (A2-A), Fowl adenovirus 11 (380), Fowl adenovirus 6 (CR1 19), Fowl adenovirus 7 (YR36), Fowl adenovirus 8a (TR59) Fowl adenovirus 8b (764) and Egg Drop Syndrome virus.
  • CELO Fowl adenovirus 1
  • Fowl adenovirus 5 340
  • Fowl adenovirus 4 KR95
  • Fowl adenovirus 10 CFA20
  • Fowl adenovirus 2 P7-A
  • Examples of Goose adenovirus are Goose adenovirus 1 , Goose adenovirus 2, Goose adenovirus 3.
  • Example of Duck adenovirus is Duck adenovirus 2.
  • Example of Pigeon adenovirus is Pigeon adenovirus 1.
  • Recombinant viruses include but are not limited to viral vectors comprising a heterologous gene.
  • a helper function(s) for replication of the viruses is provided by the host cell EBx®, a helper virus, or a helper plasmid.
  • Representative vectors include but are not limited to those that will infect avian or mammalian cells.
  • the instant invention also relates to the use of EBx® cells of the invention to replicate intracellular bacteria such as Chlamydia, Rickettsia or Coxiella.
  • the EBx® cells of the invention may also be used to produce recombinant proteins and peptides.
  • the invention also relates to a method of production of recombinant proteins and peptides, that include the steps of: (i) genetically modifying the EBx® cells of the invention by transient or stable transfection of an expression vector; (ii) optionally, selecting EBx® cells expressing said recombinant proteins or peptides; (iii) and purification of said peptides or proteins.
  • Peptides and proteins produced in EBx® cells are also included in the present invention.
  • the cultivation vessel of the invention is more preferably selected among continuous stirred tank bioreactor, WaveTM Bioreactor, BelloTM bioreactor, spinner flask, flask and a cell factory.
  • cells are scaled-up from a master or working cell bank vial through various sizes of T- flasks, roller bottles or WaveTM Bioreactor and, preferably, finally to bioreactors.
  • the resulting cell suspension is then typically fed into a seed production bioreactor (typically 20-30 L volume) for further cultivation, and in some embodiments, to a larger production bioreactor (typically 150- 180L volume and above).
  • the ratio of volume of the second (larger) bioreactor to the seed bioreactor depends upon the degree to which the cell line is propagated in the first bioreactor, but is typically from 3:1 to 10:1 , e.g., in the range of (6-8):1.
  • the cultivation vessel is a continuous stirred tank bioreactor that allows control of temperature, aeration, pH and other controlled conditions and which is equipped with appropriate inlets for introducing the cells, sterile oxygen, various media for cultivation and outlets for removing cells and media and means for agitating the culture medium in the bioreactor.
  • SFM serum-free medium
  • SFM serum-free medium
  • PF medium protein free medium
  • CDM medium chemically defined medium
  • SFM media present several advantages: (i) the first of all being the regulatory compliance of such media (indeed there is no risk of contamination by adventitious agents such as BSE, viruses); (ii) the optimization of the purification process; (iii) the better reproducibility in the process because of the better defined medium.
  • SFM media examples include: VP SFM (InVitrogen Ref 11681-020, catalogue 2003), Opti Pro (InVitrogen Ref 12309-019, catalogue 2003), Episerf (InVitrogen Ref 10732-022, catalogue 2003), Pro 293 S-CDM (Cambrex ref 12765Q, catalogue 2003), LC17 (Cambrex Ref BESP302Q), Pro CHO 5-CDM (Cambrex ref12-766Q, catalogue 2003), HyQ SFM4CHO (Hyclone Ref SH30515-02), HyQ SFM4CHO-Utility (Hyclone Ref SH30516.02), HyQ PF293 (Hyclone ref SH30356.02), HyQ PF Vera (Hyclone Ref SH30352.02), Excell 293 medium (SAFC Biosciences ref 14570-1000M), Excell 325 PF CHO Protein free medium (SAFC Biosciences ref 14335-1000M), Excell 293 medium
  • the serum-free medium N°1 and the serum-free medium N 0 2 are the same medium.
  • the serum-free medium N°1 and the serum-free medium N°2 have a different composition.
  • the process of the invention encompasses the removal of the whole or a part of serum-free medium 1 , followed by its replacement by serum-free medium N 0 2. However, it is more convenient to remove a substantial fraction (e.g., up to about 50 %) of the serum-free medium 1 and then replenish it with the serum-free medium N 0 2 while still removing medium 1 , e.g., through the spinfilter.
  • serum-free medium N°2 is directly added to serum-free medium N 0 1 without removal of a part of serum-free medium N 0 1. Between 0.25 to 10 volumes of serum-free medium N 0 2 is added to 1 volume of serum-free medium N 0 1.
  • between around 0.5 to 8 volumes of serum-free medium N 0 2 is added to 1 volume of serum-free medium N°1. In a more preferred embodiment, between around 3 to 6 volumes of serum-free medium N 0 2 is added to 1 volume of serum-free medium N 0 1.
  • the serum-free medium N 0 1 and/or the serum-free medium N 0 2 may be supplemented with at least one ingredient selected from the group consisting of amino-acids, lipids, fatty acids, cholesterol, vitamins, carbohydrates, protein hydrolyzates of non-animal origin, and a mixture thereof.
  • the process of replicating a virus of the invention is a fed-batch process that comprises the additional step of feeding the cells with at least one ingredient selected from the group consisting of amino-acids, lipids, vitamins, carbohydrates, protein hydrolyzates of non- animal origin, surfactant and a mixture thereof.
  • the feeding occurs during steps a) to d) of the process of the invention of replicating a virus, alternatively only during the steps b) to d), or alternatively only during the steps d).
  • the feeding may occur either on a daily basis or on a continuous basis.
  • the feeding may occur one time per day, more than one time per day, or less than one time per day.
  • the SFM media of the invention comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell in vitro.
  • additional ingredients are added to SFM media.
  • the choice of amino-acid(s) to add to the cell culture may be determined be an analysis of amino-acids consumption by the cells in the culture; such consumption varies according to cell species.
  • the amino-acids added to the medium may be selected from the group consisting of asparagine and glutamine, or a mixture thereof.
  • glutamine is added for chicken EBx cell culture and the feeding of glutamine is performed during step a) to d) to maintain the glutamine concentration in the medium between around 0.5 mM to around 5 mM, preferably between around 1 mM to around 3 mM, and most preferably around 2 mM.
  • the feeding of glutamine occur on a continuous basis.
  • duck EBx® cells do not consume much glutamine, because duck cells have the ability to synthetize glutamine. Therefore, glutamine may or may not be added for duck EBx cell culture.
  • the carbohydrates added to the medium are selected from the group consisting of D-glucose, D-sucrose and D-galactose or a mixture thereof.
  • the carbohydrate added is D-glucose.
  • the feeding of D-glucose is performed during step a) to d), more preferably between b) to d) to maintain the D-glucose concentration in the medium between around 0.5g/l to 25g/l of D-glucose, preferably between around 1 g/l to 10 g/l of D-glucose, preferably around 2 to 3 g/l of D-glucose.
  • the feeding of D-glucose occur on a continuous basis.
  • the lipids are selected from the group consisting of cholesterol, steroids, and fatty acids such as palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and their derivatives, or a mixture thereof. More preferably the fatty acids are from SIGMA-ALDRICH (Ref. F7050) and around 0.35 ⁇ l/ml of fatty acids solution is added to the culture medium.
  • fatty acids are from SIGMA-ALDRICH (Ref. F7050) and around 0.35 ⁇ l/ml of fatty acids solution is added to the culture medium.
  • the medium may contain auxiliary substances, such as buffer substances like sodium bicarbonate, oxidation stabilizers, stabilizers to counteract mechanical stress, or protease inhibitors.
  • auxiliary substances such as buffer substances like sodium bicarbonate, oxidation stabilizers, stabilizers to counteract mechanical stress, or protease inhibitors.
  • a non-ionic surfactant such as polypropylene glycol (PLURONIC F-61 , PLURONIC F-68, SYNPERONIC F-68, PLURONIC F-71 or PLURONIC F-108) can be added to the medium as a de-foaming agent.
  • PLURONIC F-61 polypropylene glycol
  • PLURONIC F-68 polypropylene glycol
  • SYNPERONIC F-68 PLURONIC F-71 or PLURONIC F-108
  • These agents are generally used to protect cells from the negative effects of aeration since, without an addition of a surfactant, the ascending and bursting air
  • the quantity of nonionic surfactant is preferably between about 0.05 and about 10 g/L, typically between about 0.1 and about 5 g/L.
  • the concentration of surfactant in cell culture medium may be modified to adapt (i.e increase or decrease) the size of the cell clumps.
  • the addition of serum-free medium N 0 2 to the cell culture is performed after infection step b), preferably between around 0.5 to 4 hour after step b), and more preferably around 1 hour after step b).
  • the addition of serum-free medium N 0 2 to the cell culture is performed before infection step b), preferably between around 0.5 to 4 hour after step b), and more preferably around 1 hour before step b).
  • the addition of serum-free medium N 0 2 to the cell culture is performed simultaneously to infection step b.
  • the viral infection of step b) is carried out at an m.o.i (multiplicity of infection) of about 10 to 10 ⁇ 8 , preferably 10 ⁇ 1 to 10 ⁇ 6 , more preferably about 10 ⁇ 2 to 10 ⁇ 5 , and more preferably about 10 ⁇ 4 .
  • the man skilled in the art will determine the optimal m.o.i according to the virus type.
  • the infected cells are preferably cultured during at least 24 h, at least 48 h, at least 72 h, at least 96 h, at least 120 h, at least 144 h. When the virus is a poxvirus, the infected cells are cultured at least 144 h.
  • the cell culture of step a) is carried out by batch culture, repeated batch culture, fed-batch culture or perfusion culture. More preferably, the cell culture of step a) is performed by fed-batch culture.
  • the infection in step b) is performed when the cell density is at least around 4 million, preferably 6 million cells/ml, more preferably 8 million cells/ml in batch or fed-batch process.
  • the infection in step b) is performed when the cell density is of at least at least 8 million cells/ml, preferably around 9 to 10 million cells/ml, or even higher.
  • the pH of the serum-free culture medium in steps a), b), c) and d) is preferably monitored by the bioreactor.
  • the pH shall be in a range from 6.5 to 7.8, preferably around 6.8 to 7.5, and more preferably around 7.2.
  • step d) lasts for 1 to 10 days before the harvest.
  • step d) lasts for 2 to 5 days before the harvest.
  • the time of harvest (step e) is defined according to the cell density in the cultivation vessel. The inventor have now found that the optimal time for harvest the viruses is two days after the density of viable cells have reached its optimal level and have started to decrease because of viral infection.
  • the cell culture is performed at a temperature comprises between 32 0 C to 39 0 C depending of the virus type.
  • cell culture infection is preferably performed at 33 0 C.
  • EBx® cells have the ability to grow in suspension culture with cells clumped in loose aggregates of few cells, up to more than hundred(s) of cells.
  • the size of the clumps may vary according to the composition of cell culture medium.
  • surfactant such as polypropylene glycol (PLURONIC F-61 , PLURONIC F-68, SYNPERONIC F- 68, PLURONIC F-71 or PLURONIC F-108)
  • the stirring the concentration of divalent ions, such as Mg2+ and Ca2+, may have an effect on the clumps size.
  • the viral yield may be increased by allowing the EBx® cells of the invention to aggregate to each others to form clumps during at least step a) of the process.
  • the suspension cells are generally passaged to a larger vessel, either by dilution into fresh medium or by centrifugation followed by a re-suspension of cell pellet into a fresh medium.
  • the inventor has found that during the cells passages, it is recommended to keep large cell clumps into the culture. To do so, it is better not to disrupt cells clumps in order to improve the replication of virus in EBx® cells.
  • step a) in T-flasks or roller-bottles, it is recommended to dilute the cell culture to passage the cells into larger vessel(s), and it is not recommended to centrifuge, nor to disrupt the cells clumps by pipetting or stirring.
  • too large clumps may be suboptimal for a high viral production. Consequently, the man skilled in the art will define whether a partial disruption of the clumps, by pipetting or stirring, during initial cell passages of step a) may improve viral yield.
  • poxviruses and preferably MVA, ALVAC and Fowlpox viruses are obtained by a process of the invention that include the step a) of proliferating clumped EBx® in loose aggregates of few cells, up to more than at least one hundred of cells, at least two hundred of cells, at least five hundred of cells, at least thousand(s) of cells.
  • size of EBx® cells clumps may be dependent of Mg2+ and/or Ca2+ ions concentration in anchorage-independent cell culture medium. Since too large clumps may be suboptimal for a high viral production, the size of clumps may be monitored by adjusting Mg2+ and Ca2+ concentration in cell culture medium.
  • the cell culture medium preferably contain Mg2+ concentration comprises between 0.5 mM and 2.5 mM, preferably around 1.6 mM, and Ca2+ concentration comprises between 0.01 mM and 0.5 mM, preferably around 0.1 mM.
  • the invention also relate to the virus obtainable by a process of the invention.
  • the instant invention also relates to the vaccine containing the virus of the invention.
  • the process of manufacturing a viral vaccine comprises the process of replicating a virus according to the invention wherein the step e) of virus harvest is comprising at least one step selected among filtering, concentrating, freezing and stabilizing by addition of stabilizing agent.
  • the virus harvest is performed according to technologies well-known to the man skilled in the art.
  • the step of harvesting said virus comprises collecting cell culture supernatant obtained from centrifugation of cell culture, then filtering, concentrating, freezing and stabilizing virus preparation by addition of stabilizing agent.
  • the process of manufacturing a viral vaccine according to the invention may also comprise the additional step of inactivation of harvested virus.
  • Inactivation is preferably performed by treatment with formaldehyde, beta-propiolactone, ether, ether and detergent (i.e such as Tween 80TM), cetyl-trimethyl ammonium bromide (CTAB) and Triton N102, sodium deoxycholate and tri(N-butyl)phosphate.
  • the invention also relates to a process of preparation of viral antigenic proteins from the virus obtainable by a process of the invention, said process comprises the additional steps of: a) optionally, incubating cell culture supernatant comprising whole virus with a desoxyribonucleic acid restriction enzyme, preferably DNAses (see EC3.1.21 and EC3.1.22 classification) and nucleases (see EC3.1.30 and EC3.1.31 classification).
  • a desoxyribonucleic acid restriction enzyme preferably DNAses (see EC3.1.21 and EC3.1.22 classification) and nucleases (see EC3.1.30 and EC3.1.31 classification).
  • DNA digestion enzyme is benzonase (Benzon nuclease) or DNase I; b) adjunction of cationic detergent.
  • cationic detergent examples include; without limitation: cetyl-trimethyl ammonium salt such as CTAB, myristyl-trimethyl ammonium salt, lipofectine, DOTMA and TweenTM; c) isolation of antigenic proteins. This latter step may be realized by centrifugation or ultrafiltration.
  • the virus in the vaccine may be present either as intact virus particles, or as disintegrated virus particles.
  • the vaccine is a killed or inactivated vaccine.
  • the vaccine is a live attenuated vaccine wherein said vaccines mainly comprises EBx cell culture supernatant obtainable by the process of the invention, preferably without serum, optionally filtered and/or concentrated and comprising said virus.
  • the vaccine is comprising viral antigenic proteins obtainable from a virus prepared according to the process of the invention.
  • the invention also pertain to provide a vaccine comprising an infected cell line EBx®, preferably duck or ev-0 chicken EBx®, obtainable by the process of the invention, and wherein infected cell line EBx®, preferably preferably duck or ev-0 chicken EBx®, are harvested in step d).
  • infected cell line EBx® preferably duck or ev-0 chicken EBx®
  • the vaccine of the invention may comprise the virus of the invention in combination with pharmaceutically acceptable substances which increase the immune response.
  • substances which increase the immune response comprises incomplete Freund adjuvant, saponine, aluminium hydroxide salts, lysolecithin, plutonic polyols, polyanions, peptides, bacilli Calmette-Guerin (BCG) and corynebacterium parvum.
  • BCG Bacilli Calmette-Guerin
  • Example of synthetic adjuvant is QS-21.
  • immuno-stimulating proteins immuno-stimulating proteins (interleukins 111 , II2, IL3, IL4, IL12, IL13, granulocyte-macrophage-colony-stimulating factor, ...) may be used to enhance the vaccine immune response.
  • the vaccine of the invention is preferably a liquid formulation, a frozen preparation, a dehydrated and frozen preparation, optionally adapted to intra-nasal route of administration.
  • the vaccine of the invention is use for the prophylactic and/or therapeutic treatment of a human or an animal infected by a virus previously listed.
  • the viral vaccine of the invention is preferably use for the prophylactic and/or therapeutic treatment of a human infected by a virus selected among smallpox, influenza, measles, mumps, rubella viruses, RSV.
  • the vaccine of the invention is preferably use for the prophylactic and/or therapeutic treatment of a animal infected by a virus selected among influenza, Newcastle Disease Virus, Egg Drop Syndrome Virus, Infectious Bursal Disease, Infectious Bronchitis Virus, Canine Distemper virus, Chicken Anemia Virus.
  • the recombinant viral vaccine of the invention may also be used for the prophylactic and/or therapeutic treatment of chronic diseases such as cancer and infectious diseases such as AIDS.
  • the EBx® cell lines of the invention are useful to generate and produce re-assorted virus.
  • the virus with a segmented genome such as influenza virus may be re-assorted.
  • a mix of segmented genome from two different strains is present in the same host cell.
  • Specific reassorted virus may thus be isolated by selecting or eliminating, with an antibody for example, virus with a desired traits (See Kilnourne E. D in Plotkin SA and Mortimer E.A. Eds, Vaccines 1994).
  • the EBx® cell lines of the invention are also usefull to generate and produce influenza virus by reverse genetics (See Enami, Proc. Natl. Acad. Sci. USA, 87:3802-3805 (1990); Enami et Palese, J. Virol. 65:2511-2513 (1991 ); Luytjes, Cell 59:1107-1113 (1989)).
  • the present invention also relates to the use of EBx® cell lines of the invention as a cell substrate to perform virus titration.
  • EBx® cells will efficiently in replace current cell system, such as embryonated eggs, CEFs, DF1 cells and others, used to determine the titer of a viral solution.
  • the viral titration is performed by TCID50 method (Reed L, Muench H, 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-97).
  • the present invention also relates to the use of EBx® cell lines of the invention as a cell substrate to perform sanitary testing.
  • the invention also relates to the diagnostic composition containing viruses of the invention or constituents thereof.
  • FIGURE 1 Anchorage-independent chicken EBx cells
  • FIG. 1A Anchorage-independent chicken VaIo EBv13 cells in serum free- medium. EBv13 cells were cultured at 37 0 C in suspension serum-free medium Excell 65319
  • SAFC SAFC
  • EBv13 cells have an homogeneous size and grow in loose clumps into culture.
  • the population doubling time is about 16-18 Hours and the cell density reached in agitated flask vessels were about 4-5 millions cells/ml.
  • FIGURE 1B Anchorage-independent chicken EB Line 0 cells in serum free-medium EB Line 0 cells were cultured at 39 0 C in suspension serum-free medium Excell 66444 (SAFC). EB Line 0 cells have an homogeneous size and grow in loose clumps.
  • FIGURE 2 Chicken VaIo EBv13 cells express high level of Telomerase
  • EBv 13 cells at passage p193 do express high level of telomerase in the same order of magnitude that chicken EB14-O74 cells (see WO03/076601 ) at passage p164 (Master cell Bank: MCB) or at passage p184 (Workin Cell bank: WCB).
  • Murine embryonic stem cells (mES) were used as a positive control and mouse fibroblast (FED) were used as a negative control.
  • FIGURES 3A and 3B Susceptibility of Chicken VaIo EBv13 to poxvirus
  • EBv 13 (passage 188) were seeded at 0.4x106 cells/ml in 10OmL F175 flasks either in 40ml of SFM Excell Medium 65319 or G9916 SFM Medium (SAFC) supplemented with 4mM Glutamine.
  • SAFC SFM Excell Medium
  • the cell growth and infection with MVA-GFP (MOI 10 ⁇ 2 TCID50/cell) were performed at 37 0 C. One hour post infection, 60 ml of fresh medium were added.
  • Figure 3A cell density kinetics in SFM Excell Medium 65319 or G9916 SFM Medium (SAFC).
  • Figure 3B MVA productivity expressed in TCID50/ml in SFM Excell Medium 65319 or G9916 SFM Medium (SAFC).
  • FIGURE 4 Transmission Electronic Microscopy analysis of duck EBx cells
  • Duck EBx cells display a typical embryonic stem cells morphology (i.e high nucleo-cytoplasmic ratio) that resemble the phenotype of murine embryonic stem cells and VIVALIS EB14 cells described in WO2006/108846.
  • Duck EBx cells are small round cells with a large nucleus and nucleolus, with short pseudopodia extending from the plasma membrane. They are highly metabolic active with a ribosome and mitochondria rich cytoplasm.
  • FIGURES 5A and 5B Telomerase expression in duck EBx cell lines
  • telomerase expression during different stages of establishment of duck EBx cells was investigated by using Roche telomerase detection kit (Telomerase OCR ELISA).
  • FIG. 5A Telomerase is found to be highly expressed in different adherent duck EBx cell lines just like in chicken EBv13 cells. Duck epithelial cells used as a negative control do not express telomerase.
  • Figure 5B During the process of establishment of suspension duck EBx cells, high level of telomerase expression is maintained. High level of telomerase were investigated in duck EBx cells during feeder deprivation (with or without feeder cells), during the process of adapting duck EB26 cells to suspension and after serum deprivation of dEB24 et dEB26. Duck EBx cells, such as EB24 and EB26, express high level of telomerase just like chicken EB14 cells. Duck EB66 also express high level of telomerase (Data not shown).
  • FIGURES 6A and 6B Duck EBx® cells display no endogenous reverse transcriptase activity
  • Figure 6A Endogenous reverse transcriptase expression was investigated by direct F- PERT analysis (Lovatt et al., 1999, J. Virol. Methods, 82:185-200) in Clean Cells (FRANCE).
  • Duck EBx® cell lines, EB26 and EB5-1 display no endogenous Reverse Transcriptase (RT) activity. High level of RT activity were detected in chicken EB14 and EBv13 cells culture (at different passages) as well as, to a lesser extend, in chicken embryonic fibroblast (CEF) derived from Specific Pathogen Free (SPF) chicken strain.
  • CEM cells which are RTase negative, were used as a negative control to set the detection limit of the assay.
  • Figure 6B Presence of endogenous retroviral particles, either replicative (i.e replication competent) or non-replicative, in the cell culture supernatant of duck and chicken EBx cells were investigated by an ELISA assay detecting the avian leukosis major capsid antigen P27.
  • EBx cell lines, EB26 and EB5-1 , as well as chicken EBv13 do not secrete ALV p27 antigen. In the opposite, chicken EB 14 cells do express ALV P27 antigen.
  • FIGURES 7A and 7B Duck EBx cells do not secrete replicative avian leucosis virus (ALV) Co-cultivation assay of duck EBx cells with quail QT6 cell line, known to be sensitive to endogenous and exogenous ALVs, were performed in Bioreliance (UK) to detect the presence of endogenous replicative duck viruses.
  • ALV avian leucosis virus
  • FIG. 7A described the principle of QT6 co-culture.
  • Figure 7B The presence of replicative virus is detected by an ELISA assay detecting the avian leukosis major capsid antigen P27.
  • the assay demonstrates that none of duck EBx® cells tested (dEB26 and dEB51 ) secrete replicative ALV.
  • RAV-1 virus which is known to replicate in QT6, were used as a positive control.
  • FIGURE 8 Cell surface expression of receptors SA ⁇ 2-3 and SA ⁇ 2-6 in duck EBx and chicken EB14 cell lines
  • FIGURES 9A and 9B MVA-GFP virus propagation in infected duck EBx cells
  • FIG. 9A Duck EBx® were allowed to form small clumps in T175 stirred tank flasks during cell proliferation in a cell growth SFM medium. Clumps were then infected with 10 ⁇ 2 TCID 50 /cell of MVA-GFP virus and the mixture was diluted in production SFM media. During a 6 days virus propagation period at 37 0 C, pictures of UV-exposed infected cells were taken daily. The pick of MVA infection was reached at day 4 post-infection (pi). At day 6 pi, the infected cells start to die.
  • Figure 9B MVA-GFP virus titration propagated in duck EBx® cells in a 3L fed-batch bioreactor.
  • Duck EBx-derived biomass was allowed to accumulate during cell proliferation phase in Excell growth medium (SAFC).
  • SAFC Excell growth medium
  • cell density reached 4 million cells/ml.
  • Cells were then infected with 10 ⁇ 1 TCID 50 /cell of MVA-GFP virus and the mixture was diluted in 1.5 L Excell medium.
  • samples were collected daily and TCID 50 titration (Right Panel) was performed at the end of the kinetic.
  • a yield of 8.5 log TCID50/ml were reached at 4 p.i. corresponding to a yield of 205 TCID 50 /Cell.
  • FIGURE 10 Influence of Calcium and Magnesium concentration in SFM medium on the size of EBx® cells clumps
  • FIG. 10A Chicken EBv13 cells were first cultured in the SFM medium from SAFC
  • Biosciences that comprise a high concentration of calcium (Ca2+) (Approx. 0.79 mM) and magnesium (Mg2+) ions; in this medium, cells produce large aggregates in culture.
  • the cells form smaller aggregates.
  • FIG 10B Duck EB24, EB26 and EB66 cells were first cultured in the SFM medium from SAFC Biosciences that comprise a high concentration of calcium (Ca2+) (Approx. 0.79 mM) and magnesium (Mg2+) ions; in this medium, cells produce large aggregates in culture.
  • Ca2+ calcium
  • Mg2+ magnesium
  • the cells form smaller aggregates.
  • FIGURES 11A and 11B Production of influenza virus strains A in duck EBx cells in 3L- bioreactors
  • Duck EBx® biomass was allowed to accumulate at 37 0 C during cell proliferation phase in a cell growth medium.
  • Cells were then infected with 10 '4 TCID 50 /cell of A/H1 N1/Beijing/262/95 or A/H3N2/New York/55/2004 influenza virus, the mixture was diluted in 1.5 L Excell production medium supplemented with 0.75 USP/mL of trypsin and temperature was lowered to 33 0 C.
  • samples were collected daily and stored at -8O 0 C.
  • Figure 1 1A Growth kinetic of duck EBx cells infected with A/H1 N1/Beijing/262/95 influenza virus strain
  • Left panel Cell density (rhombus, x10 6 cells. ml '1 ) and viral titer in logTCID 50 /ml.
  • the viral yield reached 20 ug of Hemagglutinin per ml of culture supernatant.
  • Figure 1 1 B Growth kinetic of duck EBx cells infected with A/H3N2/New York/55/2004 influenza virus strain
  • FIGURE 12 Production of influenza virus strain B in duck EBx® cells
  • Duck EBx® biomass was allowed to accumulate at 37 0 C during cell proliferation phase in a cell growth medium. Cells were then infected with 10 3 TCID 50 /cell of B/Jiangsu/10/2003 influenza virus, the mixture was diluted in 1.5 L Excell production medium supplemented with 0.75
  • the viral yield reached 25 ug of Hemagglutinin per ml of culture supernatant.
  • FIGURE 13 Analysis of NDV productivity and viral protein expression in suspension duck EB66 cells (MOI 10 "3 , 0.75 USP/mL trypsin) Duck and chicken EBx cells are sensitive to and replicate NDV La Sota strain. Titers (in TCID50/ml) of NDV produced in duck EB66 cells increase from day 0 to day 2 pi to reach an average of 10 6 83 T ci D5 o/mL ( Figure 13 Left Panel).
  • NDV viral proteins HN, Fo/F, NP & M expression.
  • the viral proteins composition of NDV virus produced in duck EB66 cells are similar to the one obtained with NDV virus produced in chicken EB14 cells.
  • the kinetic of release for viruses produced in chicken and Duck EBx cells are similar.
  • FIGURE 14 Analysis of recombinant Measles virus replication in suspension duck EB66 cells (MOI 10 "1 or 10 "2 ) in tissue-culture flasks in serum free medium.
  • Duck EB66 cells are at least as sensitive as VERO cells to infection by Measles Virus.
  • Titers (in TCID50/ml) of recombinant Measles virus expressing Green Fluorescent Protein (GFP) produced in duck EB66 cells reach 10 7 TCID50/mL at day 6 post-infection.
  • GFP Green Fluorescent Protein
  • FIGURES 15A and 15B SSEA-1, EMA-1 & Telomerase expression in duck EB66 cells Telomerase expression at different passages of duck EB66 cultured in roller bottles was investigated by using Roche telomerase detection kit (Telomerase OCR ELISA). SSEA-1 and EMA-1 at different passages of duck EB66 cultured in roller bottles was investigated by FACS analysis.
  • Figure 15A Telomerase is found to be highly expressed in suspension duck EB66 cell line at different passages (138, 144, 147, 150, 154).
  • Figure 15B SSEA-1 and EMA-1 cell surface markers was found to be highly expressed in suspension duck EB66 cell line at different passages (138, 144, 147, 150, 154).
  • FIGURE 16 Karyotype analysis of duck EB66 cells
  • Duck EB66 cells karyotype was performed by Pr. Franck, ENVL, Lyon. EB66 cells are diploid cells.
  • EXAMPLE 1 chicken EBv13 cell line from SPF chicken strain VALO 1.1 - RAW MATERIAL
  • SPF Eggs Specific Pathogen Free
  • the valo strain is a white Leghorn strain produced and delivered by Lohmann from Germany.
  • Those SPF chicken eggs supplied with a certificate of analysis, are tested for: CAV, Avian adenoviruses (group 1 , serotypes 1-12 and group 3), EDS, Avian Encephalomyelitis Virus, Avian Leukosis Viruses/RSV (including Serotype ALV-J), Avian Nephritis Virus, Avian Reoviruses, Fowlpox Virus, Infectious Bronchitis Virus, Infectious Bursitis Virus (IBDV), Infectious Laryngo Tracheitis Virus, Influenzavirus Typ A, Marek's Disease Virus, Mycoplasmosis (Mg + Ms), Mycobacterium avium, Newcastle Disease Virus, Reticuloendotheliosis Virus, Salmonella pullorum, Other Salmonella Infections, Avi
  • EBv13 cells from murine origin (STO cells) were used as feeder layer to maintain the pluripotency of chicken stem cells.
  • Those feeder cells are mitotically inactivated by gamma irradiation (45 to 55 Grays) before seeding on plastic.
  • This dose of irradiation is a sub-lethal dose that induces a definitive arrest of the cell cycle but still permits the production of growth factors and extracellular matrix, necessary for the promotion of the cell growth of non differentiated cells.
  • the STO cell line was derived by A. Bernstein, Ontario Cancer Institute, Toronto, Canada from a continuous line of SIM (Sandos Inbred Mice) mouse embryonic fibroblasts and it was supplied by the American Type Culture Collection (ATCC) (STO Product number: CRL-1503, Batch number 1198713).
  • Fresh feeder layers were prepared twice a week, in general on monday and thursday. Exponentially cells were dissociated and counted. A part of cells were seeded for maintenance of viable cultures and another part was irradiated. For irradiation, we prepared a cell suspension at 10x10 6 cells/mL in tubes. Cells were exposed to a 45 to 55 grey dose and were seeded on plastic. After seeding, dishes or plates coated with inactivated feeder cells were used during a maximum of 5 days
  • Optipro medium (Invitrogen, Cat n 0 12309)
  • Non essential Amino Acids (Cambrex, Cat n 0 BE13-114E)
  • Vitamines (Cambrex, Cat n 0 13-607C)
  • Beta Mercapto Ethanol (Sigma, Cat n 0 M7522) Buffer and fixators
  • DMSO Dimethyl Sulfoxyde
  • CNTF Human Ciliary Neurotrophic Factor
  • IGF1 Human Insulin Like Factor I
  • Fetal Bovine Serum Non irradiated Fetal Bovin Serum FBS
  • JRH, Cat n 12103
  • the non irradiated serum used in the program was collected and produced in United States. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
  • the irradiated batch used in this program was also collected in United States. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO or FED cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only.
  • Pronase is a recombinant protease manufactured by Roche Diagnostics, Germany, used for the dissociation of adherent avian stem cells.
  • Trypsine is used for the dissociation of STO or FED cells and at late passages for the dissociation of avian cells adapted to Serum Free Medium.
  • This enzyme of porcine origin is manufactured aseptically according to cGMP referential conditions by a validated sterile filtration method and tested according to current E. P.
  • the raw material, irradiated prior to formulation, is tested for porcine parvovirus in strict compliance with 9/CFR 113.53.
  • Non enzymatic cell dissociation solution (Sigma, Cat n° C5914) This agent of dissociation is a ready to use formulation used to gently detach cells from the growing surface of the culture vessel.
  • the formula contains no protein, and allows dislodging of cells without use of enzymes. Cellular proteins are preserved making possible immunochemical studies that are dependent upon the recognition of cell surface proteins.
  • This enzyme was used to detach cell before FACS analysis of biological markers like EMA-1 (Epithelial Membrane Antigen 1 ) and SSEA1 (Stage Specific Embryonic antigen-1 ).
  • the chicken VaIo embryos were placed in a tube containing physiological medium (1X PBS, Tris Glucose, medium, and the like). The VaIo embryos were then mechanically dissociated and inoculated on a layer of feeder STO cells into complete culture medium at 39 0 C. The feeder cells were seeded in flask at around 2.7x10 4 cell/cm 2 .
  • the complete culture medium is composed of basal commercial medium DMEM-Ham F12 supplemented with 10 % fetal calf serum, with IGF1 and CNTF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta-mercapto-ethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM, with an initial mixture of antibiotics containing penicillin at a final concentration of 100 U/ml and streptomycin at a final concentration of 100 ⁇ g/ml. Rapidly after the first passages of the cells, the mixture of antibiotics is no longer added to the medium. The expression rapidly is understood to mean after the first 3 to 5 passages in general.
  • the seeding of culture dishes was performed with around between 7 x 10 4 /cm 2 to 8 x 10 4 /cm 2 of avian ES cells in the complete culture medium.
  • the seeding is made with around 7.3 x 10 4 /cm 2 (4 x 10 6 cells/55cm 2 or 4 x 10 6 cells/100 mm dish).
  • the avian cells, preferably the avian embryonic cells of step a) are cultured during several passages in the complete medium.
  • the complete medium was depleted in growth factors IGF1 and CNTF.
  • the depletion is made directly in one step, from one passage to another.
  • the embryonic stem cells preferably the avian embryonic cells are cultured during several passages in the complete medium without IGF1 and CNTF growth factors.
  • the flask were originally seeded with around 2.7 x10 4 feeder cells/cm 2 , then around 2.2 x 10 4 feeder cells/cm 2 , then around 1.8 x 10 4 feeder cells/cm 2 , then around 1.4 x 10 4 feeder cells/cm 2 , then around 1.1 x 10 4 feeder cells/cm 2 , then around 0.9 x 10 4 feeder cells/cm 2 , then around 0.5 x 10 4 feeder cells/cm 2 . Then the flask were seeded with 6.5 x 10 4 avian cells/cm 2 to 7.5 x 10 4 avian cells/cm 2 and without feeder cells. The depletion of feeder cells started at around passage 21 and ended at around passage 65.
  • the chicken VaIo ES cells were seeded in culture flask at a lower concentration than in step a), about around 4 x 10 4 cell/cm 2 to 5 x 10 4 cell/cm 2 .
  • the avian cells are cultured for additional passages with the same feeder cells concentration before to pursue the feeder cells depletion.
  • the serum depletion were performed after the growth factor and the feeder cells depletion.
  • the culture medium were composed of basal commercial medium DMEM-HamF12 supplemented with 10 % fetal calf serum and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta-mercaptoethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM.
  • the chicken VaIo cells were adapted to the growth in a serum free medium culture in a two steps process: first, the chicken VaIo cells were rapidly adapted to a culture medium composed of commercial serum free medium (SFM), preferably ExCeII 60947 (SAFC Biosciences) supplemented with 10 % fetal calf serum and with 1 % non- essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta-mercaptoethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM.
  • SFM serum free medium
  • ExCeII 60947 SAFC Biosciences
  • a second step consisting of a slow adaptation to decreasing concentration of animal serum in the SFM medium were initiated.
  • Serum depletion was performed by a progressive decreasing starting from 10 % serum, then 7.5 %, then 5 %, then 2.5 %, then 1.25 %, then 0,75 % of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 103 and ended at passage 135.
  • anchorage dependent chicken VaIo cells named EBv13 were able to grow in absence of grow factors, in absence of feeder cells, in serum free medium. EBv13 Cells were then adapted to growth at 37 0 C, by progressively decreasing cell culture temperature of 0.5°C/day.
  • EXAMPLE 2 chicken EB Line 0 cell line from SPF chicken strain ELL-O
  • SPF Chicken Specific Pathogen Free (SPF) strain called ELL-O (East Lansing Line 0) was provided by the Avian Disease and Oncology Laboratory (USDA-ARS-MWA, USA) .
  • Those SPF chicken eggs are produced from a flock tested intensively to various poultry pathogens.
  • Disease tested include: Salmonella pullorum, Salmonella gallinarum, mycoplasma gallisepticum, mycoplasma synoviae, Avian Leukosis virus A-D and J, Marek's disease virus, Reticuloendotheliosis virus, Avian adenovirus, Infectious bronchitis, Infectious bursal disease, Avian Influenza, Newcastle disease, Avian encephalomyelitis and Avian Reovirus.
  • Line 0 chicken eggs were only submitted to a desinfection with the decontaminant to avoid any risk of contamination linked to the manipulation of eggs during transportation.
  • STO cells murine origin
  • Those feeder cells are mitotically inactivated by gamma irradiation (45 to 55 Grays) before seeding on plastic.
  • This dose of irradiation is a sub-lethal dose that induces a definitive arrest of the cell cycle but still permits the production of growth factors and extracellular matrix, necessary for the promotion of the cell growth of non differentiated cells.
  • the STO cell line was derived by A. Bernstein, Ontario Cancer Institute, Toronto, Canada from a continuous line of SIM (Sandos Inbred Mice) mouse embryonic fibroblasts and it was supplied by the American Type Culture Collection (ATCC) (STO Product number: CRL-1503, Batch number 1198713). Fresh feeder layers were prepared twice a week. Exponentially cells were dissociated and counted. A part of cells were seeded for maintenance of viable cultures and another part was irradiated. For irradiation, we prepared a cell suspension at 10x10 6 cells/mL in tubes. Cells were exposed to a 45 to 55 grey dose and were seeded on plastic. After seeding, dishes or plates coated with inactivated feeder cells were used during a maximum of 5 days.
  • DMEM- HamF12 (Cambrex, Cat n 0 BE04-687)
  • Glutamine (Cambrex, Cat n 0 BE17-605E)
  • Pencillin/streptomycin (Cambrex, Cat n 0 BE17-602E)
  • Non essential Amino Acids (Cambrex, Cat n 0 BE13-114E)
  • Beta Mercapto Ethanol (Sigma, Cat n 0 M7522)
  • DMSO Dimethyl Sulfoxyde
  • CNTF Human Ciliary Neurotrophic Factor
  • IGF1 Human Insulin Like Factor I
  • IL6 Human lnterleukin 6
  • SCF Human Stem Cell Factor
  • bFGF Human basic Fibroblast Growth Factor
  • Soluble IL6r is expressed in transfected HEK293 cells.
  • the non irradiated serum used in the program was collected and produced in Australia. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
  • the irradiated batch used in this program was collected in Australia. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO or FED cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only.
  • Dissociating agents • Trypzean ((Sigma, cat n° T3449)
  • Embryos from 13 eggs from Line 0 chicken were collected according to the process described in Exemple 1.2. Then, the Line 0 embryos were placed in a tube containing PBS 1X. Embryos were then mechanically dissociated and inoculated on a layer of feeder STO cells into complete culture medium at 39 0 C. The feeder cells were seeded in dishes at around 2.7x10 4 cell/cm 2 .
  • the complete culture medium is composed of basal commercial medium DMEM-Ham F12 supplemented with 10 % fetal calf serum, with IGF1 , CNTF, bFGF, IL6, IL6r and SCF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta- mercapto-ethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM, with yeastolate 1X and with an initial mixture of antibiotics containing penicillin at a final concentration of 100 U/ml and streptomycin at a final concentration of 100 ⁇ g/ml.
  • basal commercial medium DMEM-Ham F12 supplemented with 10 % fetal calf serum, with IGF1 , CNTF, bFGF, IL6, IL6r and SCF at a
  • the mixture of antibiotics is no longer added to the medium.
  • the seeding of culture dishes was performed with around between 7 x 10 4 /cm 2 to 8 x 10 4 /cm 2 of avian ES cells in the complete culture medium.
  • the seeding is made with around 7.3 x 10 4 /cm 2 (4 x 10 6 cells/55cm 2 or 4 x 10 6 cells/100 mm dish).
  • the avian cells, preferably the avian embryonic cells of step a) are cultured during several passages in the complete medium supplemented with 10 or 15% of FBS.
  • the complete medium was depleted in growth factors bFGF, IL6, IL6r and SCF.
  • the depletion was made directly in one step, from one passage to another.
  • the embryonic stem cells preferably the avian embryonic cells, were cultured during several passages in the complete medium without those 4 growth factors.
  • the 2 last factors IGF1 and CNTF were removed from the medium and cells were amplified without factor.
  • DMEM Ham F12 from passage 1 to passage 18
  • Exell GTM-3 from passage 18 to passage 26
  • Excell 66788 and Excell 66522 after passage 26.
  • Duck eggs from Peking strains GL30 were obtained from GRIMAUD FRERES SELECTION (La Corbiere, Roussay France).
  • the parent ducks were vaccinated against Escherichia CoIi (Autogenous vaccine CoIi 01 & 02), Pasteurella multocida (Landavax), Duck viral hepatitis (Hepatovax), Erysipelothhx rhusiopathiae (Ruvax), Avian metapneumovirus (Nemovac), Salmonella typhimurium & Enteridis (Autogenous vaccine), Riemerella antipestifer (Autovaccine Riemerella), Avian metapneumovirus (Nobilis RTV inactive) and Erysipelothhx rhusiopathiae (Ruvax).
  • fertilized Peking duck eggs were submitted to a disinfection in an hypochloryde bath followed by a decontamination with Fermacidal (Thermo) to avoid
  • STO cells cells from murine origin
  • Those feeder cells are mitotically inactivated by gamma irradiation (45 to 55 Grays) before seeding on plastic.
  • This dose of irradiation is a sublethal dose that induces a definitive arrest of the cell cycle but still permits the production of growth factors and extracellular matrix, necessary for the promotion of the cell growth of non differentiated cells.
  • the STO cell line was derived by A.
  • Glutamine (Cambrex, Cat n 0 BE17-605E)
  • Pencillin/streptomycin (Cambrex, Cat n 0 BE17-602E)
  • Non essential Amino Acids (Cambrex, Cat n 0 BE13-114E) Sodium pyruvate (Cambrex, Cat n°BE13-115 )
  • Vitamines (Cambrex, Cat n 0 13-607C)
  • Beta Mercapto Ethanol (Sigma, Cat n 0 M7522)
  • CNTF Human Ciliary Neurotrophic Factor
  • IGF1 Human Insulin Like Factor I
  • Non irradiated Fetal Bovin Serum (FBS) (JRH, Cat n° 12003)
  • the non irradiated serum used in the program was collected and produced in Australia. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
  • Irradiated serum JRH, Cat n 0 12107
  • the irradiated batch used in this program was collected in United States. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only. Dissociating agents:
  • Pronase is a recombinant protease manufactured by Roche Diagnostics, Germany, used for the dissociation of adherent avian stem cells.
  • Trypsine is used for the dissociation of STO cells and at late passages for the dissociation of avian cells adapted to Serum Free Medium.
  • This enzyme of porcine origin is manufactured aseptically according to cGMP referential conditions by a validated sterile filtration method and tested according to current EP.
  • the raw material, irradiated prior to formulation, is tested for porcine parvovirus in strict compliance with 9/CFR 113.53.
  • Trypzean solution is formulated with a recombinant bovine trypsin, expressed in corn and manufactured by Sigma Aldrich utilizing ProdiGene's proprietary transgenic plant protein expression system. This product is optimized for cell dissociation in both serum free and serum- supplemented adherent cell cultures.
  • This agent of dissociation is a ready to use formulation used to gently detach cells from the growing surface of the culture vessel.
  • the formula contains no protein, and allows dislodging of cells without use of enzymes. Cellular proteins are preserved making possible immunochemical studies that are dependent upon the recognition of cell surface proteins.
  • This enzyme was used to detach cell before FACS analysis of biological markers like EMA-1 (Epithelial Membrane Antigen 1 ) and SSEA1 (Stage Specific Embryonic antigen-1 ).
  • the duck embryos were placed in 50 ml_ tubes containing PBS 1X. The duck embryos were then mechanically dissociated, washed with PBS, and seeded on an inactivated layer of feeder STO cells into complete culture medium at 39 0 C, 7,5 % CO 2 . The feeder cells were seeded in 6 well plates or dishes at around 2,7 x10 4 cell/cm 2 .
  • the complete culture medium is composed of serum free medium DMEM-Ham F12 supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 ⁇ g/ml and yeastolate 1X. Rapidly at the passage 4, the mixture of antibiotics is no longer added to the medium.
  • the duck ES cells were cultured in the DMEM-Ham F12 medium up to passage 4.
  • the base medium is modified and DMEM-Ham F12 complete medium is replaced by the SFM GTM-3 medium supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, at a final concentration of 1 ng/ml, with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM and yeastolate 1X.
  • the duck ES cells were further cultured during 14 passages in this new medium of culture, then growth factors deprivation was performed at passage 18.
  • IGF1 and CNTF were simultaneously removed from the medium, thus from passage 19 to passage 24, the medium of culture was GTM-3 medium supplemented with 10 % FBS, with 1 % non- essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM and yeastolate 1X.
  • the seeding of culture dish was performed with around between 7 x 10 4 /cm 2 to 12 x 10 4 /cm 2 of duck ES cells in the complete culture medium.
  • the dishes were originally seeded with around 2,7 x10 4 feeder cells/cm 2 , then around 1 ,8 x 10 4 feeder cells/cm 2 between passage 25 and 31 , then around 1 ,4 x10 4 cells/cm 2 between passage 32 and 35, then around 1 x 10 4 feeder cells/cm 2 between passage 36 and 41 , then around 0,7 x 10 4 feeder cells/cm 2 between passage 42 and 44, and finally from passage 45 dishes were seeded only with avian cells and without feeder cells.
  • the dishes are seeded with 9 x 10 4 avian cells/cm 2 to 12.7 x 10 4 avian cells/cm 2 .
  • the depletion of feeder cells started at passage 25 and ended at passage 45.
  • the duck ES cells are seeded in culture dishes at a higher concentration than in step a), about around 9 x 10 4 cell/cm 2 to 12.7 x 10 4 cell/cm 2 .
  • PDT Population Doubling Time
  • Density Density
  • the culture medium was Excell 65788 supplemented with 10 % FBS, 2,5 mM glutamine and 1X yeastolate.
  • 4x10 6 cells were transferred in a Ultra Low Attachment (ULA) dish maintained under constant agitation to initiate anchorage- independent cells growth.
  • ULA Ultra Low Attachment
  • the base medium was modified and percentage of serum was decreased from 10 % to 5 % for the seeding in the ULA dish.
  • the medium of culture was SFM GTM-3 supplemented with 5 % FBS, 2.5mM glutamine and 1X yeastolate. Slow decrease of FBS was initiated on EB66 cell suspension after passage 85.
  • Serum depletion was performed by a progressive decreasing starting from 2.5 % serum, then 1 ,5 % of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 86 and ended at passage 94. At the end of serum depletion, anchorage independent dEB66 cells were able to grow at 37 0 C in absence of grow factors, in absence of feeder cells, in serum free medium.
  • suspension duck EB66 cell could also realized in presence or absence of yeastolate EXAMPLE 4: Duck EBx cell line EB26
  • CNTF Human Ciliary Neurotrophic Factor
  • IGF1 Human Insulin Like Factor I
  • IL6 Human lnterleukin 6
  • SCF Stem Cell Factor
  • bFGF Human basic Fibroblast Growth Factor
  • the duck embryos were collected as previously described with EB66.
  • the duck embryos were placed in 50 mL tubes containing PBS 1X.
  • the duck embryos were then mechanically dissociated, washed in PBS, and seeded on an inactivated layer of feeder STO cells into complete culture medium at 39 0 C, 7,5 % CO 2 .
  • the feeder cells were seeded in 6 well plates or dishes at around 2,7 x10 4 cell/cm 2 .
  • the complete culture medium is composed of serum free medium GTM-3 supplemented with 5 % fetal bovine serum, with IGF1 , CNTF, II-6, II-6R, SCF and FGF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 ⁇ g/ml and yeastolate 1X.
  • the duck ES cells were cultured in the complete medium up to passage 9. After passage 9, the complete medium is partially depleted in factors. Thus, between passage 10 and 13, SCF, IL6, IL6r and bFGF were removed for the medium and only recombinant IGF1 and CNTF were maintained at a concentration of 1 ng/mL. A simultaneous decease of concentration of IGF1 and CNTF is secondly performed between passage 13 and 16 to finally obtain cells able to grow without recombinant factors at passage 17. The factor depletion were made by a progressive adaptation to lower concentrations of factors.
  • the seeding of culture dish was performed with around between 7 x 10 4 /cm 2 to 12 x 10 4 /cm 2 of duck ES cells in the complete culture medium.
  • the seeding is made with around 7.3 x 10 4 /cm 2 (4 x 10 6 cells/55cm 2 or 4 x 10 6 cells/100 mm dish).
  • a decrease of yeastolate were performed at passage 23 reaching the final concentration at 0,5X.
  • depletion of feeder cells were performed by a progressive decrease of feeder cells concentration over several passages..
  • the dishes were originally seeded with around 2,7 x10 4 feeder cells/cm 2 , then around 1 ,8 x 10 4 feeder cells/cm 2 between passage 32 and 38, then around 1 ,4 x10 4 cells/cm 2 between passage 39 and 44, then around 1 x 10 4 feeder cells/cm 2 between passage 45 and 47, then around 0,7 x 10 4 feeder cells/cm 2 between passage 48 and 50, and finally from passage 51 dishes were seeded only with avian cells and without feeder cells,.
  • the dishes are seeded with 9 x 10 4 avian cells/cm 2 to 12,7 x 10 4 avian cells/cm 2 .
  • the depletion of feeder cells started at passage 32 and ended at passage 51.
  • the duck ES cells are seeded in culture dishes at a higher concentration than in step a), about around 9 x 10 4 cell/cm 2 to 12,7 x 10 4 cell/cm 2 .
  • growth parameters Population Doubling Time (PDT) and Density
  • PDT Population Doubling Time
  • Density Density
  • the culture medium was supplemented with 5 % FBS, 0,5 X yeastolate and 2,5 mM glutamine only.
  • the serum depletion is performed on cell suspensions already depleted in growth factor, feeder cells, vitamins, non essential amino acids, sodium pyruvate and beta-mercaptoethanol.
  • Serum depletion was performed by a progressive decreasing starting from 5 % serum, then 2.5 %, then 1 ,5 %,of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 61 and ended at passage 79.
  • anchorage independent duck EB26 cells were able to grow at 39 0 C in absence of grow factors, in absence of feeder cells, in serum free medium. EB26 cells were then adapted to growth in absence of 0.5X yeastolate at 37 0 C, by decreasing cell culture temperature at passage 80.
  • EXAMPLE 5 Duck EBx cell line EB24
  • DMEM F12 (Cambrex, Cat n° BE04-687)
  • DMEM (Cambrex, Cat n° BE 12-614F) Factors
  • CNTF Human Ciliary Neurotrophic Factor
  • IGF1 Human Insulin Like Factor I
  • IL6 Human lnterleukin 6
  • SCF Stem Cell Factor
  • bFGF Human basic Fibroblast Growth Factor
  • the duck embryos were collected as previously described with EB66.
  • the duck embryos were placed in 50 mL tubes containing PBS IX.
  • the duck embryos are then mechanically dissociated and seeded on an inactivated layer of feeder STO cells into complete culture medium at 39 0 C, 7,5 % CO 2 .
  • the feeder cells were seeded in 6 well plates or dishes at around 2,7 x10 4 cell/cm 2 .
  • the complete culture medium is composed of serum free medium DMEM-Ham F12 supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, II-6, II-6R, SCF and FGF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 ⁇ g/ml and 1X yeastolate. Rapidly after the first passages of the cells, the mixture of antibiotics is no longer added to the medium. The expression rapidly is understood to mean after the first 3 to 9 passages in general.
  • the duck ES cells are cultured in the DMEM-Ham F12 complete medium up to passage 7.
  • the base medium is modified and DMEM-Ham F12 complete medium is replaced by the GTM-3 complete medium supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, II- 6, II-6R, SCF and FGF at a final concentration of 1 ng/ml, with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 ⁇ g/ml and yeastolate 1X.
  • the serum concentration is decreased at 5 % and SCF, IL6, IL6r and bFGF are removed for the medium.
  • the medium is composed of 5 % FBS, with IGF1 and CNTF at a final concentration of 1 ng/ml_ with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 ⁇ g/ml and yeastolate 1X.
  • a simultaneous withdrawal of IGF1 and CNTF is performed at passage 22. No recombinant factors are present in the GTM-3 culture medium after passage 22. Duck cells were maintained in a such medium between passage 23 and passage 28.
  • the seeding of culture dish was performed with around between 7 x 10 4 /cm 2 to 12 x 10 4 /cm 2 of duck ES cells in the complete culture medium.
  • the seeding is made with around 7.3 x 10 4 /cm 2 (4 x 10 6 cells/55cm 2 or 4 x 10 6 cells/100 mm dish).
  • the dishes were originally seeded with around 2,7 x10 4 feeder cells/cm 2 , then around 1 ,8 x 10 4 feeder cells/cm 2 between passage 29 and 33, then around 1 ,4 x10 4 cells/cm 2 between passage 34 and 37, then around 1 x 10 4 feeder cells/cm 2 between passage 38 and 42, then around 0,7 x 10 4 feeder cells/cm 2 between passage 43 and 46, and finally from passage 47 dishes were seeded only with avian cells and without feeder cells,.
  • the dishes are seeded with 9 x 10 4 avian cells/cm 2 to 12,7 x 10 4 avian cells/cm 2 .
  • the depletion of feeder cells started at passage 29 and ended at passage 47.
  • the duck ES cells are seeded in culture dishes at a higher concentration than in step a), about around 9 x 10 4 cell/cm 2 to 12,7 x 10 4 cell/cm 2 .
  • growth parameters Population Doubling Time (PDT) and Density
  • Cells are considered as enough robust to be submitted to a culture in suspension if, PDT is lower than around 40 hours and cell density higher than around 26 x 10 4 cells/cm 2 . Moreover, cells morphology should be: round, refringent, very small and the cells shall not attached to the plastic dish too much.
  • culture in suspension is initiated at passage 48. 8 x10 6 cells were transferred in a Ultra Low attachment dish and maintained under constant agitation at around 50 to 70 rpm. For the next passages, cells were seeded in T175 flasks (Sarsted, ref 831812502) at a concentration comprise between 0,4 to 0,5x10 6 cells/mL.
  • cell PDT decreased from around 248 H to 128 hours and the next step of deprivation is then performed.
  • vitamines, non essential amino acids, sodium pyruvate and beta mercaptethanol are removed.
  • the serum deprivation was initiated.
  • the culture medium GTM-3 was supplemented with 5 % FBS, 1X yeastolate and 2,5 mM glutamine only. The serum depletion is performed on cell suspensions already depleted in growth factors, feeder cells, vitamins, non essential amino acids, sodium pyruvate and beta- mercaptoethanol.
  • Serum depletion was performed by a progressive decreasing starting from 5 % serum, then 2.5 %, then 2 %, then 1.5 % of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 57 and ended at passage 77. During this serum depletion, adaptation to growth at 37 0 C was also performed. Thus at passage 65, cells growing in the culture medium supplemented with 2,5 % FBS were transferred at 37 0 C avoiding a progressive temperature shift. At the end of serum depletion, anchorage independent duck EB24 cells were able to grow at 37 0 C in absence of grow factors, in absence of feeder cells, in serum free medium.
  • EXAMPLE 6 SPF Duck Muscovy EBx cell line
  • Duck SPF eggs from Muscovy strains were obtained from Le Couvoir de Cerveloup (France). Those SPF duck eggs, are produced from a flock tested intensively to various poultry pathogens. Disease tested include: Salmonella gallinarum-pullorum, Mycoplasma synoviae, Mycoplasma meleagridis, Mycoplasma galliepticum, Marek's disease virus, Avian Influenza, Type 2 Paramyxovirus, Type 3 Paramyxovirus, Newcastle disease, Type 3 Adenovirus (EDS), Gumboro disease, Avian reovirus, Reticuloendotheliosis virus, Avian encephalomyelitis, infectious rhinotracheitis virus and Chlamydiosis. Muscovy duck eggs were only submitted to a disinfection with the decontaminant to avoid any risk of contamination linked to the manipulation of eggs during the transport. Feeder cells (see previous examples) Media
  • Glutamine (Cambrex, Cat n 0 BE17-605E)
  • Pencillin/streptomycin (Cambrex, Cat n 0 BE17-602E))
  • Non essential Amino Acids (Cambrex, Cat n 0 BE13-114E)
  • Vitamines (Cambrex, Cat n 0 13-607C)
  • Beta Mercapto Ethanol (Sigma, Cat n 0 M7522)
  • DMSO Dimethyl Sulfoxyde
  • CNTF Human Ciliary Neurotrophic Factor
  • IGF1 Human Insulin Like Factor I
  • the non irradiated serum used in the program was collected and produced in Australia. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
  • the irradiated batch used in this program was collected in Australia. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only. Dissociating agents: • Pronase (Roche, Cat n° 165 921) • Trypzean (Sigma, cat n° T3449)
  • Embryos from 20 fertilized SPF eggs from Muscovy ducks were collected according to the process described in Example 3. The duck embryos were placed in 50 ml_ tubes containing
  • Embryonic cells were seeded into complete culture medium and transferred at 39 0 C, 7,5%5 %
  • the feeder cells were seeded at around 2,7 x10 4 cell/cm 2 .
  • the complete culture medium used is composed of DMEM-Ham F12 supplemented with 10 % fetal bovine serum, with IGF1 ,
  • CNTF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of
  • the duck ES cells were cultured in the complete GTM-3 medium up to passage 8. After passage 8, concentration of IGF1 and CNTF are reduced to 0,5 ng/mL. The duck ES cells were further cultured during 2 passages in this new medium of culture, then growth factor deprivation was performed at passage 10. IGF1 and CNTF were simultaneously removed from the medium.
  • the medium of culture was GTM-3 medium supplemented with 10 % FBS, with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM and yeastolate 1X.
  • Anchorage-independent Muscovy duck EBx cells express ES cells markers, such as telomerase, SSEA-1 and EMEA-1 (data not shown).
  • EXAMPLE 7 EBx Cell Lines Characterization 7.1 - CHICKEN VALO EBv13 CELLS CHARACTERIZATION
  • Telomerase detection is achieved by using the TeIo TAGGG Telomerase PCR ELISA developed by Roche Applied Science (Telomeric Repeat Amplification Protocol (TRAP) - Cat. No. 1 1 854 666 910 ) according to the supplier protocol.
  • the TeIo TAGGG Telomerase PCR ELISA allows amplification of Telomerase-mediated elongation products combined with non radioactive detection following an ELISA protocol.
  • the assay is valid if absorbance value of the negative control is less than or equal to 0.25 A 450Hm - A 690nm and if absorbance value of the positive control is higher than or equal to 1.5 A 450Hm - A 690nm when using 1 x 10 3 cell equivalents in the assay.
  • telomerase positive if the difference in absorbance is higher than 0,2 A 450Hm - A 690nm units
  • Two controls were used: the negative control is murine fibroblasts (FED cells) and the positive controls are FGB8 cells (Embryonic Stem cells established by Vivalis from 129 SV mouse embryos) and chicken EB14-O74 cells previously established in WO 03/076601. Results obtained are summarized on the figure N°2 .
  • EBv13 cells do express high level of telomerase. At passage p193 and 195, the telomerase activity is equivalent to the one of chicken EB14-074 cells.
  • Embryonic stem cells are characterized by the expression of biological markers expressed on the cell membrane.
  • FED cells mouse fibroblasts cells
  • murine ES FGB8 cells as a positive control
  • chicken EB14-O74 cells as a positive control EBx cells and EBv 13 cells.
  • FED cells do not express biological markers whereas FGB8 and EB14-O74 cells present an important staining, respectively of, 60,13 % and 78,7 for EMA-1 and 94,45 % and 95 % for SSEA-1 (data not shown).
  • Chicken valo EBv 13 cells population do not present any staining for EMA1 (2 %) and a very light one for SSEA-1 (22 %).
  • dEBx® cells Transmission Electronic Microscopy analysis of dEBx® cells were performed by Dr. A Rilude (Lyon, France).
  • Duck EBx® cells display a typical embryonic stem cells morphology (i.e high nucleo-cytoplasmic ratio) that resemble the phenotype of murine embryonic stem cells and VIVALIS EB14 cells described in WO2006/108846.
  • Duck EBx® cells are small round cells (diameter ⁇ 10 ⁇ m) with a large nucleus and nucleolus, with short pseudopodia extending from the plasma membrane ( Figure 4). They are highly metabolic active with a ribosome and mitochondria rich cytoplasm. They contain numerous intracellular vacuoles, a very developed Golgi system and a granulous reticulum endoplasmic.
  • Telomerase expression during different stages of establishment of in duck EBx® cells was investigated by using Roche telomerase detection kit (Telomerase OCR ELISA). Telomerase is found to be highly expressed in adherent duck EBx® cells, as well as during feeder deprivation, during the process of adapting duck EBx® cells to suspension and during feeder deprivation.
  • FIG. 5 shows that duck EB24 and EB26 express high level of telomerase, just like chicken EB14 cells. Duck EB66 also express high level of telomerase all along cell passages. This high telomerase activity is stable in EB66 cells after adaptation in different SFM ( Figure 15). 7.2.3 - Duck EBx® cells display no endogenous reverse transcriptase activity
  • RT activity were detected in chicken EB14 cells culture as well as, to a lesser extend, in chicken Embryonic fibroblast derived from Specific Pathogen Free (SPF) chicken strain.
  • MAA Maackia amurensis
  • Chicken EB14 and duck EBx cells were washed in 1 OmM HEPES, 15OmM NaCI pH7.5 and resuspended in the same buffer at a 5.10 6 final concentration. Cells were incubated 30 min on ice, then for an additional 15 to 30 minutes in presence of SNA or MAA. Lectin treated cells were washed in 1OmM HEPES, 15OmM NaCI pH7.5, prior to incubation on ice during 15 to 30 minutes with FITC-labelled anti-digoxygenin antibody. Then cells are washed in NaCI 0.9 % and
  • Chicken EB14 and duck EBx cells express cell surface receptors comprising oligosaccharides with Sia ⁇ 2-6Gal and Sia ⁇ 2-3Gal residues (Figure 8).
  • Figure 16 shows diploid karyotype of duck EBx66 cells ( Figure 16).
  • EBv13 cells Susceptibility of EBv13 cells to infection with poxvirus was investigated using a recombinant Modified Vaccinia Ankara (MVA) encoding a GFP gene (Green Fluorescent Protein).
  • MVA Modified Vaccinia Ankara
  • Virus infectivity was measured through microscopic observation of global cytopathic effect (CPE) and UV-exposed infected cells. Then, TCID50 titers were calculated according the Reed and Muench method (1938, A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-97). All along the experiment cell proliferation and viability are monitored. Chicken VaIo EBv13 cells appear to be highly sensitive to MVA-GFP infection ( Figures 3A-3B).
  • Duck EBx cells were stored in cryovials in liquid nitrogen at -196 0 C (20x10 6 cells/vial). The cryovial is directly thawed into a +37 0 C pre-warmed water bath. The cell suspension is put into a 50 ml sterile tube with 30 ml pre-warmed culture medium. After centrifugation (5 min at 300 ⁇ 20 g, at room temperature), 15 ml of fresh culture medium is added on the pellet and gently homogenised. The sample is numbered using Trypan blue. Numeration has to be > 20 x10 6 cells and viability has to be > 70 % to guarantee a good culture.
  • the cell suspension is plated into a T75 cm 2 flask and incubate at + 37 0 C under an 7.5 % CO 2 atmosphere on an orbital shaker at 50 rpm. Fresh medium is then added daily. The cells are then passaged to increase cells biomass to seed a 3L-bioreactor. 320.10 6 cells are needed to inoculate a 3L-bioreactor. A sample is taken after gently mixing to perform a numeration using trypan blue to determine cell density. A 150 ml_ cell mix is prepared in order to obtain a cell concentration of 0.4x10 6 cells. ml "1 into the 800 ml final culture volume in the bioreactor.
  • the pH Prior to seed cells, the pH is set in the vessel to 7.2 (because pH will be decrease by CO 2 surface injection).
  • the p ⁇ 2 is set to 50 % O 2 saturation (the mass flow controller is adjusted to 100 % which correspond to a maximum sparger flow rate to 50 ml. min '1 ).
  • the pH is maintained by CO 2 surface injection, later, it is controlled by addition of 7.5 % NaHCO 3 .
  • the surface aeration is started with air at a flow rate of 0.3 ml. min '1 . Cell numeration is performed on a routine basis.
  • cell density should be higher than 4-5 x 10 6 cells. ml "1 .
  • the virus infection is performed at a MOI of 10 ⁇ 4 .
  • the vessel temperature is set to 33 0 C.
  • the virus strain is thawed on ice.
  • the infection mix is prepared in 10 ml of production medium. After inoculation of the infection mix into the bioreactor, viral adsorption is performed during 1 hour.
  • the final production medium is prepared: in 1.5 L of production medium, trypsin is added in order to obtain a final concentration in the vessel of 0.3 U. ml "1 (2.3 L on the whole). The pre-warmed final production medium is then added.
  • a sample of approximatively 15 ml is collected from the bioreactor to perform cell numeration, cell morphology analysis and to observe CPE.
  • the metabolites such as glutamate, glutamine, lactate and glucose are analyzed all along the culture with the BioProfile Basic software. Concentration of the metabolites is adjusted if necessary. For example, glutamine concentration is adjusted to 2 mM if necessary. The glucose concentration is adjusted to 2 g.L "1 if necessary.
  • Virus titration is carried-out at the end of the experiment using all collected samples.
  • Duck EBx® cells are routinely cultured in stirred-tank bioreactor.
  • Duck EBx®-derived biomass is allowed to accumulate at 37 0 C in a cell growth medium until a cell density of 5-6.10 6 cells/mL was reached. Then the mixture is diluted from around 3 to 10 fold, and cell growth kinetic is followed-up over a 10 days period. In such conditions, cell density of 12 to 20 million cells/ml is routinely reached around day 5 to 8.
  • Duck EBx® cells display a range of splitting ratio that goes at least up to 10 to 15 fold.
  • Duck EBx® -derived biomass was allowed to accumulate during cell proliferation phase in Excell 66444 growth medium. Cells were then infected with 10 ⁇ 2 TCID 50 /cell of MVA-GFP virus and the mixture was diluted in Excell 66444 production medium. Following addition of fresh Excell medium, cell density dropped down on day 2, and at day 4, the cell density of infected cells increased and reached 12 million cell/ml. In such conditions, the MVA-GFP productivity is high. Since at day 4 post-infection, the MVA-GFP titer is around 10 8 TCID50/ml ( Figure 9B). A MVA-GFP yield of 205 TCID50/cell was obtained in duck EBx® cells.
  • EXAMPLE 9 Production of Influenza Virus in duck EBx cell lines 9.1 - Materials & Methods
  • the concentration of haemagglutinin in samples derived from influenza virus infected-EB14 cells was determined as described by Wood and colleagues*. Briefly, glass plates were coated with an agarose gel containing anti-Influenza serum (recommended concentration provided by NIBSC). After the gel has set, 10 ⁇ L of appropriate dilutions of the reference and the samples were loaded in 3mm 0 punched wells. Following a 18-24h incubation in a moist chamber at room temperature, plates were soaked in 0.9 % NaCI and washed in distilled water. The gel was then pressed and dried.
  • Blots were blocked for 1 h at room temperature with a mixture composed of 5 % fat dry milkpowder in TBST suplemented with 1 % FCS (SAFC). Then, the blots were incubated overnight in blocking solution supplemented with specific polyclonal anti- HA sheep serum (1 :500 (NIBSC). The blots were washed 6 times with TBST and incubated for 1 h at room temperature with a hrp-conjugated rabbit anti-sheep IgG polyclonal antibody (1 :5000 (Rockland) in blocking solution. After 6 washes with TBST, the protein-conjugate complex was finally revealed using chemiluminescence (ECL kit, Amersham) and films (Hyperfilm, Amersham).
  • chemiluminescence ECL kit, Amersham
  • films Hyperfilm, Amersham
  • Virus titration, haemmaglutinin assays (HAU) and HA antigen quantifications are carry out at the end of the experiment using all collected samples.
  • Duck EBx® cells were grown in Excell medium (SFAC) in T175 flasks at 37 0 C under 7.5 % CO 2 atmosphere on an orbital shaker at 60 rpm. At day 0, cells are seeded at 0.4x10 6 cells/mL in 40 ml fresh medium. Cell culture was incubated at 37 0 C, 7.5 % CO 2 under shaking (60 rpm). Cell growth kinetics were followed until cell density has reached a concentration between 4x10 6 to 6x10 6 cells/ml (usually at day 3 post seeding).
  • SFAC Excell medium
  • cells are inoculated with NDV La Sota strain at two different MOI (10 3 and 10 ⁇ 4 TCID 50 /cells) and incubated for one additional hour at 37 0 C, 7.5 % CO 2 under shaking (60 RPM). Then the cell culture was diluted with the addition of 60 mL fresh viral production medium and the incubation pursued at 37 0 C and 7.5 %CO 2 under shaking (60 rpm). The cell growth and virus production kinetics were performed over 7 days. As a source of protease, recombinant trypsin (SAFC) was added every day in the culture medium; two concentration of trypsin (0.4 and 0.75 USP/mL) were tested. Daily aliquots were removed for cell numeration, virus titration and Western blotting analysis.
  • SAFC recombinant trypsin
  • the samples were separated using 10 % SDS-PAGE and blotted onto PDVF membrane (Amersham) by the semi-dry technique. Immunodetection was performed using chicken polyclonal antiserum against NDV (1 :2000, CHARLES RIVER laboratories), followed by Alkaline phosphatase-conjugated rabbit anti-chicken (1 :5000, SIGMA). Bound secondary antibody was detected using the ECL-Chemiluminescence detection system kit (ROCHE).
  • ROCHE ECL-Chemiluminescence detection system kit
  • NDV viral proteins HN, Fo/F, NP & M expression.
  • the viral proteins composition of NDV virus produced in duck EBx® cells are similar to the one obtained with NDV virus produced in chicken EBx® cells.
  • the kinetic of release for viruses produced in chicken and Duck EBx cells are similar.
  • EXAMPLE 11 Measles Virus Replication in duck EB66 cells
  • EB66 cells were grown in Excell medium in T175 flasks at 37 0 C under 7.5 % CO 2 atmosphere on an orbital shaker at 60 rpm. At day 0, cells are seeded at 0.4x10 6 cells/mL in 40 ml fresh medium. Cell culture was incubated at 37 0 C, 7.5 % CO 2 under shaking (60 rpm). Cell growth kinetics were followed until cell density has reached a concentration between 4x10 6 to 6x10 6 cells/ml (usually at day 3 post seeding).
  • cells are inoculated with recombinant measles virus at two different MOI (10 "1 and 10 ⁇ 2 TCID 50 /cells) and incubated for one additional hour at 37 0 C, 7.5 % CO 2 under shaking (60 RPM). Then the cell culture was diluted with the addition of 60 mL fresh viral production medium and the incubation pursued at 37 0 C and 7.5 %CO 2 under shaking (60 rpm). The cell growth and virus production kinetics were performed over 7 days. Daily aliquots were removed for cell numeration and virus titration.
  • EB66 cells are sensitive to and replicate measles virus.
  • titers (in TCID50/ml) of measles produced in EB66 cells reach an average of 10 7 TCID50/mL ( Figure 14).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

Description

DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES
The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more specifically to the use of duck cell lines derived from embryonic stem cells that are free of avian endogenous retrovirus, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
BACKGROUND
Vaccines effectively reduce and prevent death and disease from many viral infections such as for example flu, measles, mumps, smallpox, yellow fever.
Many viral vaccines are currently produced on embryonated chicken eggs or on primary chicken embryo fibroblasts isolated from chicken embryos. However, vaccine production occasionally has been complicated by inadvertent contamination with adventitious agents that may have originated from avian cell substrates used to propagate vaccine strains. Indeed reverse- transcriptase (RT) activity, an indication of the presence of retroviruses, was detected in chick cell-derived live, attenuated vaccines including those produced by European and US manufacturers for yellow fever, Measles and Mumps (Hussain et al., 2003, J. Virol 77:1105- 1111 ; Johnson et Heneine, 2001 , J. Virol., 75:3605-3612). Investigations of the origin of RT activity in those vaccines found evidence of particles containing RNA from endogenous avian leucosis virus (ALV-E) and endogenous avian virus (EAV) (Johnson et Heneine, 2001 , J. Virol 75:3605-3612; Tsang et al., 1999, J. Virol 73:5843-5851 ; Weissmahr et al., 1997, J. Virol 71 :3005-3012).
Both ALV-E and EAV are members of endogenous retrovirus families present in the chicken germ line. ALV-E are expressed from ev loci, which are inheritable proviral elements. Based on their envelope sequences, ALV-E are differentiated from ALV subgroups A to D and J which are exogenously acquired infections. While exogenous ALVs cause several neoplastic diseases, such as myocarditis and osteopetrosis in infected chickens, ALV-E are not known to be pathogenic to chickens. The lack of oncogenic potential with ALV-E infections may be attributed to the absence of both a viral oncogene and enhancer activity in the endogenous long terminal repeat (LTR). More than 20 different ev loci have been identified in White Leghorn chickens (ev- 1 to ev-22). Ev loci designations are assigned in the order discovered and are phenotypically categorized with regard to the gene products they express and their capacity to generate infectious particles. ALV-E phenotypes conferred by ev loci range from structurally and enzymatically complete infectious particles to structurally or enzymatically (RT-) defective to no detectable viral protein expression. Most ev loci are structurally incomplete and therefore do not encode all sequences necessary for production of infectious virus particles. Chicken strain, named ev-0, has been obtained by breeding to be resistant to ALV-E. Line-0 chickens are lacking ev loci (i.e ev-0) but EAV proviral sequences are present in the genome line 0 chickens (Dunwiddie and Faras, 1985, Proc Natl. Acad. Sci USA, 82: 5097-5101 ).
Little is known about the EAV family, which is distinct from but related to ALV family. EAV elements are present in at least 50 copies per chicken genome. However, none of the known EAV sequences represents full-length and intact retroviral genomes and no infectious EAV isolates have been yet identified. However EAV have been shown to be highly expressed in embryonic cells derived from the avian genus, gallus. Weissmahr et al. (1997, J. Virol 71 :3005- 3012) have shown that particles from the EAV endogenous retrovirus family are most likely responsible for a large portion of the particles-associated RT activity found in the supernatants of cultured chick embryo fibroblasts.
The risk of inadvertent transmission is particularly high for live attenuated virus vaccine since they cannot be subjected to an inactivation procedure and most of them are injected into human, thus by-passing non-specific immune protection mechanisms. Thus, to ensure safety of vaccines for animal and human use, the cell substrates for vaccine production have now to be tested for the presence of replication-competent retroviruses that could be passed to animal or human hosts during immunization (WHO technical reports Series, 1994).
On the other hands, embryonated chicken eggs and primary chicken embryo fibroblasts production systems are associated with several serious limitations, including: a lengthy, cumbersome and resource-consuming manufacturing process that requires the procurement and quality control of large quantities of eggs or CEFs for each individual production campaign; the need in many cases to use costly specific pathogen free (SPF) chicken embryos; the risks of insufficient supply of eggs in cases of epidemic infections in donor chicken flocks; - the inflationist costs associated with the use of bovine sera originating from BSE- exempt countries; the inability to use eggs for the propagation of viruses that are highly virulent and lethal to chickens. There is therefore an urgent need to improve on the current viral vaccines production technologies based on eggs or chicken-embryonic fibroblasts. The development of cell-culture platforms as an alternative to the eggs and CEF production systems for the manufacture of viral vaccines is likely the most rapid and promising solution to overcome current vaccines production bottlenecks and time constrains. Moreover, the use of cell lines for manufacture of viral vaccines, instead of egg or CEF platforms, would have the additional following advantages in connection with the safety of the vaccine: no antibiotic additives present in the vaccine formulation; no toxic preservatives (such as thiomersal) needed; reduced endotoxin levels, no egg allergy issue; no risk of adventitious agent/BSE by cell culture in protein and serum free media; higher purity of virus vaccine preparation.
Examples of cell lines for the production of viral vaccines are MDCK (cells derived from the kidney of Madin-Darby dog), PerC6 (cells derived from human embryonic retinal cells genetically modified by inserting the E1 genes from the human adenovirus type 5) developed by CRUCELL (Netherland)), VERO (cells derived from epithelial cells of kidney from African green monkey (Cercopithecus aethiops) isolate at the Chiba University in Chiba, Japan), BHK21 (Cells immortalized from baby hamster kidney cells). None of the cell lines available fulfil all the medical, regulatory and industrial requirements. For example, most of these cell lines are tumorigenic and there are important regulatory concern about the use of tumorigenic cells for the production of human vaccines; therefore, today the regulatory authorities are reluctant to approve tumorigenic cell substrates to produce mass vaccines. In addition, some of these cell lines are anchorage-dependant, which constitutes a serious hurdle for the industrial scaling-up of the vaccine production.
Therefore, there is a need to develop anchorage-independent cell lines, free of replication competent of retroviruses, that are non-tumorigenic and industrially compliant, which is susceptible to infection with a wide range of viruses. This is the purpose of the instant invention.
Thus, the inventor has taken advantage of its expertise in avian biology and in avian embryonic stem (ES) cells to undertake the development of novel stable duck cell lines that enables the efficient replication of a large group of human and veterinarian vaccines and vaccine candidates. By adapting a proprietary process (see WO 03/076601 and WO 05/007840), the inventor was able to generate a series of well characterized and documented duck cell lines (i.e the dEBx® cells) that are derived from duck ES cells, with no steps of genetic, chemical or viral immortalization and that do not produce replication-competent retroviruses in culture.
DESCRIPTION The instant invention provides a process for obtaining continuous diploid avian cell lines, named EBx, derived from avian embryonic stem cells (ES), wherein said avian cell lines do not produce replication-competent endogenous retrovirus particles.
The cell lines of the invention are "continuous" because they have the characteristics to be cultured in vitro over an extended period of time. Advantageously, the cells of the invention are capable of proliferating for at least 50 generations, at least 75 generations, at least 100 generations, at least 125 generations, at least 150 generations, at least 175 generations, at least 200 generations, at least 250 generations. The 250 generations do not constitute a time limit because the cells obtained are still alive and can still be passaged for additional passages. Without to be bond by a theory, it is postulated that the cells of the invention can be cultured "continuously" as long as telomerase is expressed by the cells. Indeed, it is assumed that the high level of telomerase expression of avian cells of the invention is responsible for genetic stability (i.e avian cells of the invention are diploid) and the continuous cell growth.
By "passage" it is meant the transfer of transplantation of cells, with or without dilution, from one culture vessel to another. It is understood that any time cells are transferred from one vessel to another, a certain portion of the cells may be lost and therefore, dilution of cells, whether deliberate or not, may occur. This term is synonymous with the term 'subculture'. The passage number is the number of times the cells in the culture, that grow either in suspension or in adherence, have been sub-cultured or passed in a new vessel. This term is not synonymous with population doubling or generation which is the time needed by a cell population to replicate one time; that is to say, roughly the time for each cells of a population to replicate. For example, Avian ES cells of step a) of the invention have a population doubling time (PDT) of around > 40 hours. The avian EBx cells of the invention have a PDT of around < 30 hours; usually for EBx® cells, there is one passage every 3 generations.
By "diploid", it is mean that cells of the invention have two copies (2n) of each chromosome, usually one from the mother and one from the father.
The fact that avian EBx® cell lines of the invention are continuous and diploid (i.e genetically stable) constitutes a remarkable and unique feature because these terms are usually antagonist. Thus, cancer cells and/or immortalized cells obtained by chemical, physical (U.V irradiation, X-ray or g-irradiation, ...) or genetic modification (virus transformation, oncogenes overexpression, ...) are continuous cells because they are able to replicate indefinitely into culture, but they are not genetically stable because they display polyploid karyotypes. On the other hand, primary cells such as chicken embryonic fibroblasts, MRC5, WI38 which are non- transformed cells, are not continuous because they have a finite life-span after few generation, but they are genetically stable (i.e diploid) cells. In the present invention, the terms "cell line" and "cells" will be used indistinctly.
The term "avian, "bird", "aves" or "ava" as used herein is intended to have the same meaning, and will be used indistinctly. "Birds" refer to any species, subspecies or race of organism of the taxonomic class « ava ». In a preferred embodiment, "birds" refer to any animal of the taxonomix order:
- "Anseriformes" (i.e duck, goose, swan and allies). The order Anseriformes contains about 150 species of birds in three families: the Anhimidae (the screamers), Anseranatidae (the Magpie- goose), and the Anatidae, which includes over 140 species of waterfowl, among them the ducks, geese, and swans. All species in the order are highly adapted for an aquatic existence at the water surface. All are web-footed for efficient swimming (although some have subsequently become mainly terrestrial).
- "Galliformes" (i.e chicken, quails, turkey, pheasant and allies). The Galliformes is an order of birds containing the chicken, turkeys, quails and pheasants. About 256 species are found worldwide.
- "Columbiformes" (i.e Pigeon and allies). The bird order Columbiformes includes the very widespread doves and pigeons.
In the instant invention, by the term "endogenous retroviral particle" or "endogenous retrovirus particle", terms that could be used indistinctively, it is meant a retroviral particle or retrovirus encoded by and/or expressed from ALV-E or EAV proviral sequences present in some avian cell genomes. In the birds, ALV-E proviral sequences are known to be present in the genome of domestic chicken (except Line-0 chicken), red jungle fowl and Ringneck Pheasant. In the birds,
EAV proviral sequences are known to be present in all genus gallus that includes domestic chicken, Line-0 chicken, red jungle fowl, green jungle fowl, grey jungle fowl, Ceylonese jungle fowl and allies) (see Resnick et al., 1990, J. Virol., 64:4640-4653).
According to a preferred embodiment, the bird of the invention are selected among the birds that does not comprises ALV-E and EAV proviral sequences in its genome. A man skilled in the art is able to determine whether ALV-E and EAV sequences are present in a bird genome (Johnson and Heneine, 2001 ; Weissmahr et al., 1996). Preferably the bird is selected in the group comprising Anseriformes (i.e duck, goose, swan), turkeys, quails, Japanese quail, Guinea fowl, Pea Fowl. Therefore, cells derived from such bird do not produce replication-competent endogenous ALV-E and/or EAV particles. In a preferred embodiment, the bird of the present invention is selected among the group comprising ducks, geese, swans, turkeys, quails and Japanese quails, Guinea Fowls and Pea Fowls. According to a more preferred embodiment, the bird is a duck, more preferably a Pekin or Muscovy ducks. According to a more preferred embodiment, the bird is a Pekin duck. Therefore, the instant invention provides a process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles. According to a second preferred embodiment, the bird of the invention are selected among the birds that does not comprises complete ALV-E proviral sequences in its genome but eventually EAV proviral sequences. A man skilled in the art is able to determine whether partial or complete ALV-E and EAV sequences are present in a bird genome (Johnson and Heneine, 2001 ). Several chicken strains have been selected by breeding that do not contain complete ALV-E proviral sequences (i.e: ev-0 strain) and therefore do not produce infectious ALV-E retroparticles, such as: - Line 0 domestic chicken of East Lansing USDA poultry stock (ELL-O strain). The
East Lansing Line-0 chickens do not contain any endogenous viral (ev) loci related to ALV (Dunwiddie and Faras, 1985). - Lines DE and PE1 1 from lnstitut National de Ia Recherche Agronomique (Domaine de Magneraud, Surgeres, France).
Therefore, cells derived from ev-0 birds do not produce replication-competent endogenous ALV- E particles. According to a preferred embodiment, the bird is an ev-0 domestic chicken (Gallus Gallus subspecies domesticus), preferably selected among ELL-O, DE and PE11.
Usually, ev-0 chickens still contain EAV proviral sequence but so far no infectious EAV isolates have been identified. Therefore, the instant invention provides a process for obtaining continuous diploid chicken cell lines derived from embryonic stem cells (ES) of ev-0 chicken strains, wherein said ev-0 chicken cell lines do not produce replication-competent endogenous retrovirus particles.
According to a third embodiment, the bird of the invention are selected among the birds that comprise complete and/or incomplete ALV-E and EAV proviral sequences in its genome but that are unable to produce replication competent ALV-E and EAV retroparticles. A man skilled in the art is able to determine whether ALV-E and/or EAV infectious and/or non-infectious retroparticles are produced from a bird cells (Johnson and Heneine, 2001 ; Weissmahr et al., 1996). Preferably the bird is selected in the group comprising specific pathogen free (SPF) chicken, preferably from VaIo strain (Lohman) or Line 22 (SPAFAS).
By "replication-competent" it is meant that the endogenous retroviral particles are infectious, that is to say that such retroviral particules are able to infect and to replicate in avian cells of the invention.
The process of establishment of continuous diploid avian cell lines, named EBx®, of the invention comprises two steps: a) isolation, culture and expansion of embryonic stem cells from birds that do not contain complete endogenous proviral sequences, or a fragment thereof, susceptible to produce replication competent endogenous retroviral particles, more specifically EAV and/or ALV-E proviral sequences or a fragment thereof, in a complete culture medium containing all the factors allowing their growth and in presence of a feeder layer and supplemented with animal serum; optionally, said complete culture medium may comprise additives, such as additional amino-acids (i.e glutamine, non essential amino acids...), sodium pyruvate, beta-mercaptoethanol, vitamins, protein hydrolyzate of non- animal origin (i.e yeastolate, plant hydrolyzates (soy, wheat, ...); b) passage by modifying the culture medium so as to obtain a total withdrawal of said factors, said feeder layer and said serum, and optionally said additives, and further obtaining adherent or suspension avian cell lines, named EBx®, that do not produce replication-competent endogenous retrovirus particles, capable of proliferating over a long period of time, in a basal medium in the absence of exogenous growth factors, feeder layer and animal serum.
The modification of the culture medium of step b) of the process of establishment EBx® cell lines, so as to obtain progressive or total withdrawal of growth factors, serum and feeder layer, can be made simultaneously, successively or separately. The sequence of the weaning of the culture medium may be chosen among: feeder layer / serum / growth factors; feeder layer / growth factors / serum; serum / growth factors / feeder layer; serum / feeder layer / growth factors; - growth factors / serum / feeder layer; growth factors / feeder layer / serum.
In a preferred embodiment, the sequence of the weaning is growth factors / feeder layer / serum. In a preferred embodiment, the withdrawal of additives such as sodium pyruvate, non essential amino acids (NNEA), vitamins, yeastolate are performed after the weaning of feeder layer and before the weaning of serum. Preferably, the withdrawal of yeastolate is performed after the withdrawal of sodium pyruvate, NNEA and vitamins.
According to a preferred embodiment, the avian embryonic stem cells according to step a) of the invention are collected from avian embryo at oviposition, that is to say when the egg is laid. According to Sellier et al. (2006, J. Appl. Poult. Res., 15:219-228), oviposition corresponds to the following development stages according to Eyal-Giladi's classification (EYAL-G I LAD I 's classification: EYAL-GILADI and KOCHAN, 1976, « From cleavage to primitive streack formation : a complementary normal table and a new look at the first stages of the development in the chick ». "General Morphology" Dev. Biol. 49:321-337):
Muscovy duck (also called Barbari duck) : stage VII
Guinea fowl: stage VII - VIII - Turkey: stage VII-VIII
Pekin duck: stage VIII
Chicken: Stage X
Japanese Quail: stage Xl
Goose: stage Xl.
Preferably, the duck embryonic stem (ES) cells of step a) are obtained by dissociating Pekin duck embryo(s) at around stage VIII (oviposition) of Eyal-Giladi's classification. If the laid egg collected at oviposition is not enough developed to collect embryonic stem cells, the laid egg may be further incubated between several hours (overnight) to one to two days to mature the embryo. According to a second embodiment the duck embryonic stem (ES) cells of step a) is from a Muscovy duck. At oviposition, Muscovy duck is not enough mature because it is around stage VII, therefore, the egg is incubated overnight to mature the egg up to stage VIII to X of Eyal-Giladi's classification.
Preferably, the chicken embryonic stem (ES) cells, preferably from ev-0 chicken strain, of step a) is obtained by dissociating embryo(s) at around stage X (oviposition) of Eyal-Giladi's classification.
Alternatively, the avian embryonic stem cells according to step a) of the invention are collected from embryo before oviposition. The main limitations encountered before oviposition is the fact that the egg has to be surgically removed from hens and that the amount of ES cells per embryo is less important. Moreover at very early stages of avian embryo development, ES cells are not well individualized rendering difficult in vitro culture of ES cells. A man skilled in the Art will be able to define the timeframe prior egg laying that allows to collect avian ES cells.
Alternatively, the avian embryonic stem cells according to step a) of the invention may be collected from avian embryo after oviposition up to hatching. However, avian embryonic stem cells will progressively enter into differentiation to generate differentiated tissues; therefore, it is preferred to collect avian ES not to long after the lay. A man skilled in the Art will be able to define the timeframe after egg laying that allows to collect avian embryonic stem cells.
According to another embodiment, the cells of step a) are a population of embryonic stem cells enriched in primordial germ cells (PGC). More preferably, the avian ES cells of step a) are purified PGCs. In avian species, Primordial Germ Cells arise from the central region of the blastoderm (Ginsburg and Eyal-Giladi, 1987 Development 101(2):209-19; Karagenc et al, 1996 Dev Genet 19(4):290-301 ; Petitte et al, 1997 Poultry Sci. 76(8): 1084-92). Then they move to an anterior, extra-embryonic site, the germinal crescent until collected by the vasculature between 2.5 and 5 days of embryonic development to reach the germinal ridge. They colonize the germinal ridge where they eventually differentiate into oocytes or spermatocytes (Nieuwkoop and Sutasurya, 1979. The Migration of the primordial germ cells. In: Primordial germ cell in Chordates. London: Cambridge University Press p113-127). Methods for isolation of PGCs from donor avian embryos have been reported in the literature and can easily be performed by one skilled in the art (See, e.g. JP924997 published sept. 7, 1993 Pub. N° 05-227947; Chang et al. 1992. Cell Biol. Int. 19(2): 143-149 ; Naito et al. 1994 MoI. Reprod. Dev. 39: 153-161 ; Yasuda et al. 1992. J. Reprod. Fert. 96: 521-528 ; Chang et al. 1992 Cell Biol. Int. Reporter 16(9): 853- 857). According to an embodiment, PGCs are collected from embryonic blood collected from the dorsal aorta of a chicken embryo at stage 12-14 of Hamburger & Hamilton's classification (Hamburger & Hamilton 1951 A series of normal stages in the development of chick embryo. J. Morphol. 88: 49-92). In another preferred embodiment, PGCs were collected from the germinal crescent by mechanical dissection of chicken embryo or from the gonads. However, as discussed above, others methods for isolating PGCs are known and can alternatively be used.
These avian embryonic stem cells are characterized by a slow doubling time comprises between 48 to 72 hours in culture at 390C.
Without to be bound by a theory, the defined cell culture conditions of avian ES cells followed by the progressive weaning in grow factors, feeder layer, additives and serum, allow to adapt and select cells that maintain most of the desirable feature of ES cells (stability of karyotype, indefinite proliferation, expression of ES markers) but in addition display industrial-friendly characteristics like growth in suspension up to high cell densities in serum-free medium. Telomerase constitutes one of the most important ES markers. Due to the sustained and maintained telomerase expression over the cell passages, EBx® cell are continuous (i.e immortal) but in addition are genetically stable (i.e diploid).
More specifically, the present invention provides a process for obtaining continuous diploid avian cell lines derived from ES cells, wherein said avian cell lines do not produce replication competent endogenous retroviral particles, said process comprising the following steps of: a) isolating bird embryo(s), preferably from duck or from ev-0 chicken, at a developmental stage comprises from around stage Vl of Eyal-Giladi's classification
(EYAL-GILADI's classification: EYAL-GILADI and KOCHAN, 1976, « From cleavage to primitive streack formation : a complementary normal table and a new look at the first stages of the development in the chick ». "General Morphology" Dev. Biol., 49:321-337) and before hatching, preferably around oviposition, wherein the genome of said bird does not contain endogenous proviral sequences susceptible to produce replication competent endogenous retroviral particles; b) suspending avian embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with: - Insulin Growth factor 1 (IGF-1 ) and Ciliary Neurotrophic factor (CNTF);
- animal serum; and
- optionally, growth factors selected in the group comprising interleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF); c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ES cells for at least one passage; d) optionally withdrawing all the growth factors selected from the group comprising IL- 6, IL-6R, SCF, FGF from the culture medium over a range of several passages from 1 to around 15 passages, preferably from 3 to around 15 passages and further culturing the avian ES cells for at least one passage. Preferably, the withdrawing of all the growth factors selected from the group comprising IL-6, IL-6R, SCF, FGF from the culture medium is performed simultaneously over one passage. Usually, the withdrawing of IL- 6, IL-6R, SCF, FGF is performed at around passage 10 to 15; e) withdrawing IGF-1 and CNTF from the culture medium and further culturing the avian ES cells for at least one passage. Preferably, the withdrawing of the growth factors selected from the group comprising IGF-1 and CNTF from the culture medium is performed simultaneously, over one passage. Usually, the withdrawing of IGF-1 and CNTF is performed at around passage N0 15 to N0 25. Alternatively, the withdrawing of IGF-1 and CNTF is performed by progressive decreasing over several passages (at least 2 passages and approximately up to 15 passages); f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of additives in the culture medium so as to obtain a total withdrawal of additives after at least one passage; and, h) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and, i) obtaining adherent avian cell lines, named EBx®, derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum and additives, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; j) optionally, further adapting said adherent avian EBx® cell lines to suspension culture conditions. The step of adaptation of cell culture to suspension can take place all along the process of establishment of EBx® cells. For example, with duck EBx® cells derived from Muscovy embryonic stem cells, the cells were adapted to the growth in suspension prior feeder layer withdrawal. For duck EB® cells (EB24, EB26, EB66) derived from Pekin duck, the cells were adapted to the growth in suspension prior animal serum withdrawal. k) Optionally further subcloning said avian EBx® cells, for example by limit dilution.
In a preferred embodiment, the present invention relates to a process for obtaining continuous diploid avian cell lines, named EBx®, derived from avian embryonic stem cells (ES), wherein said avian cell lines do not produce replication-competent endogenous retrovirus particles, and said process comprising the steps of: a) isolating bird embryo(s) at a developmental stage around oviposition, wherein the genome of said bird does not contain endogenous proviral sequences susceptible to produce replication competent endogenous retroviral particles ; b) suspending avian embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with at least:
- Insulin Growth factor 1 (IGF-1 ) and Ciliary Neurotrophic factor (CNTF); and
- mammalian serum such as foetal bovine serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ES cells for at least one passage; e) withdrawing IGF-1 and CNTF from the culture medium, and further culturing the cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, and further culturing the cells; g) progressively decreasing the concentration of said mammalian serum in the culture medium so as to obtain a total withdrawal of mammalian serum after several passages and: h) obtaining adherent avian EBx® cell lines derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, feeder layer and mammalian serum, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent avian EBx® cell lines to suspension culture conditions, preferably by promoting the growth as suspension, more preferably by transferring the adherent avian EBx® cell lines obtained in step h) in another support having lower attachment characteristic than the initial support (i.e. such as Ultra Low attachment support).
Step j) of adapting adherent avian EBx® cell lines to suspension culture conditions, when carried out, can be effected in another preferred embodiment before the step g) of progressively decreasing the concentration of mammalian serum in the culture medium.
In another preferred embodiment, the basal culture medium in step b) of the process for obtaining continuous diploid avian cell lines according to the present invention, is further supplemented with a growth factor selected in the group comprising interleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF), and the said prcess further comprises a step d) of: d) optionally withdrawing all the growth factors selected from the group comprising IL- 6, IL-6R, SCF, FGF from the culture medium and further culturing the ES cells for at least one passage.
In a more preferred embodiment, when step d) is carried out, the step e) of withdrawing IGF-1 and CNTF from the culture medium, is effected after the step d) of withdrawing all the growth factors selected from the group comprising IL-6, IL-6R, SCF, FGF from the culture medium.
According to the invention, "basal culture medium" meant a culture medium with a classical media formulation that allows, by itself, at least cells survival, and even better, cell growth. Examples of basal media are BME (basal Eagle Medium), MEM (minimum Eagle Medium), medium 199, DMEM (Dulbecco's modified Eagle Medium), GMEM (Glasgow modified Eagle medium), DMEM-HamF12, Ham-F12 and Ham-F10, Iscove's Modified Dulbecco's medium, MacCoy's 5A medium, RPMI 1640, GTM3. Basal medium comprises inorganic salts (for examples: CaCI2, KCI, NaCI, NaHCO3, NaH2PO4, MgSO4, ...), amino-acids, vitamins (thiamine, riboflavin, folic acid, D-Ca panthothenate, ...) and others components such as glucose, beta- mercapto-ethanol, sodium pyruvate. Preferably basal medium is a synthetic medium. Table 1 gives the composition of DMEM / HAM F12:
Table 1 : DMEM-HAM F12 Formulation (mg/l)
Inorganic Salts
Calcium Chloride anhydrous 116.60
Ferric(lll)-Nitrate - 9H2O 0.05
Ferric(ll)-Sulphate • 7H2O 0.417
Potassium Chloride 311.80
Cupric(ll)-Sulphate • 5H2O 0.0013
Magnesium Chloride • 6H2O 61.20
Magnesium Sulphate anhydrous 48.84
Sodium Chloride 6996.00
Sodium Dihydrogen Phosphate • H2O 62.50 Di-Sodium Dihydrogen Phosphate anhydrous 71.02
Zinc Sulphate • 7H2O 0.432
Sodium Hydrogen Carbonate 1200.00
Amino Acids
L-Alanine 4.45
L-Arginine • HCI 147.50
L-Asparagine • H2O 7.50
L-Aspartic Acid 6.65
L-Cystine • HCI • H2O 31.29
L-Cysteine • 2HCI 17.56
L-Glutamic Acid 7.35
L-Glutamine in E15-813 365.00
Glycine 18.75
L-Histidine • HCI • H2O 31.48
L-lsoleucine 54.47
L-Leucine 59.05
L-Lysine « HCI 91.25
L-Methionine 17.24
L-Phenylalanine 35.48
L-Proline 17.25
L-Serine 26.25
L-Threonine 53.45
L-Tryptophan 9.02
L-Tyrosine 38.70
L-Valine 52.85
Vitamins
D(+)-Biotin 0.0035
D-Calcium Pantothenate 2.24
Choline Chloride 8.98
Folic Acid 2.65
Myo-lnositol 12.60 Nicotinamide 2.02
Pyridoxal • HCI 2.00
Pyridoxine • HCI 0.031
Riboflavin 0.219
Thiamine - HCI 2.17
Thymidine 0.365
Vitamin B12 0.68
Other Components
D-Glucose anhydrous 3151.00
Hypoxanthine 2.10
DL-68-Lipoic Acid 0.105
Linoleic Acid 0.042
Phenol Red 8.10
Putrescine • 2HCI 0.081
Sodium Pyruvate 55.00
In addition, basal medium of the invention may be complemented with additives selected in the following group:
- 0.1 to 5 mM L-glutamine, preferably between 2 to 3 mM L-Glutamine; - 0.05 to 2 mM sodium pyruvate, preferably between 0.1 mM to 1 mM sodium pyruvate;
- 0.1 to 2.5 % non-essential amino-acids, preferably around 1 % non-essential amino- acids;
- 0.1 to 2.5% vitamins, preferably around 1 % vitamins
- 0.05 to 5 mM beta-mercapto-ethanol, preferably around 0.16 mM beta-mercapto- ethanol;
- protein hydrolyzate of non-animal origin.
For the establishment of duck EBx® cells of the invention, the basal medium is preferably complemented with protein hydrolyzate of non-animal origin. Protein hydrolyzates of non-animal origin are selected from the group consisting bacteria tryptone, yeast tryptone, plant hydrolyzates, such as soy hydrolyzates, or a mixture thereof. In a preferred embodiment, the protein hydrolyzates of non-animal origin is yeast hydrolyzate. The term "hydrolyzate" includes an enzymatic digest of soy peptone or yeast extract. The hydrolysate can be obtained from a plurality of soy peptone or yeast extract preparations, respectively, which can be further enzymatically digested (for example, by papain), and/or formed by autolysis, thermolysis and/or plasmolysis. Hydrolysates also may be obtained commercially, such as Yeastolate, Hy-Soy, Hy- Yeast 412 and Hi-Yeast 444, from sources such as SAFC BioSciences (formerly JRH) (Lenaxa, KA), Quest International (Norwich, N. Y.), OrganoTechnie S.A. (France) or Deutsche Hefewerke GmbH (Germany). Sources of yeast extracts also are disclosed in WO 98/15614. Sources of yeast extracts and soy hydrolysates also are disclosed in WO00/03000. The hydrolysates used in media of the invention are preferably purified from a crude fraction, because impurities which could interfere with efficient cultivation are preferably eliminated during this purification, thereby improving the consistency of the hydrolysate. Purification can be by ultrafiltration or Sephadex chromatography (for example, with Sephadex G25 or Sephadex G10 or equivalent materials), ion-exchange chromatography, affinity chromatography, size exclusion chromatography or "reversed-phase" chromatography. Preferably, purification is performed by ultrafiltration utilizing a 1OkDa cut-off filter. These processes are known in the field. Using these methods, fractions can be selected which contain soy or yeast hydrolysate of defined molecular weight. Preferably, the average molecular weights of the soy and yeast hydrolysates are preferably between about 220 and 375 daltons. Preferably, yeast hydrolyzate is present in the cell culture medium. Yeast hydrolyzate 5OX (around 200 g/l) obtained for example from SAFC-BIOSCIENCES (Ref 58902C) is present in the cell culture medium at a final concentration comprises between around 0.1X to 2X, preferably around 0.5X to around 1X into the culture medium. Soy hydrolyzate may also be added to the cell culture medium. Soy hydrolyzate 5OX obtained for example from SAFC-BIOSCIENCES (Ref 58903C) is added at a final concentration comprises between around 0.1X to 2X, preferably around 1X into the culture medium. Alternatively a mixture of soy hydrolyzate and yeast hydrolyzate may be added to the cell culture medium as described in US2004/0077086.
According to a preferred basal medium of the invention is DMEM-HamF12 that are complemented with 2 mM L-glutamin, 1 mM sodium pyruvate, 1 % non-essential amino-acids, vitamins 1 %, 0.16 mM beta-mercapto-ethanol, and optionally with 1X yeast hydrolyzate.
By "complete culture medium", it is meant a basal culture medium complemented or not, preferably a basal synthetic medium, supplemented with at least one growth factor and animal serum. Example of complete culture medium is described in WO 03/076601 , WO 05/007840, EP 787180, US 6,114,168, US 5,340,740, US 6,656,479, US 5,830,510 and in Pain et a/. (1996, Development 122:2339-2348). Alternatively, the complete culture medium may a conditioned medium, preferably BRL conditioned medium. By way of example, BRL conditioned media is prepared according to art-recognized techniques, such as described by Smith and Hooper (1987, Dev. Biol. 121 :1-9). BRL cells are available from ATCC accession number CRL-1442. Conditioned medium may be supplemented with exogenous growth factors and animal serum as described below.
The term "growth factors" as used herein meant growth factor necessary for the survival and the growth of the undifferentiated avian ES cells in culture in a basal culture medium. It is possible to schematically distinguish two families of growth factors: the cytokines and the trophic factors. The cytokines are mainly cytokines whose action is through a receptor which is associated with the gp130 protein. Thus, leukemia inhibitory factor (LIF), interleukin 11 , interleukin 6, interleukin 6 receptor, Ciliary Neurotrophic factor (CNTF), oncostatin and cardiotrophin have a similar mode of action with the recruitment at the level of the receptor of a specific chain and the combination of the latter with the gp130 protein in monomeric or sometimes hetero-dimeric form. The trophic factors are mainly Stem cell Factor (SCF), Insulin Growth factor 1 (IGF-1 ) and Fibroblast Growth Factor (FGF), preferably basic FGF (bFGF) or human FGF (hFGF).
The complete culture medium according to the invention comprises basal culture medium, preferably basal synthetic medium, and at least one cytokine whose action is through a receptor which is associated with the gp130 protein and/or at least one trophic factors. Preferably, the complete culture medium according to the invention comprises basal medium and at least one growth factor selected in the group consisting of Leukemia Inhibitory factor (LIF), oncostatin, cardiotrophin, Insulin Growth factor 1 (IGF-1 ), Ciliary Neurotrophic factor (CNTF), lnterleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF), Fibroblast Growth Factor (FGF), interleukin 11 (IL-11 ). According to a first preferred embodiment, the complete culture medium is basal medium supplemented with animal serum and with at least IGF-1 and CNTF. According to a second preferred embodiment, the complete culture medium is basal medium supplemented with animal serum and at least IGF-1 , CNTF, IL-6 and IL-6R. According to a third preferred embodiment, the complete culture medium is basal medium supplemented with animal serum and at least IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF. According to another embodiment, the complete culture medium is a conditioned culture medium comprising growth factors (i.e expressed by BRL or STO cells for example) and optionally supplemented with at least one exogenous growth factors selected in the group comprising: LIF, IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF, IL-11. The concentration of growth factors IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF, IL-11 in the basal medium or in the conditioned culture medium is comprised between about 0.01 to 10 ng/ml, preferably, 0.1 to 5 ng/ml, and more preferably about 1 ng/ml.
The culture medium of the invention may also comprise in addition antibiotics, such as for example, gentamicine, penicilline and streptomycine, to prevent bacterial contamination. Antibiotics may be added to the culture medium at the early passages of ES cells culture. For example, gentamycin at a final concentration of 10 ng/ml, penicillin at a final concentration of 100 U/ml and streptomycin at a final concentration of 100 μg/ml may be added to the culture medium. In a preferred embodiment, no antibiotics is added to the culture medium during the late steps of process of establishment of continuous diploid avian cell lines of the invention.
During the process of establishment of avian embryonic stem cells of the invention, the cells are cultured on a layer of feeder cells. More preferably, feeder cells are animal cells or cell lines cultured for the purpose of culturing avian ES cells. Alternatively, the feeder cells can be substituted with extra-cellular matrix plus bound growth factors. Feeder matrix will thereafter refers to either feeder cells or extra-cellular matrix. A feeder matrix as used herein is constructed in accordance with procedures known in the art. As noted above, it is preferred that the feeder matrix be preconditioned. By the term "preconditioned" it is meant that the feeder matrix is cultured in the presence of media for a period of time prior to the depositing of cells originating from the blastoderm disk fertilized avian eggs in contact with the feeder matrix, e.g. a time sufficient to initiate and establish production of, for example, growth factors or other factors by the feeder matrix; usually a feeder matrix is preconditioned by culturing the feeder matrix by itself for one to two days prior to the depositing of cells originating from the blastoderm disk fertilized avian eggs in contact with the feeder matrix. The feeder cells preferably comprises mouse fibroblast cells. STO fibroblasts are preferred, but primary fibroblasts are also suitable. Also while the present invention has been described with respect to the use of mouse cell feeder matrices, it is contemplated that feeder matrices comprising cells from other murine species (e.g. rat); other mammalian species (e.g; ungulate, bovine, porcine species); or avian species (e.g. Gallinacea, chicken, turkey, duck, goose, quail, pheasant) may also be used. In another embodiment, feeder cells of the invention may be transfected with expression vector(s) allowing for example the constitutive expression of growth factors such as avian SCF in STO cells. Thus, this "feeder" produces the factor in a form which is soluble and/or attached in the plasma membrane of the cells. Thus, the culturing process of the present invention may optionally comprise establishing a monolayer of feeder cells. Feeder cells are mitotically inactivated using standard techniques. For example, the feeder cells may be exposed to X or gamma radiation (e.g. 4000 Rads of gamma radiation) or may be treated with Mitomycin C (e.g. 10 μg/ml for 2-3 hours). Procedures for mitotically inactivating cells are also detailed in the information typically sent with cells from the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 (e.g. STO feeder cells are available under ATCC accession number 1503). Mono-layers may optionally be cultured to about 80 % confluency, preferably to about 90 % confluency, and more preferably about 100 % confluency. While configuration of the feeder cells as a monolayer is the preferred configuration for the culture, any suitable configuration is contemplated to be within the scope of the present invention. Thus, for example, layers, mono-layers, clusters, aggregates or other associations or groupings of feeder cells are contemplated to fall within the scope of the present invention and are particularly contemplated to fall with the meaning of the term "matrix".
The culture medium of the invention is supplemented with animal serum. The animal serum preferably used is fetal animal serum. Fetal bovine serum is preferred. Also while the present invention has been described with respect to the use of fetal bovine serum, it is contemplated that animal serum comprising serum from other animal species (e.g. chicken, horse, porcine, ungulate, etc.) may also be used. The final concentration of animal serum in the culture medium is comprises between approximately 1 to 25 %, preferably between 5 % to 20 %, more preferably between 8% and 12 %. In the preferred embodiment, the final concentration of animal serum in the culture medium is approximately 10 %. According to a preferred embodiment, the culture medium comprises approximately 10 % of fetal calf serum.
In a first preferred embodiment, the bird of the present invention is selected in the Order of
Anseriformes, and is preferably a duck, more preferably a Pekin Duck, and more preferably Pekin duck strain M 14 or GL30. According to a second preferred embodiment, the bird of the present invention is a Muscovy duck. Therefore, the instant invention provides a first process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles, and said process is comprising the steps of: a) isolating duck embryo(s) at oviposition (i.e egg laying), or slightly prior or after oviposition. Optionally, the egg may be incubated, usually overnight, to mature (i.e
Muscovy duck); b) suspending duck embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with Insulin Growth factor 1 (IGF-1 ), Ciliary Neurotrophic factor (CNTF), interleukin 6 (IL-6), interleukin 6 receptor (IL-6R),
Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF) and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the duck ES cells for at least 1 passage; d) withdrawing all the growth factors selected from the group comprising IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the duck ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium, from a passage to another, so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 25 passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and: h) obtaining adherent duck cell lines derived from ES cells, named duck EBx®, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid duck cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent duck cell lines to suspension culture conditions. Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
The animal serum concentration at step b) is preferably of 5 to 10 %. The concentration of with Insulin Growth factor 1 (IGF-1 ), Ciliary Neurotrophic factor (CNTF), interleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF) are preferably of about 1 ng/ml.
The instant invention also provides a second process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles, and said process is comprising the steps of: a) isolating duck embryo(s) at oviposition (i.e egg laying), or slightly prior or after oviposition. Optionally, the egg may be incubated, usually overnight, to mature (i.e Muscovy duck); b) suspending duck embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 , CNTF, IL-6, IL-6R, SCF and FGF and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the duck ES cells for at least 1 passage; d) withdrawing all the growth factors selected from the group comprising IL-6, IL-6R,
SCF, FGF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the duck ES cells for at least one passage; e) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the duck ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 25 passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and h) obtaining adherent duck cell lines derived from ES cells, named duck EBx®, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid duck cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent duck cell lines to suspension culture conditions. Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
The animal serum concentration at step b) is preferably of 5 to 10 %. The concentration of IGF- 1 , CNTF, IL-6, IL-6R, SCF and FGF are preferably of about 1 ng/ml.
The instant invention also provides a third process for obtaining continuous diploid duck cell lines derived from embryonic stem cells (ES), wherein said duck cell lines do not produce replication-competent endogenous retrovirus particles, and said process is comprising the steps of: a) isolating duck embryo(s) at oviposition (i.e egg laying), or slightly prior or after oviposition. Optionally, the egg may be incubated, usually overnight, to mature (i.e Muscovy duck); b) suspending duck embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with Insulin Growth factor 1 (IGF-1 ), and Ciliary Neurotrophic factor (CNTF) and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the duck ES cells for at least 1 passage; d) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the duck ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 25 passages, and further culturing the cells; Removal of additives? g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and, h) obtaining adherent duck cell lines derived from ES cells, named duck EBx®, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent duck EBx® cell lines to suspension culture conditions. Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
The animal serum concentration at step b) is preferably of 5 to 10 %. The concentration of with IGF-1 and CNTF are preferably of about 1 ng/ml.
Once adherent or suspension duck cell lines have been obtained, the process of the invention may also comprises the additional step of adapting, duck EBx® cells to the growth in cell culture medium without protein hydrolyzate of non-animal origin, such as yeast hydrolyzates.
Preferably, duck EBx® cell lines of the invention do not display reverse transcriptase activity by Q-PERT analysis. Moreover, no replication-competent endogenous retrovirus particles is produced by duck EBx® cells as demonstrated by co-culture experiments of duck EBx® cells of the invention with ALV replication competent cells, such as quail QT6 cells or chicken DF1 cells. In addition, transmission electronic microscopy (TEM) analysis also demonstrate the absence of replication-competent endogenous retrovirus particles in duck EBx® cells. Preferably, the duck EBx® cell line of the invention is selected among duck EB24, duck EB26 and duck EB66 as described hereinafter.
In another preferred embodiment, the bird of the present invention is selected in the Order of Galliformes and more preferably is a chicken, preferably an a ev-0 domestic chicken (Gallus Gallus subspecies domesticus). Therefore, the instant invention provides a process for obtaining continuous diploid ev-0 domestic chicken cell lines derived from embryonic stem cells (ES), wherein said ev-0 domestic chicken cell lines do not produce replication-competent endogenous ALV-E retrovirus particles, and said process is comprising the steps of: a) isolating ev-0 domestic chicken embryo(s) at oviposition (i.e egg laying) or slightly prior or after oviposition; b) suspending ev-0 domestic chicken embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 , CNTF, IL-6, IL-6R, SCF and FGF and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ev-0 domestic chicken ES cells for at least 1 passage; d) withdrawing all the growth factors selected from the group comprising IGF-1 , CNTF, IL-6, IL-6R, SCF, FGF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the chicken ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 25 passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages and : h) obtaining adherent ev-0 domestic chicken cell lines derived from ES cells, named EBx ev-0, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous ALV-E retrovirus particles; i) optionally, further adapting adherent avian cell lines EBx ev-0 to suspension culture conditions.
Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
The animal serum concentration at step b) is preferably of 5 to 10 %. The concentration of IGF- 1 , CNTF, IL-6, IL-6R, SCF and FGF are preferably of about 1 ng/ml. The instant invention also provides a second process for obtaining continuous diploid ev-0 domestic chicken cell lines derived from embryonic stem cells (ES), wherein said ev-0 domestic chicken cell lines do not produce replication-competent endogenous ALV-E retrovirus particles, and said process is comprising the steps of: a) isolating ev-0 domestic chicken embryo(s) at oviposition (i.e egg laying) or slightly prior or after oviposition; b) suspending ev-0 domestic chicken embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 ,
CNTF, IL-6, IL-6R, SCF and FGF and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ev-0 domestic chicken ES cells for at least 1 passage; d) withdrawing all the growth factors selected from the group comprising IL-6, IL-6R, SCF, FGF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the chicken ES cells for at least one passage; e) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the ev-0 domestic chicken ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 45 passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages and: h) obtaining adherent ev-0 domestic chicken cell lines derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid ev-0 domestic chicken cell lines, named chicken EBx®, do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent ev-0 domestic chicken cell lines to suspension culture conditions.
Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
The animal serum concentration at step b) is preferably of 5 to 10 %. The concentration of with IGF-1 , CNTF, IL-6, IL-6R, SCF and FGF are preferably of about 1 ng/ml.
The instant invention also provides a third process for obtaining continuous diploid ev-0 domestic chicken cell lines derived from embryonic stem cells (ES), wherein said ev-0 domestic chicken cell lines do not produce replication-competent endogenous ALV-E retrovirus particles, and said process is comprising the steps of: a) isolating ev-0 domestic chicken embryo(s) at oviposition (i.e egg laying) or slightly prior or after oviposition; b) suspending ev-0 domestic chicken embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with IGF-1 and CNTF and animal serum; c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ev-0 domestic chicken ES cells for at least 1 passage; d) withdrawing the growth factors IGF-1 and CNTF from the culture medium over a range of 1 to around 15 passages, preferably simultaneously over one passage, and further culturing the ev-0 domestic chicken ES cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, preferably, after around 5 to around 45 passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and, h) obtaining adherent ev-0 domestic chicken cell lines derived from ES cells, named chicken EBx® ev-0, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid chicken cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent ev-0 domestic chicken cell lines to suspension culture conditions. Additives to basal medium are withdrawn during the process, and preferably between steps f) and g) or between steps g) and h).
The animal serum concentration at step b) is preferably of 5 to 10 %. The concentration of with IGF-1 and CNTF are preferably of about 1 ng/ml.
In another preferred embodiment, the bird of the present invention is a domestic chicken (Gallus Gallus subspecies domesticus) obtained from a specific-pathogen-free (SPF) flock. More preferably, the chicken strain is White-Leghorn. SPF chicken eggs has been screened for the absence of known chicken bacterial pathogens and viruses, including the reticuloendotheliosis virus (REV) and the avian exogenous leucosis virus (ALV-A, ALV-B, ALV-C, ALV-D, ALV-J). The SPF egg of the invention may VALO eggs from LOHMANN (Cuxhaven, Germany) or L22 eggs from CHARLES RIVER (Spafas). Therefore, the instant invention also provides processes for obtaining continuous diploid chicken cell lines derived from embryonic stem cells (ES) obtained from SPF chicken eggs, like described with ev-0 chicken eggs. Preferably, the chicken EBx® cell line obtained from SPF eggs is EBv13.
Chicken EBx® cell lines of the invention may display reverse transcriptase activity by Q-PERT analysis, but without producing replication-competent endogenous retrovirus particles. The absence of replication-competent endogenous retrovirus particles may be demonstrated by co- culture experiments of chicken EBx® ev-0 cells of the invention with ALV replication competent cells, such as quail QT6 cells or chicken DF1 cells. In addition, the absence of endogenous retrovirus particles in chicken EBx® ev-0 cells may be also demonstrate by TEM.
Body temperature of bird is usually around 390C. Therefore, the processes of the invention may also comprise the additional step of decreasing the cell culture temperature to 370C in order to adapt the avian cell lines of the invention to grow at 370C. Preferably, the temperature adaptation is performed after feeder depletion and prior serum depletion. Alternatively, the temperature adaptation is performed after the serum depletion step or after the step of adapting the cell lines to suspension culture.
The established lines EBx® of the invention have the characteristic to grow either as adherent cells or as suspension cells in a culture medium free of exogenous growth factors and animal serum and without feeder cells. Different techniques can be used alone or in combination to adapt cells to suspension culture, among them:
- Adherent cells are seeded at high cell density, slightly above cell confluence to force the cells to go into suspension;
- Adherent cells are seeded in a cell culture medium with a low animal serum concentration;
- Adherent cells are seeded onto cell culture vessels made of plastic that do not allow cell adhesion or a weak cell adhesion, such as bacterial dishes and plates and ultra-low attachment plates developed by companies like Corning (tissue culture dishes & plates Ref. 3262, 3473, 3471 , 3474; Flasks Ref. 3814...) or Sarstedt (Flask ref 831810502...); - Adherent cells are seeded on vessel and cultured under agitation (Approx. 50 rpm) .
The EBx® cells, preferably duck EBx® and chicken EBx® ev-0, can be in vitro cultured over a considerable period of time. Advantageously, the adherent or anchorage-independent (i.e "suspension) EBx® cells obtained by the process of the invention are capable to proliferate for at least 50 generation, at least 75 generation, at least 100 generation, at least 125 generation, at least 150 generation, at least 175 generation, at least 200 generation, at least 250 generation. The expression "line" is understood to mean any population of cells capable of proliferating indefinitely in culture in vitro while retaining to a greater or lesser degree the same morphological and phenotypic characteristics. Clones may be obtained, for example by limit dilution, from EBx® cells of the invention. These clones are cells which are genetically identical to the cell from which they are derived by division.
The present invention also relates to the continuous diploid avian cell lines, named EBx®, obtainable by the process of the invention, said EBx® being small, round (i;e diameter around 10 urn), individualized cells with a doubling time of around 30 hours or less at 370C or 390C. The avian EBx® cells, preferably the duck EBx® or chicken EBx® ev-0, express an embryonic stem cell phenotype with the following characteristics: a high nucleo-cytoplasmic ratio, - an endogenous telomerase activity, optionally, they may express one or more additional ES markers such as alkaline phosphatase, SSEA-1 , EMA-1 , ENS1 markers.
A doubling time shorter than the doubling time of the avian ES cells of step a) of the process of the invention (48h to 72h at 390C), of about 30 hours or less (preferably 24 hours) at 370C.
Said cells do not produce replication competent endogenous retrovirus particles.
The avian EBx® cell lines of the invention are capable of proliferating indefinitely in a basal medium, in particular in a medium such as SAFC Excell media, DMEM, GMEM, DMEM- HamF12 or McCoy, free of exogenous growth factors, serum and/or inactivated feeder layer, optionally complemented with various additives commonly used by persons skilled in the art. Examples of additives are non-essential amino acids, vitamins, sodium pyruvate and antibiotics. Duck EBx® cells of the invention have the remarkable feature to grow in a basal culture medium that is not complemented with glutamine.
The present invention also relates to a cell culture medium to maintain pluri-or multipotent avian embryonic stem cells, preferably pluri-or multipotent duck embryonic stem (ES) cells, into culture in an undifferentiated state. According to a preferred embodiment, the present invention relates to cell culture medium for duck embryonic stem cells comprising a basal culture medium, supplemented with animal serum and supplemented with at least IGF-1 and CNTF. According to a second preferred embodiment, the present invention relates to cell culture medium for duck embryonic stem cells comprising a basal culture medium supplemented with animal serum and supplemented with at least IGF-1 , CNTF, II-6, II-6R. According to a third preferred embodiment, the present invention relates to a cell culture medium for duck embryonic stem cells comprising a basal culture medium supplemented with animal serum and supplemented with at least IGF-1 , CNTF, II-6, II-6R, SCF and FGF. Said media are sufficient for the maintenance of said duck ES cells into culture for at least 7 days, preferably for at least 20 days, preferably for at least 100 days in an undifferentiated state. Said culture media of the invention may further comprise optionally at least one compound selected in the group comprising lnterleukin-11 , cardiotrophin, oncostatin and leukaemia inhibitory factor (LIF). Preferably, said culture media further comprise protein hydrolyzate of non-animal origin as previously described; more preferably it is yeast hydrolyzate at 1X concentration. The culture medium of avian (preferably duck) ES cells of the invention may further comprise a layer of feeder cells.
The instant invention also provide a sustained duck ES cell culture consisting essentially of undifferentiated duck ES cells expressing stem cell phenotype with the following characteristics: a high nucleo-cytoplasmic ratio, an endogenous telomerase activity, - optionally, duck ES cells may express one or more additional ES markers such as alkaline phosphatase, SSEA-1 , EMA-1 , ENS1 markers.
A doubling time of about around than 40 hours at 370C or 390C.
Said undifferentiated duck cells according to the invention are capable of maintaining said stem cell phenotype when grown on feeder cells in a cell culture medium for duck embryonic stem cells as previously described. Said undifferentiated duck cells are useful to produce chimeric or transgenic ducks.
Therefore, the present invention also relates to a method of obtaining chimeric duck, said method comprising the steps of: a) introducing a sustained duck ES cell culture as described above into the sub- germinal cavity of a recipient duck embryo; and b) incubating the embryo obtained in step a) to hatch as a duckling; c) selecting said chimeric duckling comprising heterologous cells having colonized said duckling. The present invention also relates to a method of obtaining genetically modified chimeric duck, comprising the steps of: a) introducing a genetically modified duck ES cells as described above into the sub- germinal cavity of a recipient duck embryo; and b) incubating the embryo obtained in step a) to hatch as a duckling; c) selecting said chimeric duckling comprising genetically modified heterologous cells having colonized said duckling.
The present invention also relates to a method of obtaining a progeny of said chimeric duckling wherein said method comprises the following steps: a) allowing the selected chimeric duckling obtained at steps c) to mature as an adult bird; b) breeding said adult bird having heterologous cells herein, thereby producing a bird progeny; c) selecting the birds of interest in the progeny. The invention may comprise the additional step of expressing an heterologous polypeptide encoded by an expression vector comprised in said genetically modified duck ES cells. Preferably, the heterologous polypeptide is delivered into biological fluid of duck, such as blood, sperm, urine, or the white of a developing avian egg produced by a female of the genetically modified duck.
The EBx® cells of the invention have all the above mentioned characteristics and are useful for the production of biologies such as viral vaccines and recombinant peptides and proteins.
The instant invention also provide a process of replicating a virus in the continuous diploid avian EBx® cell lines of the invention. More preferably, the invention provides a process of replicating a virus in the continuous diploid avian EBx® cell lines of the invention, preferably duck or chicken EBx® cell lines, that comprise the steps of: infecting an avian EBx® cell culture with a virus of interest; said avian EBx® cells being preferably cultured in animal serum free medium; culture of infected avian EBx® cells in order to replicate said virus; harvest the virus in cell culture supernatant and/or inside said cells. According to a preferred embodiment, said process comprises the steps of: a) proliferating said avian EBx® in a cultivation vessel, in suspension, in a serum-free medium N°1 ; b) infecting said cells with the selected virus when the cell density is of at least 1.5 million cells/ml; c) optionally, shortly before infection, simultaneously to infection, or shortly after infection adding to the cell culture serum-free medium N0 2; and d) further culturing said infected cells in order to allow virus replication; and e) optionally, harvesting said virus.
Said process of the invention may comprise the additional step of adding proteolytic enzyme in the culture medium in conditions that allow virus propagation. The proteolytic enzyme is selected from the group consisting of trypsin, chymotrypsine, thermolysine, pepsine, pancreatine, papaϊne, pronase, subtilisine A, elastase, furine and carboxypeptidase. According to a preferred embodiment, the enzyme is trypsin. Preferably, the proteolytic enzyme is a recombinant protein produced on a procaryotic host or on plants (i.e: trypzean). The proteolytic enzyme may added before, during and/or after the virus infection. Preferably, the addition of proteolytic enzyme is performed after virus infection. The addition of proteolytic enzyme in the culture medium may be performed one time per day, more than one time per day, or less than one time per day until the virus harvest.
The term "virus" as used herein includes not only naturally occurring viruses but also attenuated viruses, reassortant viruses, vaccine strains, as well as recombinant viruses and viral vectors derived thereof. The virus of the invention are preferably selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnavriruses and retroviruses.
In a preferred embodiment, the viruses, the related viral vectors, viral particles and viral vaccines belong to the family of poxviridae, and more preferably to the chordopoxviridae. In one embodiment, the virus or the related viral vectors, viral particles and viral vaccines are a poxvirus, preferably an avipoxvirus selected among fowlpox virus (i.e TROVAC), canarypox virus (i.e ALVAC), juncopox virus, mynahpox virus, pigeonpox virus, psittacinepox virus, quailpoxvirus, sparrowpoxvirus, starling poxvirus, turkeypox virus. According to another preferred embodiment, the virus is a vaccinia virus selected among Lister-Elstree vaccinia virus strain, modified vaccinia virus such as Modified Vaccinia virus Ankara (MVA) which can be obtained from ATCC (ATCC Number VR-1508), NYVAC (Tartaglia et al., 1992, Virology, 188:217-232), LC16m8 (Sugimoto et Yamanouchi, 1994, Vaccine, 12:675-681 ), CVI78 (Kempe et al., 1968, Pediatrics 42:980-985) and other recombinant or non-recombinant vaccinia virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of ortho-myxoviridae, in particular influenza virus. The influenza virus is selected from the group consisting of human influenza virus, avian influenza virus, equine influenza virus, swine influenza virus, feline influenza virus. Influenza virus is preferably selected in strains A, B and C. Among strains A, one can recite viruses with different subtypes of haemagglutinin and neuraminidase, such as without limitation H1 N1 , H2N2, H3N2, H4N2, H4N6, H5N1 , H5N2, H7N7 et H9N2. Among H1 N1 strains, one can recite A/Porto Rico/8/34, A/New Caledonia/20/99, A/Beijing/262/95, A/Johannesburg/282/96, A/Texas/36/91 , A/Singapore, A/Solomon lslands/03/2006. Among strains H3N2, one can recite A/Panama/2007/99, A/Moscow/10/99, A/Johannesburg/33/94, A/Wisconsin/10/04. Among B strains, one can recite without limitation B/Porto Rico/8/34, B/Johannesburg/5/99, BΛ/ienna/1/99, B/Ann Arbor/1/86, B/Memphis/1/93, B/Harbin/7/94, N/Shandong/7/97, B/Hong Kong/330/01 , B/Yamanashi/166/98, B/Jiangsu/10/03, B/Malaysia. The influenza Virus of the invention is selected among wild type virus, primary viral isolate obtained from infected individual, recombinant virus, attenuated virus, temperature sensitive virus, low-temperature adapted virus, reassortant virus, reverse genetic engineered virus. When the virus of the invention is influenza virus, the process of the invention comprises the additional step of adding proteolytic enzyme in the culture medium in conditions that allow virus propagation. According to a preferred embodiment, the enzyme is trypsin. The final concentration of trypsin in cell culture medium is comprises between around 0.01 μg/ml up to 10 μg/ml. More preferably, the final concentration of trypsin in cell culture medium is comprised between 0.01 to 10 usp/ml (usp: US pharmacopea unit) preferably around between 0.05 to 2 usp/ml, more preferably around between 0.3 to 1 usp/ml and more preferably around 0.75 usp/ml.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of paramyxoviridae. Preferably the virus is a naturally occuring paramyxovirus or a recombinant paramyxovirus selected in the group comprising measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human parainfluenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, duck para-influenza virus. According to preferred embodiment, the virus is measles virus or a recombinant measles virus. According to another preferred embodiment, the virus is Newcastle Disease virus (NDV) or a recombinant NDV. Example of NDV strain is LaSota strain. When the virus of the invention is NDV, the process of the invention comprises preferably the additional step of adding proteolytic enzyme in the culture medium in conditions that allow virus propagation. According to a preferred embodiment, the enzyme is trypsin. The final concentration of trypsin in cell culture medium is comprises between around 0.01 μg/ml up to 10 μg/ml. More preferably, the final concentration of trypsin in cell culture medium is comprised between 0.01 to 10 usp/ml (usp: US pharmacopea unit) preferably around between 0.3 to 1 usp/ml, more preferably around between 0.4 to 0.75 usp/ml. Interestingly, the EBx® cell lines of the invention that may grow in adherence are useful to perform virus titration, and preferably NDV titration, on a plaque assay. Indeed, unlike CEFs and chicken DF1 fibroblasts for which is was not possible to observe any cytopathic effects, virus growth in EBx® cells leads to the formation of characteristic giant cells. In addition, NDV viral particles may be determined by haemagglutination assay. Therefore, the invention also pertain to the use of EBx® cells of the invention for the titration of virus, such as NDV virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of togaviridae. Preferably the virus is a naturally occurring alphavirus or a recombinant alphavirus selected in the group comprising Sinbis virus, Semliki forest virus, O'nyong'nyong virus, Chikungunya virus, Mayaro virus, Ross river virus, Eastern equine encephalitis virus, Western Equine encephalitis virus, Venezuelan Equine encephalitis virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of herpesviridae. Preferably the virus is a naturally occuring Marek Disease virus or a recombinant Marek Disease virus. The Marek Disease virus (MDV) is preferably selected among the license vaccine strains of MDV such as : FC126 (HTV), SB-1 , 301 B/1 , CVI988 Clone C, CV1988/C/R6, CVI988/Rispens, R2/23 (Md 11/75). In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of hepadnaviridae. Preferably the virus is a naturally occuring naturally occuring hepadnavirus or a recombinant hepadnavirus, preferably selected among avian and human hepadnavirus. The avian hepadnavirus is preferably selected among the group consisting of duck hepatitis B virus (DHBV), heron hepatitis B virus (HHBV) and snow goose (SGHBV).
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of birnaviridae, in particular Infectious Bursal Disease virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of flaviviridae, in particular Dengue virus, Japanese encephalitis virus and West Nile virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of coronaviridae, in particular Infectious Bronchitis virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of circoviridae, in particular Chicken Anemia virus.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of retroviridae. Preferably the virus is a naturally occurring retrovirus selected among reticulo-endotheliosis virus, duck infectious anemia virus, suck spleen necrosis virus, or a recombinant retrovirus thereof.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of parvoviridae. Preferably the virus is a naturally occurring parvovirus such as duck parvovirus or a recombinant parvovirus thereof.
In another preferred embodiment, the viruses, the related viral vectors, the viral particles and vaccines belong to the family of adenoviridae. Preferably the virus is a naturally occurring adenovirus preferably selected among fowl adenovirus, goose adenovirus, duck adenovirus and pigeon adenovirus or a recombinant adenovirus thereof. Examples of Fowl adenovirus are Fowl adenovirus 1 (CELO), Fowl adenovirus 5 (340), Fowl adenovirus 4 (KR95), Fowl adenovirus 10 (CFA20), Fowl adenovirus 2 (P7-A), Fowl adenovirus 3 (75), Fowl adenovirus 9 (A2-A), Fowl adenovirus 11 (380), Fowl adenovirus 6 (CR1 19), Fowl adenovirus 7 (YR36), Fowl adenovirus 8a (TR59) Fowl adenovirus 8b (764) and Egg Drop Syndrome virus. Examples of Goose adenovirus are Goose adenovirus 1 , Goose adenovirus 2, Goose adenovirus 3. Example of Duck adenovirus is Duck adenovirus 2. Example of Pigeon adenovirus is Pigeon adenovirus 1. Recombinant viruses include but are not limited to viral vectors comprising a heterologous gene. In some embodiments, a helper function(s) for replication of the viruses is provided by the host cell EBx®, a helper virus, or a helper plasmid. Representative vectors include but are not limited to those that will infect avian or mammalian cells.
The instant invention also relates to the use of EBx® cells of the invention to replicate intracellular bacteria such as Chlamydia, Rickettsia or Coxiella.
The EBx® cells of the invention may also be used to produce recombinant proteins and peptides. The invention also relates to a method of production of recombinant proteins and peptides, that include the steps of: (i) genetically modifying the EBx® cells of the invention by transient or stable transfection of an expression vector; (ii) optionally, selecting EBx® cells expressing said recombinant proteins or peptides; (iii) and purification of said peptides or proteins. Peptides and proteins produced in EBx® cells are also included in the present invention.
The cultivation vessel of the invention is more preferably selected among continuous stirred tank bioreactor, Wave™ Bioreactor, Bello™ bioreactor, spinner flask, flask and a cell factory. Typically, cells are scaled-up from a master or working cell bank vial through various sizes of T- flasks, roller bottles or Wave™ Bioreactor and, preferably, finally to bioreactors. The resulting cell suspension is then typically fed into a seed production bioreactor (typically 20-30 L volume) for further cultivation, and in some embodiments, to a larger production bioreactor (typically 150- 180L volume and above). The ratio of volume of the second (larger) bioreactor to the seed bioreactor depends upon the degree to which the cell line is propagated in the first bioreactor, but is typically from 3:1 to 10:1 , e.g., in the range of (6-8):1. According to a preferred embodiment, the cultivation vessel is a continuous stirred tank bioreactor that allows control of temperature, aeration, pH and other controlled conditions and which is equipped with appropriate inlets for introducing the cells, sterile oxygen, various media for cultivation and outlets for removing cells and media and means for agitating the culture medium in the bioreactor.
According to the present invention, "serum-free medium" (SFM) meant a cell culture medium ready to use, that is to say that it does not required animal serum addition allowing cells survival and cell growth. This medium is not necessary chemically defined, and may contained hydrolyzates of various origin, from plant or yeast for instance. Preferably, said SFM are "non animal origin" qualified, that is to say that it does not contain components of animal or human origin (FAO status: "free of animal origin"). In SFM, the native serum proteins are replaced by recombinant proteins. Alternatively SFM medium according to the invention does not contain protein (PF medium: "protein free medium") and/or are chemically defined (CDM medium: "chemically defined medium"). SFM media present several advantages: (i) the first of all being the regulatory compliance of such media (indeed there is no risk of contamination by adventitious agents such as BSE, viruses); (ii) the optimization of the purification process; (iii) the better reproducibility in the process because of the better defined medium. Examples of commercially available SFM media are: VP SFM (InVitrogen Ref 11681-020, catalogue 2003), Opti Pro (InVitrogen Ref 12309-019, catalogue 2003), Episerf (InVitrogen Ref 10732-022, catalogue 2003), Pro 293 S-CDM (Cambrex ref 12765Q, catalogue 2003), LC17 (Cambrex Ref BESP302Q), Pro CHO 5-CDM (Cambrex ref12-766Q, catalogue 2003), HyQ SFM4CHO (Hyclone Ref SH30515-02), HyQ SFM4CHO-Utility (Hyclone Ref SH30516.02), HyQ PF293 (Hyclone ref SH30356.02), HyQ PF Vera (Hyclone Ref SH30352.02), Excell 293 medium (SAFC Biosciences ref 14570-1000M), Excell 325 PF CHO Protein free medium (SAFC Biosciences ref 14335-1000M), Excell VPRO medium (SAFC Biosciences ref 14560-1000M), Excell 302 serum free medium (SAFC Biosciences ref 14312-1000M), Excell 65319, Excell 65421 , Excell 65625, Excell 65626, Excell 65627, Excell 65628, Excell 65629 (JRH Biosciences), Excell MDCK SFM (SAFC-Biosciences Ref. 14581 C), Excell MDCK Prod (Ref. M3678), Gene Therapy Medium 3 (animal component free) (SIGMA-Aldrich, ref. G-9916 or Excell GTM-3) (hereinafter named G9916 medium), HYQ CDM4 HEK-293 (Hyclone Ref. SH30859), HYQ SFM4 HEK-293 (HYCLONE Ref. SH30521 ), AEM (InVitrogen). According to the first preferred embodiment, the serum-free medium N°1 and the serum-free medium N0 2 are the same medium. According to a second preferred embodiment the serum-free medium N°1 and the serum-free medium N°2 have a different composition.
The process of the invention encompasses the removal of the whole or a part of serum-free medium 1 , followed by its replacement by serum-free medium N0 2. However, it is more convenient to remove a substantial fraction (e.g., up to about 50 %) of the serum-free medium 1 and then replenish it with the serum-free medium N0 2 while still removing medium 1 , e.g., through the spinfilter. According to a preferred embodiment, serum-free medium N°2 is directly added to serum-free medium N0 1 without removal of a part of serum-free medium N0 1. Between 0.25 to 10 volumes of serum-free medium N0 2 is added to 1 volume of serum-free medium N0 1. In a preferred embodiment, between around 0.5 to 8 volumes of serum-free medium N0 2 is added to 1 volume of serum-free medium N°1. In a more preferred embodiment, between around 3 to 6 volumes of serum-free medium N0 2 is added to 1 volume of serum-free medium N0 1.
The serum-free medium N0 1 and/or the serum-free medium N0 2 may be supplemented with at least one ingredient selected from the group consisting of amino-acids, lipids, fatty acids, cholesterol, vitamins, carbohydrates, protein hydrolyzates of non-animal origin, and a mixture thereof. Alternatively, the process of replicating a virus of the invention is a fed-batch process that comprises the additional step of feeding the cells with at least one ingredient selected from the group consisting of amino-acids, lipids, vitamins, carbohydrates, protein hydrolyzates of non- animal origin, surfactant and a mixture thereof. According to a first preferred embodiment, the feeding occurs during steps a) to d) of the process of the invention of replicating a virus, alternatively only during the steps b) to d), or alternatively only during the steps d). The feeding may occur either on a daily basis or on a continuous basis. When the feeding is discontinuous, the feeding may occur one time per day, more than one time per day, or less than one time per day.
The SFM media of the invention comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell in vitro. However, in order to improve cell growth or viral productivity, additional ingredients are added to SFM media.
The choice of amino-acid(s) to add to the cell culture may be determined be an analysis of amino-acids consumption by the cells in the culture; such consumption varies according to cell species. According to a preferred embodiment, the amino-acids added to the medium may be selected from the group consisting of asparagine and glutamine, or a mixture thereof. In a more preferred embodiment, glutamine is added for chicken EBx cell culture and the feeding of glutamine is performed during step a) to d) to maintain the glutamine concentration in the medium between around 0.5 mM to around 5 mM, preferably between around 1 mM to around 3 mM, and most preferably around 2 mM. In a preferred embodiment, the feeding of glutamine occur on a continuous basis. Interestingly, duck EBx® cells do not consume much glutamine, because duck cells have the ability to synthetize glutamine. Therefore, glutamine may or may not be added for duck EBx cell culture.
According to a preferred embodiment, the carbohydrates added to the medium are selected from the group consisting of D-glucose, D-sucrose and D-galactose or a mixture thereof. According to a more preferred embodiment, the carbohydrate added is D-glucose. The feeding of D-glucose is performed during step a) to d), more preferably between b) to d) to maintain the D-glucose concentration in the medium between around 0.5g/l to 25g/l of D-glucose, preferably between around 1 g/l to 10 g/l of D-glucose, preferably around 2 to 3 g/l of D-glucose. In a preferred embodiment, the feeding of D-glucose occur on a continuous basis.
According to a preferred embodiment, the lipids are selected from the group consisting of cholesterol, steroids, and fatty acids such as palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and their derivatives, or a mixture thereof. More preferably the fatty acids are from SIGMA-ALDRICH (Ref. F7050) and around 0.35 μl/ml of fatty acids solution is added to the culture medium.
The medium may contain auxiliary substances, such as buffer substances like sodium bicarbonate, oxidation stabilizers, stabilizers to counteract mechanical stress, or protease inhibitors. If required, a non-ionic surfactant, such as polypropylene glycol (PLURONIC F-61 , PLURONIC F-68, SYNPERONIC F-68, PLURONIC F-71 or PLURONIC F-108) can be added to the medium as a de-foaming agent. These agents are generally used to protect cells from the negative effects of aeration since, without an addition of a surfactant, the ascending and bursting air bubbles can lead to damage of those cells that are located on the surface of these air bubbles ("sparging"). The quantity of nonionic surfactant is preferably between about 0.05 and about 10 g/L, typically between about 0.1 and about 5 g/L. According to another embodiment of the invention, the concentration of surfactant in cell culture medium may be modified to adapt (i.e increase or decrease) the size of the cell clumps.
According to an embodiment of the process of replicating a virus of the invention, the addition of serum-free medium N0 2 to the cell culture, is performed after infection step b), preferably between around 0.5 to 4 hour after step b), and more preferably around 1 hour after step b). According to another embodiment of the invention, the addition of serum-free medium N0 2 to the cell culture, is performed before infection step b), preferably between around 0.5 to 4 hour after step b), and more preferably around 1 hour before step b). According to another embodiment of the invention, the addition of serum-free medium N0 2 to the cell culture, is performed simultaneously to infection step b. The viral infection of step b) is carried out at an m.o.i (multiplicity of infection) of about 10 to 10~8, preferably 10~1 to 10~6, more preferably about 10~2 to 10~5, and more preferably about 10~4. The man skilled in the art will determine the optimal m.o.i according to the virus type. In step c), the infected cells are preferably cultured during at least 24 h, at least 48 h, at least 72 h, at least 96 h, at least 120 h, at least 144 h. When the virus is a poxvirus, the infected cells are cultured at least 144 h.
In the process of the invention, the cell culture of step a) is carried out by batch culture, repeated batch culture, fed-batch culture or perfusion culture. More preferably, the cell culture of step a) is performed by fed-batch culture. The infection in step b) is performed when the cell density is at least around 4 million, preferably 6 million cells/ml, more preferably 8 million cells/ml in batch or fed-batch process. When a perfusion process is used, the infection in step b) is performed when the cell density is of at least at least 8 million cells/ml, preferably around 9 to 10 million cells/ml, or even higher.
The pH of the serum-free culture medium in steps a), b), c) and d) is preferably monitored by the bioreactor. The pH shall be in a range from 6.5 to 7.8, preferably around 6.8 to 7.5, and more preferably around 7.2. In the process of the invention, step d) lasts for 1 to 10 days before the harvest. According to a preferred embodiment, step d) lasts for 2 to 5 days before the harvest. The time of harvest (step e) is defined according to the cell density in the cultivation vessel. The inventor have now found that the optimal time for harvest the viruses is two days after the density of viable cells have reached its optimal level and have started to decrease because of viral infection.
The cell culture is performed at a temperature comprises between 320C to 390C depending of the virus type. For influenza virus and poxvirus production, cell culture infection is preferably performed at 330C.
EBx® cells have the ability to grow in suspension culture with cells clumped in loose aggregates of few cells, up to more than hundred(s) of cells. Without to be bind by a theory, the size of the clumps may vary according to the composition of cell culture medium. For example, presence of surfactant such as polypropylene glycol (PLURONIC F-61 , PLURONIC F-68, SYNPERONIC F- 68, PLURONIC F-71 or PLURONIC F-108), the stirring, the concentration of divalent ions, such as Mg2+ and Ca2+, may have an effect on the clumps size. The inventor has now found that the viral yield may be increased by allowing the EBx® cells of the invention to aggregate to each others to form clumps during at least step a) of the process. During the scaling-up from the master and working cell bank vial through the various sizes of T-flasks or roller-bottles to bioreactors, the suspension cells are generally passaged to a larger vessel, either by dilution into fresh medium or by centrifugation followed by a re-suspension of cell pellet into a fresh medium. The inventor has found that during the cells passages, it is recommended to keep large cell clumps into the culture. To do so, it is better not to disrupt cells clumps in order to improve the replication of virus in EBx® cells. For example, during the initial phases of culture of step a) in T-flasks or roller-bottles, it is recommended to dilute the cell culture to passage the cells into larger vessel(s), and it is not recommended to centrifuge, nor to disrupt the cells clumps by pipetting or stirring. However, too large clumps may be suboptimal for a high viral production. Consequently, the man skilled in the art will define whether a partial disruption of the clumps, by pipetting or stirring, during initial cell passages of step a) may improve viral yield. According to a preferred embodiment, poxviruses, and preferably MVA, ALVAC and Fowlpox viruses are obtained by a process of the invention that include the step a) of proliferating clumped EBx® in loose aggregates of few cells, up to more than at least one hundred of cells, at least two hundred of cells, at least five hundred of cells, at least thousand(s) of cells.
The inventors have found that size of EBx® cells clumps, preferably duck EBx® cells clumps, may be dependent of Mg2+ and/or Ca2+ ions concentration in anchorage-independent cell culture medium. Since too large clumps may be suboptimal for a high viral production, the size of clumps may be monitored by adjusting Mg2+ and Ca2+ concentration in cell culture medium. For duck EBx® cells, the cell culture medium preferably contain Mg2+ concentration comprises between 0.5 mM and 2.5 mM, preferably around 1.6 mM, and Ca2+ concentration comprises between 0.01 mM and 0.5 mM, preferably around 0.1 mM.
The invention also relate to the virus obtainable by a process of the invention. The instant invention also relates to the vaccine containing the virus of the invention. The process of manufacturing a viral vaccine comprises the process of replicating a virus according to the invention wherein the step e) of virus harvest is comprising at least one step selected among filtering, concentrating, freezing and stabilizing by addition of stabilizing agent. The virus harvest is performed according to technologies well-known to the man skilled in the art. According to a preferred embodiment, the step of harvesting said virus comprises collecting cell culture supernatant obtained from centrifugation of cell culture, then filtering, concentrating, freezing and stabilizing virus preparation by addition of stabilizing agent. For example, for influenza virus see Furminger, In Nicholson, Webster and Hay (Eds) Textbook of influenza, chapter 24 pp324- 332.
The process of manufacturing a viral vaccine according to the invention may also comprise the additional step of inactivation of harvested virus. Inactivation is preferably performed by treatment with formaldehyde, beta-propiolactone, ether, ether and detergent (i.e such as Tween 80™), cetyl-trimethyl ammonium bromide (CTAB) and Triton N102, sodium deoxycholate and tri(N-butyl)phosphate.
According to another embodiment, the invention also relates to a process of preparation of viral antigenic proteins from the virus obtainable by a process of the invention, said process comprises the additional steps of: a) optionally, incubating cell culture supernatant comprising whole virus with a desoxyribonucleic acid restriction enzyme, preferably DNAses (see EC3.1.21 and EC3.1.22 classification) and nucleases (see EC3.1.30 and EC3.1.31 classification). Preferably, DNA digestion enzyme is benzonase (Benzon nuclease) or DNase I; b) adjunction of cationic detergent. Examples of cationic detergent are; without limitation: cetyl-trimethyl ammonium salt such as CTAB, myristyl-trimethyl ammonium salt, lipofectine, DOTMA and Tween™; c) isolation of antigenic proteins. This latter step may be realized by centrifugation or ultrafiltration.
The virus in the vaccine may be present either as intact virus particles, or as disintegrated virus particles. According to an embodiment, the vaccine is a killed or inactivated vaccine. According to another embodiment, the vaccine is a live attenuated vaccine wherein said vaccines mainly comprises EBx cell culture supernatant obtainable by the process of the invention, preferably without serum, optionally filtered and/or concentrated and comprising said virus. According to a third embodiment, the vaccine is comprising viral antigenic proteins obtainable from a virus prepared according to the process of the invention.
The invention also pertain to provide a vaccine comprising an infected cell line EBx®, preferably duck or ev-0 chicken EBx®, obtainable by the process of the invention, and wherein infected cell line EBx®, preferably preferably duck or ev-0 chicken EBx®, are harvested in step d).
The vaccine of the invention may comprise the virus of the invention in combination with pharmaceutically acceptable substances which increase the immune response. Non limitating examples of substances which increase the immune response comprises incomplete Freund adjuvant, saponine, aluminium hydroxide salts, lysolecithin, plutonic polyols, polyanions, peptides, bacilli Calmette-Guerin (BCG) and corynebacterium parvum. Example of synthetic adjuvant is QS-21. In addition, immuno-stimulating proteins (interleukins 111 , II2, IL3, IL4, IL12, IL13, granulocyte-macrophage-colony-stimulating factor, ...) may be used to enhance the vaccine immune response.
The vaccine of the invention is preferably a liquid formulation, a frozen preparation, a dehydrated and frozen preparation, optionally adapted to intra-nasal route of administration.
The vaccine of the invention is use for the prophylactic and/or therapeutic treatment of a human or an animal infected by a virus previously listed. Preferably, the viral vaccine of the invention is preferably use for the prophylactic and/or therapeutic treatment of a human infected by a virus selected among smallpox, influenza, measles, mumps, rubella viruses, RSV. Alternatively, the vaccine of the invention is preferably use for the prophylactic and/or therapeutic treatment of a animal infected by a virus selected among influenza, Newcastle Disease Virus, Egg Drop Syndrome Virus, Infectious Bursal Disease, Infectious Bronchitis Virus, Canine Distemper virus, Chicken Anemia Virus. The recombinant viral vaccine of the invention may also be used for the prophylactic and/or therapeutic treatment of chronic diseases such as cancer and infectious diseases such as AIDS.
The EBx® cell lines of the invention are useful to generate and produce re-assorted virus. The virus with a segmented genome, such as influenza virus may be re-assorted. When infecting simultaneously EBx® cells of the invention with at least two different strains of influenza virus, a mix of segmented genome from two different strains is present in the same host cell. During virus assembly, all combination of genomic segments can theoretically be generated. Specific reassorted virus may thus be isolated by selecting or eliminating, with an antibody for example, virus with a desired traits (See Kilnourne E. D in Plotkin SA and Mortimer E.A. Eds, Vaccines 1994). The EBx® cell lines of the invention are also usefull to generate and produce influenza virus by reverse genetics (See Enami, Proc. Natl. Acad. Sci. USA, 87:3802-3805 (1990); Enami et Palese, J. Virol. 65:2511-2513 (1991 ); Luytjes, Cell 59:1107-1113 (1989)).
The present invention also relates to the use of EBx® cell lines of the invention as a cell substrate to perform virus titration. EBx® cells will efficiently in replace current cell system, such as embryonated eggs, CEFs, DF1 cells and others, used to determine the titer of a viral solution. Preferable the viral titration is performed by TCID50 method (Reed L, Muench H, 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-97).
The present invention also relates to the use of EBx® cell lines of the invention as a cell substrate to perform sanitary testing.
The invention also relates to the diagnostic composition containing viruses of the invention or constituents thereof.
The examples below explain the invention in more detail. The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. The present invention, however, is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only, and methods which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. For the remainder of the description, reference will be made to the legend to the figures below.
FIGURES
FIGURE 1 : Anchorage-independent chicken EBx cells
Figure 1A: Anchorage-independent chicken VaIo EBv13 cells in serum free- medium. EBv13 cells were cultured at 370C in suspension serum-free medium Excell 65319
(SAFC). EBv13 cells have an homogeneous size and grow in loose clumps into culture. The population doubling time is about 16-18 Hours and the cell density reached in agitated flask vessels were about 4-5 millions cells/ml.
Figure 1B: Anchorage-independent chicken EB Line 0 cells in serum free-medium EB Line 0 cells were cultured at 390C in suspension serum-free medium Excell 66444 (SAFC). EB Line 0 cells have an homogeneous size and grow in loose clumps. FIGURE 2: Chicken VaIo EBv13 cells express high level of Telomerase
EBv 13 cells at passage p193 do express high level of telomerase in the same order of magnitude that chicken EB14-O74 cells (see WO03/076601 ) at passage p164 (Master cell Bank: MCB) or at passage p184 (Workin Cell bank: WCB). Murine embryonic stem cells (mES) were used as a positive control and mouse fibroblast (FED) were used as a negative control.
FIGURES 3A and 3B: Susceptibility of Chicken VaIo EBv13 to poxvirus
EBv 13 (passage 188) were seeded at 0.4x106 cells/ml in 10OmL F175 flasks either in 40ml of SFM Excell Medium 65319 or G9916 SFM Medium (SAFC) supplemented with 4mM Glutamine. The cell growth and infection with MVA-GFP (MOI 10~2 TCID50/cell) were performed at 370C. One hour post infection, 60 ml of fresh medium were added.
Figure 3A: cell density kinetics in SFM Excell Medium 65319 or G9916 SFM Medium (SAFC).
Figure 3B: MVA productivity expressed in TCID50/ml in SFM Excell Medium 65319 or G9916 SFM Medium (SAFC).
FIGURE 4: Transmission Electronic Microscopy analysis of duck EBx cells
Transmission Electronic Microscopy analysis of dEBx cells were performed by Dr. A Rivoire (Lyon, France). Duck EBx cells display a typical embryonic stem cells morphology (i.e high nucleo-cytoplasmic ratio) that resemble the phenotype of murine embryonic stem cells and VIVALIS EB14 cells described in WO2006/108846. Duck EBx cells are small round cells with a large nucleus and nucleolus, with short pseudopodia extending from the plasma membrane. They are highly metabolic active with a ribosome and mitochondria rich cytoplasm.
FIGURES 5A and 5B: Telomerase expression in duck EBx cell lines
Telomerase expression during different stages of establishment of duck EBx cells was investigated by using Roche telomerase detection kit (Telomerase OCR ELISA).
Figure 5A: Telomerase is found to be highly expressed in different adherent duck EBx cell lines just like in chicken EBv13 cells. Duck epithelial cells used as a negative control do not express telomerase.
Figure 5B: During the process of establishment of suspension duck EBx cells, high level of telomerase expression is maintained. High level of telomerase were investigated in duck EBx cells during feeder deprivation (with or without feeder cells), during the process of adapting duck EB26 cells to suspension and after serum deprivation of dEB24 et dEB26. Duck EBx cells, such as EB24 and EB26, express high level of telomerase just like chicken EB14 cells. Duck EB66 also express high level of telomerase (Data not shown).
FIGURES 6A and 6B: Duck EBx® cells display no endogenous reverse transcriptase activity Figure 6A: Endogenous reverse transcriptase expression was investigated by direct F- PERT analysis (Lovatt et al., 1999, J. Virol. Methods, 82:185-200) in Clean Cells (FRANCE). Duck EBx® cell lines, EB26 and EB5-1 , display no endogenous Reverse Transcriptase (RT) activity. High level of RT activity were detected in chicken EB14 and EBv13 cells culture (at different passages) as well as, to a lesser extend, in chicken embryonic fibroblast (CEF) derived from Specific Pathogen Free (SPF) chicken strain. CEM cells, which are RTase negative, were used as a negative control to set the detection limit of the assay.
Figure 6B: Presence of endogenous retroviral particles, either replicative (i.e replication competent) or non-replicative, in the cell culture supernatant of duck and chicken EBx cells were investigated by an ELISA assay detecting the avian leukosis major capsid antigen P27. Duck
EBx cell lines, EB26 and EB5-1 , as well as chicken EBv13 do not secrete ALV p27 antigen. In the opposite, chicken EB 14 cells do express ALV P27 antigen.
FIGURES 7A and 7B: Duck EBx cells do not secrete replicative avian leucosis virus (ALV) Co-cultivation assay of duck EBx cells with quail QT6 cell line, known to be sensitive to endogenous and exogenous ALVs, were performed in Bioreliance (UK) to detect the presence of endogenous replicative duck viruses.
Figure 7A: described the principle of QT6 co-culture.
Figure 7B: The presence of replicative virus is detected by an ELISA assay detecting the avian leukosis major capsid antigen P27.
The assay demonstrates that none of duck EBx® cells tested (dEB26 and dEB51 ) secrete replicative ALV. RAV-1 virus, which is known to replicate in QT6, were used as a positive control.
FIGURE 8: Cell surface expression of receptors SAα2-3 and SAα2-6 in duck EBx and chicken EB14 cell lines
Cells are incubated with digoxygenin labelled lectins: Sambuca nigra agglutinin lectin specifically binds to Sia2-6Gal, while Maackia amurensis agglutinin lectin specifically binds to Sia2-3Gal. Lectins that bind to cells are revealed with anti-digoxygenin antibody FITC-labelled according to well-known techniques by the man skilled in the art. FITC-labelled cells are numbered with a fluorescent cell sorter (FACS). SAα2-3 and SAα2-6 molecules are been described to be the receptors for the avian and human influenza viruses, respectively. Almost all duck EBx cells higly express cell surface receptors SAα2-3 and SAα2-6.
FIGURES 9A and 9B: MVA-GFP virus propagation in infected duck EBx cells
Figure 9A: Duck EBx® were allowed to form small clumps in T175 stirred tank flasks during cell proliferation in a cell growth SFM medium. Clumps were then infected with 10~2 TCID50/cell of MVA-GFP virus and the mixture was diluted in production SFM media. During a 6 days virus propagation period at 370C, pictures of UV-exposed infected cells were taken daily. The pick of MVA infection was reached at day 4 post-infection (pi). At day 6 pi, the infected cells start to die.
Figure 9B: MVA-GFP virus titration propagated in duck EBx® cells in a 3L fed-batch bioreactor. (Left Panel) Duck EBx-derived biomass was allowed to accumulate during cell proliferation phase in Excell growth medium (SAFC). At day 4, cell density reached 4 million cells/ml. Cells were then infected with 10~1 TCID50/cell of MVA-GFP virus and the mixture was diluted in 1.5 L Excell medium. During a 6 days virus propagation period at 370C, samples were collected daily and TCID50 titration (Right Panel) was performed at the end of the kinetic. A yield of 8.5 log TCID50/ml were reached at 4 p.i. corresponding to a yield of 205 TCID50/Cell.
FIGURE 10: Influence of Calcium and Magnesium concentration in SFM medium on the size of EBx® cells clumps
Figure 10A: Chicken EBv13 cells were first cultured in the SFM medium from SAFC
Biosciences that comprise a high concentration of calcium (Ca2+) (Approx. 0.79 mM) and magnesium (Mg2+) ions; in this medium, cells produce large aggregates in culture.
Three days after having changed the cell culture medium with the same SFM medium that comprises a lower concentration of Ca2+ (0.03 mM final) and Mg2+ (1.6 mM final), the cells form smaller aggregates.
Figure 10B: Duck EB24, EB26 and EB66 cells were first cultured in the SFM medium from SAFC Biosciences that comprise a high concentration of calcium (Ca2+) (Approx. 0.79 mM) and magnesium (Mg2+) ions; in this medium, cells produce large aggregates in culture.
Three days after having changed the cell culture medium with the same SFM medium that comprises a lower concentration of Ca2+ (0.03 mM final) and Mg2+ (1.6 mM final), the cells form smaller aggregates.
FIGURES 11A and 11B: Production of influenza virus strains A in duck EBx cells in 3L- bioreactors
Duck EBx® biomass was allowed to accumulate at 370C during cell proliferation phase in a cell growth medium. Cells were then infected with 10'4 TCID50/cell of A/H1 N1/Beijing/262/95 or A/H3N2/New York/55/2004 influenza virus, the mixture was diluted in 1.5 L Excell production medium supplemented with 0.75 USP/mL of trypsin and temperature was lowered to 330C.
During a 14 days virus propagation period, samples were collected daily and stored at -8O0C.
Figure 1 1A: Growth kinetic of duck EBx cells infected with A/H1 N1/Beijing/262/95 influenza virus strain Left panel: Cell density (rhombus, x106 cells. ml'1) and viral titer in logTCID50/ml.
Right panel: Total number of cells (square), viability (black circles, %) and haemagglutinin concentration in ug/ml (red circles, %).
The viral yield reached 20 ug of Hemagglutinin per ml of culture supernatant.
Figure 1 1 B: Growth kinetic of duck EBx cells infected with A/H3N2/New York/55/2004 influenza virus strain
Left panel: Cell density (rhombus, x106 cells. ml"1)
Right panel: Total number of cells (square), viability (black circles, %) and haemagglutinin concentration in ug/ml (red circles, %). The viral yield reached 30 ug of Hemagglutinin per ml of culture supernatant.
FIGURE 12: Production of influenza virus strain B in duck EBx® cells
Duck EBx® biomass was allowed to accumulate at 370C during cell proliferation phase in a cell growth medium. Cells were then infected with 103 TCID50/cell of B/Jiangsu/10/2003 influenza virus, the mixture was diluted in 1.5 L Excell production medium supplemented with 0.75
USP/mL of trypsin and temperature was lowered to 330C. During a 14 days virus propagation period, samples were collected daily and stored at -8O0C.
Left panel: Cell density (rhombus, x106 cells. ml"1)
Right panel: Total number of cells (square), viability (black circles, %) and haemagglutinin concentration in ug/ml (red circles, %).
The viral yield reached 25 ug of Hemagglutinin per ml of culture supernatant.
FIGURE 13: Analysis of NDV productivity and viral protein expression in suspension duck EB66 cells (MOI 10"3, 0.75 USP/mL trypsin) Duck and chicken EBx cells are sensitive to and replicate NDV La Sota strain. Titers (in TCID50/ml) of NDV produced in duck EB66 cells increase from day 0 to day 2 pi to reach an average of 106 83 TciD5o/mL (Figure 13 Left Panel).
Western blot analysis (Figure 13 right Panel) showed NDV viral proteins (HN, Fo/F, NP & M) expression. The viral proteins composition of NDV virus produced in duck EB66 cells are similar to the one obtained with NDV virus produced in chicken EB14 cells. In addition, the kinetic of release for viruses produced in chicken and Duck EBx cells are similar.
FIGURE 14: Analysis of recombinant Measles virus replication in suspension duck EB66 cells (MOI 10"1 or 10"2) in tissue-culture flasks in serum free medium. Duck EB66 cells are at least as sensitive as VERO cells to infection by Measles Virus. Titers (in TCID50/ml) of recombinant Measles virus expressing Green Fluorescent Protein (GFP) produced in duck EB66 cells reach 107 TCID50/mL at day 6 post-infection.
FIGURES 15A and 15B: SSEA-1, EMA-1 & Telomerase expression in duck EB66 cells Telomerase expression at different passages of duck EB66 cultured in roller bottles was investigated by using Roche telomerase detection kit (Telomerase OCR ELISA). SSEA-1 and EMA-1 at different passages of duck EB66 cultured in roller bottles was investigated by FACS analysis.
Figure 15A: Telomerase is found to be highly expressed in suspension duck EB66 cell line at different passages (138, 144, 147, 150, 154).
Figure 15B: SSEA-1 and EMA-1 cell surface markers was found to be highly expressed in suspension duck EB66 cell line at different passages (138, 144, 147, 150, 154).
FIGURE 16: Karyotype analysis of duck EB66 cells
Duck EB66 cells karyotype was performed by Pr. Franck, ENVL, Lyon. EB66 cells are diploid cells.
EXAMPLES
EXAMPLE 1 : chicken EBv13 cell line from SPF chicken strain VALO 1.1 - RAW MATERIAL
Eggs Specific Pathogen Free (SPF) strain called VaIo. The valo strain is a white Leghorn strain produced and delivered by Lohmann from Germany. Those SPF chicken eggs, supplied with a certificate of analysis, are tested for: CAV, Avian adenoviruses (group 1 , serotypes 1-12 and group 3), EDS, Avian Encephalomyelitis Virus, Avian Leukosis Viruses/RSV (including Serotype ALV-J), Avian Nephritis Virus, Avian Reoviruses, Fowlpox Virus, Infectious Bronchitis Virus, Infectious Bursitis Virus (IBDV), Infectious Laryngo Tracheitis Virus, Influenzavirus Typ A, Marek's Disease Virus, Mycoplasmosis (Mg + Ms), Mycobacterium avium, Newcastle Disease Virus, Reticuloendotheliosis Virus, Salmonella pullorum, Other Salmonella Infections, Avian Rhinotracheitis Virus (ART), Hemophilus paragallinarum. VaIo chicken eggs were only submitted to a disinfection with the decontaminant to avoid any risk of contamination linked to the manipulation of eggs during the transport. Feeder cells
In the first step of the process of establishment of EBv13, cells from murine origin (STO cells) were used as feeder layer to maintain the pluripotency of chicken stem cells. Those feeder cells are mitotically inactivated by gamma irradiation (45 to 55 Grays) before seeding on plastic. This dose of irradiation is a sub-lethal dose that induces a definitive arrest of the cell cycle but still permits the production of growth factors and extracellular matrix, necessary for the promotion of the cell growth of non differentiated cells.
The STO cell line was derived by A. Bernstein, Ontario Cancer Institute, Toronto, Canada from a continuous line of SIM (Sandos Inbred Mice) mouse embryonic fibroblasts and it was supplied by the American Type Culture Collection (ATCC) (STO Product number: CRL-1503, Batch number 1198713). Fresh feeder layers were prepared twice a week, in general on monday and thursday. Exponentially cells were dissociated and counted. A part of cells were seeded for maintenance of viable cultures and another part was irradiated. For irradiation, we prepared a cell suspension at 10x106 cells/mL in tubes. Cells were exposed to a 45 to 55 grey dose and were seeded on plastic. After seeding, dishes or plates coated with inactivated feeder cells were used during a maximum of 5 days
Medium DMEM- HamF12 (Cambrex, Cat n0 BE04-687)
Optipro medium (Invitrogen, Cat n0 12309)
EX-CELL ™ 65195, 60947 and 65319 (SAFC, customized medium) Additives
Glutamine (Cambrex, Cat n0 BE17-605E) Pencillin/streptomycin (Cambrex, Cat n0 BE17-602E))
Non essential Amino Acids (Cambrex, Cat n0 BE13-114E)
Sodium pyruvate (Cambrex, Cat n°BE13-115 )
Vitamines (Cambrex, Cat n0 13-607C)
Beta Mercapto Ethanol (Sigma, Cat n0 M7522) Buffer and fixators
PBS 1X (Cambrex, Cat n0 BE17-516F)
Paraformaldehyde 4 % (Sigma, Cat n0 P6148)
KCI 5,6 % (Sigma, Cat n0 P9333)
Methanol/ Acetic acid (3/1 ): Methanol (Merck, Cat n0 K34497209 ; Acetic acid Sigma Cat n°A6283)
Colcemid, Karyomax (Gibco, Cat n0 15212-046) Cryoprotective agent
Dimethyl Sulfoxyde (DMSO) (Sigma, Cat n0 D2650) Factors Two different recombinant factors were used:
□ Recombinant Human Ciliary Neurotrophic Factor (CNTF) (Peprotech Inc, Cat n0 450-13)
□ Recombinant Human Insulin Like Factor I (IGF1 ) (Peprotech Inc, Cat n0 100-11 ) The two factors were produced in E. CoIi bacteria.
Fetal Bovine Serum Non irradiated Fetal Bovin Serum (FBS) (JRH, Cat n" 12103 )
The non irradiated serum used in the program was collected and produced in United States. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
Irradiated serum (JRH, Cat n0 12107)
The irradiated batch used in this program was also collected in United States. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO or FED cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only.
Dissociating agents: • Pronase (Roche, Cat n° 165 921)
Pronase is a recombinant protease manufactured by Roche Diagnostics, Germany, used for the dissociation of adherent avian stem cells.
• Trypsine EDTA (Cambrex, cat n" BE17-161E)
Trypsine is used for the dissociation of STO or FED cells and at late passages for the dissociation of avian cells adapted to Serum Free Medium. This enzyme of porcine origin is manufactured aseptically according to cGMP referential conditions by a validated sterile filtration method and tested according to current E. P. The raw material, irradiated prior to formulation, is tested for porcine parvovirus in strict compliance with 9/CFR 113.53.
• Non enzymatic cell dissociation solution (Sigma, Cat n° C5914) This agent of dissociation is a ready to use formulation used to gently detach cells from the growing surface of the culture vessel. The formula contains no protein, and allows dislodging of cells without use of enzymes. Cellular proteins are preserved making possible immunochemical studies that are dependent upon the recognition of cell surface proteins. This enzyme was used to detach cell before FACS analysis of biological markers like EMA-1 (Epithelial Membrane Antigen 1 ) and SSEA1 (Stage Specific Embryonic antigen-1 ).
1.2 - PROCESS OF ESTABLISHMENT OF EBv13 CELL LINE
Eggs are opened, the yolk were separated from the albumen during the opening. The embryos were removed from the yolk either directly with the aid of a Pasteur pipette, or with the aid of a small absorbent filter paper (Whatmann 3M paper), cut out beforehand in the form of a perforated ring with the aid of a punch. The diameter of the perforation were about 5 mm. These small rings were sterilized using dry heat for about 30 minutes in an oven. This small paper ring is deposited on the surface of the yolk and centered on the embryo which is thus surrounded by the paper ring. The latter is then cut out with the aid of small pairs of scissors and the whole removed is placed in a Petri dish, filled with PBS or with a physiological saline. The embryo thus carried away by the ring were cleaned of the excess yolk in the medium and the embryonic disk, thus free of the excess vitellin, is collected with a Pasteur pipette.
The chicken VaIo embryos were placed in a tube containing physiological medium (1X PBS, Tris Glucose, medium, and the like). The VaIo embryos were then mechanically dissociated and inoculated on a layer of feeder STO cells into complete culture medium at 390C. The feeder cells were seeded in flask at around 2.7x104 cell/cm2. The complete culture medium is composed of basal commercial medium DMEM-Ham F12 supplemented with 10 % fetal calf serum, with IGF1 and CNTF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta-mercapto-ethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM, with an initial mixture of antibiotics containing penicillin at a final concentration of 100 U/ml and streptomycin at a final concentration of 100 μg/ml. Rapidly after the first passages of the cells, the mixture of antibiotics is no longer added to the medium. The expression rapidly is understood to mean after the first 3 to 5 passages in general.
When the avian ES cells from chicken VaIo embryos is passaged from a culture dish to another, the seeding of culture dishes was performed with around between 7 x 104/cm2 to 8 x 104/cm2 of avian ES cells in the complete culture medium. Preferably, the seeding is made with around 7.3 x 104/cm2 (4 x 106 cells/55cm2 or 4 x 106 cells/100 mm dish). The avian cells, preferably the avian embryonic cells of step a) are cultured during several passages in the complete medium.
At passage 15, the complete medium was depleted in growth factors IGF1 and CNTF. The depletion is made directly in one step, from one passage to another. The embryonic stem cells, preferably the avian embryonic cells are cultured during several passages in the complete medium without IGF1 and CNTF growth factors.
Then depletion of feeder cells were performed after the depletion of growth factors IGF1 and CNTF by a progressive decreasing of feeder cells concentration over several passages. Practically, the same concentration of the feeder cells were used for 2 to 4 passages, then a lower concentration of the feeder cells were used for an additional 2 to 4 passages, and so on. The flask were originally seeded with around 2.7 x104 feeder cells/cm2, then around 2.2 x 104 feeder cells/cm2, then around 1.8 x 104 feeder cells/cm2, then around 1.4 x 104 feeder cells/cm2, then around 1.1 x 104 feeder cells/cm2, then around 0.9 x 104 feeder cells/cm2, then around 0.5 x 104 feeder cells/cm2 . Then the flask were seeded with 6.5 x 104 avian cells/cm2 to 7.5 x 104 avian cells/cm2 and without feeder cells. The depletion of feeder cells started at around passage 21 and ended at around passage 65. During the depletion of feeder cells, the chicken VaIo ES cells were seeded in culture flask at a lower concentration than in step a), about around 4 x 104 cell/cm2 to 5 x 104 cell/cm2. In the hypothesis that VaIo ES cells were not in good shape following a decrease of feeder cells concentration in the flask, then the avian cells are cultured for additional passages with the same feeder cells concentration before to pursue the feeder cells depletion.
The serum depletion were performed after the growth factor and the feeder cells depletion. At the beginning of serum depletion, the culture medium were composed of basal commercial medium DMEM-HamF12 supplemented with 10 % fetal calf serum and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta-mercaptoethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM. The chicken VaIo cells were adapted to the growth in a serum free medium culture in a two steps process: first, the chicken VaIo cells were rapidly adapted to a culture medium composed of commercial serum free medium (SFM), preferably ExCeII 60947 (SAFC Biosciences) supplemented with 10 % fetal calf serum and with 1 % non- essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta-mercaptoethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM. Once this rapid adaptation to a new medium (DMEM-HamF12 to Excell 60947) was performed, a second step is performed consisting of a slow adaptation to decreasing concentration of animal serum in the SFM medium were initiated. Serum depletion was performed by a progressive decreasing starting from 10 % serum, then 7.5 %, then 5 %, then 2.5 %, then 1.25 %, then 0,75 % of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 103 and ended at passage 135.
At the end of the process of deprivation of serum when the remaining concentration of serum in SFM medium was either 0.75 % or 0 %, the adaptation of anchorage-dependent EBv 13 cells to suspension culture started. Among the several attempts performed to isolate anchorage- independent EBv13 isolates, 62.5 % of the attempts were successful and allow to get different isolates of suspension EBv 13 cells. One isolate of EBv13 cells were selected according to the population doubling time (around 18h), the optimal cell concentration into flask culture (around 4 million cell/ml), the cell viability, the cell culture homogeneity (presence and size of cells clumps) and the easiness to manipulate the cells (Figure 1 ).
At the end of serum depletion, anchorage dependent chicken VaIo cells, named EBv13 were able to grow in absence of grow factors, in absence of feeder cells, in serum free medium. EBv13 Cells were then adapted to growth at 370C, by progressively decreasing cell culture temperature of 0.5°C/day.
EXAMPLE 2: chicken EB Line 0 cell line from SPF chicken strain ELL-O
2.1 - RAW MATERIAL
Eggs:
Chicken Specific Pathogen Free (SPF) strain called ELL-O (East Lansing Line 0) was provided by the Avian Disease and Oncology Laboratory (USDA-ARS-MWA, USA) . Those SPF chicken eggs, are produced from a flock tested intensively to various poultry pathogens. Disease tested include: Salmonella pullorum, Salmonella gallinarum, mycoplasma gallisepticum, mycoplasma synoviae, Avian Leukosis virus A-D and J, Marek's disease virus, Reticuloendotheliosis virus, Avian adenovirus, Infectious bronchitis, Infectious bursal disease, Avian Influenza, Newcastle disease, Avian encephalomyelitis and Avian Reovirus. Line 0 chicken eggs were only submitted to a desinfection with the decontaminant to avoid any risk of contamination linked to the manipulation of eggs during transportation.
Feeder cells
In the first step of the process of establishment of EB Line 0, cells from murine origin (STO cells) were used as feeder layer to maintain the pluripotency of chicken stem cells. Those feeder cells are mitotically inactivated by gamma irradiation (45 to 55 Grays) before seeding on plastic. This dose of irradiation is a sub-lethal dose that induces a definitive arrest of the cell cycle but still permits the production of growth factors and extracellular matrix, necessary for the promotion of the cell growth of non differentiated cells.
The STO cell line was derived by A. Bernstein, Ontario Cancer Institute, Toronto, Canada from a continuous line of SIM (Sandos Inbred Mice) mouse embryonic fibroblasts and it was supplied by the American Type Culture Collection (ATCC) (STO Product number: CRL-1503, Batch number 1198713). Fresh feeder layers were prepared twice a week. Exponentially cells were dissociated and counted. A part of cells were seeded for maintenance of viable cultures and another part was irradiated. For irradiation, we prepared a cell suspension at 10x106 cells/mL in tubes. Cells were exposed to a 45 to 55 grey dose and were seeded on plastic. After seeding, dishes or plates coated with inactivated feeder cells were used during a maximum of 5 days.
Media
DMEM- HamF12 (Cambrex, Cat n0 BE04-687)
Medium GTM-3 (Sigma, Cat n0 G9916)
Medium EX-CELL ™ 66522, 65788 and 66444 (SAFC, customized medium) Additives
Glutamine (Cambrex, Cat n0 BE17-605E)
Pencillin/streptomycin (Cambrex, Cat n0 BE17-602E))
Non essential Amino Acids (Cambrex, Cat n0 BE13-114E)
Sodium pyruvate (Cambrex, Cat n°BE13-115 ) Vitamines (Cambrex, Cat n0 13-607C)
Beta Mercapto Ethanol (Sigma, Cat n0 M7522)
Yeastolate (SAFC, Cat n0 58902C) Buffer and fixators
PBS 1X (Cambrex, Cat n0 BE17-516F) Cryoprotective agent
Dimethyl Sulfoxyde (DMSO) (Sigma, Cat n0 D2650)) Factors Six different recombinant factors were used:
□ Recombinant Human Ciliary Neurotrophic Factor (CNTF) (Peprotech Inc, Cat n0 450-13) □ Recombinant Human Insulin Like Factor I (IGF1 ) (Peprotech Inc, Cat n0 100-11 )
□ Recombinant Human lnterleukin 6 (IL6) (Peprotech Inc, Cat n0 200-06)
□ Recombinant Human soluble lnterleukin 6 receptor (slL6r) (Peprotech Inc, Cat n0 200-06 R)
□ Recombinant Human Stem Cell Factor (SCF) (Peprotech Inc, Cat n0 300-07) π Recombinant Human basic Fibroblast Growth Factor (bFGF) (Peprotech Inc, Cat n0 100-
18B)
All those factors, excepted IL6r, are produced in E. CoIi bacteria. Soluble IL6r is expressed in transfected HEK293 cells.
Fetal Bovine Serum
Non irradiated Fetal Bovin Serum (FBS) (SAFC, Cat n° 12003)
The non irradiated serum used in the program was collected and produced in Australia. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
Irradiated serum (JRH, Cat n° 12007)
The irradiated batch used in this program was collected in Australia. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO or FED cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only.
Dissociating agents: • Trypzean ((Sigma, cat n° T3449)
2.2 - PROCESS OF ESTABLISHMENT OF THE LINE 0 CELL LINE
Embryos from 13 eggs from Line 0 chicken were collected according to the process described in Exemple 1.2. Then, the Line 0 embryos were placed in a tube containing PBS 1X. Embryos were then mechanically dissociated and inoculated on a layer of feeder STO cells into complete culture medium at 390C. The feeder cells were seeded in dishes at around 2.7x104 cell/cm2. The complete culture medium is composed of basal commercial medium DMEM-Ham F12 supplemented with 10 % fetal calf serum, with IGF1 , CNTF, bFGF, IL6, IL6r and SCF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 1 mM, with beta- mercapto-ethanol at a final concentration of 0.2 mM, glutamine at a final concentration of 2.9 mM, with yeastolate 1X and with an initial mixture of antibiotics containing penicillin at a final concentration of 100 U/ml and streptomycin at a final concentration of 100 μg/ml. After 7 passages, the mixture of antibiotics is no longer added to the medium. When the avian ES cells from chicken Line 0 embryos are transferee! from a culture dish to another, the seeding of culture dishes was performed with around between 7 x 104/cm2 to 8 x 104/cm2 of avian ES cells in the complete culture medium. Preferably, the seeding is made with around 7.3 x 104/cm2 (4 x 106 cells/55cm2 or 4 x 106 cells/100 mm dish). The avian cells, preferably the avian embryonic cells of step a) are cultured during several passages in the complete medium supplemented with 10 or 15% of FBS. At passage 7, the complete medium was depleted in growth factors bFGF, IL6, IL6r and SCF. The depletion was made directly in one step, from one passage to another. The embryonic stem cells, preferably the avian embryonic cells, were cultured during several passages in the complete medium without those 4 growth factors. At passage 12, the 2 last factors IGF1 and CNTF were removed from the medium and cells were amplified without factor.
To promote cell growth 3 base medium were used successively: DMEM Ham F12 from passage 1 to passage 18, Exell GTM-3 from passage 18 to passage 26 and a mixture of Excell 66788 and Excell 66522 after passage 26.
After passage 30, depletion of feeder cells was performed by a progressive decreasing of feeder cells concentration over several passages following the step by step process previously described. During this phase of feeder deprivation, some cells able to grow in suspension were isolated using Excell 66444 as growth medium and serum deprivation was initiated (Figurei B).
EXAMPLE 3: Duck EBx cell line EB66 3.1 - RAW MATERIAL Duck Eggs
Duck eggs from Peking strains GL30 were obtained from GRIMAUD FRERES SELECTION (La Corbiere, Roussay France). The parent ducks were vaccinated against Escherichia CoIi (Autogenous vaccine CoIi 01 & 02), Pasteurella multocida (Landavax), Duck viral hepatitis (Hepatovax), Erysipelothhx rhusiopathiae (Ruvax), Avian metapneumovirus (Nemovac), Salmonella typhimurium & Enteridis (Autogenous vaccine), Riemerella antipestifer (Autovaccine Riemerella), Avian metapneumovirus (Nobilis RTV inactive) and Erysipelothhx rhusiopathiae (Ruvax). After receipt, fertilized Peking duck eggs were submitted to a disinfection in an hypochloryde bath followed by a decontamination with Fermacidal (Thermo) to avoid any risk of contamination linked to dusts attached on the shell. Feeder cells
In the first step of the process, cells from murine origin (STO cells) were used as feeder layer to maintain the pluripotency of duck stem cells. Those feeder cells are mitotically inactivated by gamma irradiation (45 to 55 Grays) before seeding on plastic. This dose of irradiation is a sublethal dose that induces a definitive arrest of the cell cycle but still permits the production of growth factors and extracellular matrix, necessary for the promotion of the cell growth of non differentiated cells. The STO cell line was derived by A. Bernstein, Ontario Cancer Institute, Toronto, Canada from a continuous line of SIM (Sandos Inbred Mice) mouse embryonic fibroblasts and it was supplied by the American Type Culture Collection (ATCC) (STO Product number: CRL-1503, Batch number 1198713). Fresh feeder layers were prepared twice a week. Exponentially cells were dissociated and counted. A part of cells were seeded for maintenance of viable cultures and another part was irradiated. For irradiation, we prepared a cell suspension at 10x106 cells/mL in tubes. Cells were exposed to a 45 to 55 grey dose and were seeded on plastic. After seeding, dishes or plates coated with inactivated feeder cells were used during a maximum of 5 days. Medium
Medium EX-CELL ™ 65788, 65319, 63066 and 66444 (SAFC, customized medium)
Medium GTM-3 (Sigma, Cat n0 G9916)
DMEM- HamF12 (Cambrex, Cat n0 BE04-687) DMEM (Cambrex, Cat n0 BE 12-614F) Additives
Glutamine (Cambrex, Cat n0 BE17-605E)
Pencillin/streptomycin (Cambrex, Cat n0 BE17-602E))
Non essential Amino Acids (Cambrex, Cat n0 BE13-114E) Sodium pyruvate (Cambrex, Cat n°BE13-115 )
Vitamines (Cambrex, Cat n0 13-607C)
Beta Mercapto Ethanol (Sigma, Cat n0 M7522)
Yeastolate (SAFC, Cat n0 58902C) Buffer and fixators PBS 1X (Cambrex, Cat n0 BE17-516F) Cryoprotective agent
Dimethyl Sulfoxyde (DMSO) (Sigma, Cat n0 D2650) Factors
Two different recombinant factors were used: □ Recombinant Human Ciliary Neurotrophic Factor (CNTF) (Peprotech Inc, Cat n0 450-13)
□ Recombinant Human Insulin Like Factor I (IGF1 ) (Peprotech Inc, Cat n0 100-11 ) Those 2 factors are produced in E. CoIi bacteria. Fetal Bovine Serum
Non irradiated Fetal Bovin Serum (FBS) (JRH, Cat n° 12003) The non irradiated serum used in the program was collected and produced in Australia. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture. Irradiated serum (JRH, Cat n0 12107)
The irradiated batch used in this program was collected in United States. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only. Dissociating agents:
• Pronase (Roche, Cat n° 165 921)
Pronase is a recombinant protease manufactured by Roche Diagnostics, Germany, used for the dissociation of adherent avian stem cells.
• Trypsine EDTA (Cambrex, cat n" BE17-161E)
Trypsine is used for the dissociation of STO cells and at late passages for the dissociation of avian cells adapted to Serum Free Medium. This enzyme of porcine origin is manufactured aseptically according to cGMP referential conditions by a validated sterile filtration method and tested according to current EP. The raw material, irradiated prior to formulation, is tested for porcine parvovirus in strict compliance with 9/CFR 113.53.
• Trypzean (Sigma, cat n° T3449)
Trypzean solution is formulated with a recombinant bovine trypsin, expressed in corn and manufactured by Sigma Aldrich utilizing ProdiGene's proprietary transgenic plant protein expression system. This product is optimized for cell dissociation in both serum free and serum- supplemented adherent cell cultures.
• Non enzymatic cell dissociation solution (Sigma, Cat n° C5914)
This agent of dissociation is a ready to use formulation used to gently detach cells from the growing surface of the culture vessel. The formula contains no protein, and allows dislodging of cells without use of enzymes. Cellular proteins are preserved making possible immunochemical studies that are dependent upon the recognition of cell surface proteins. This enzyme was used to detach cell before FACS analysis of biological markers like EMA-1 (Epithelial Membrane Antigen 1 ) and SSEA1 (Stage Specific Embryonic antigen-1 ).
3.2 - PROCESS OF ESTABLISHMENT OF DUCK EBx CELL LINE EB66
Around 360 Fertilized duck eggs were opened, the yolk were separated from the albumen during the opening. The embryos were removed from the yolk with the aid of a small absorbent filter paper (Whatmann 3M paper), cut out beforehand in the form of a perforated ring with the aid of a punch. The diameter of the perforation is about 5 mm. These small rings were sterilized using dry heat for about 30 minutes in an oven. In practice, during the step of embryo collection, a small paper ring is deposited on the surface of the yolk and centered on the embryo which is thus surrounded by the paper ring. The latter is then cut out with the aid of small pairs of scissors and the whole removed is placed in a Petri dish, filled with PBS. The embryo thus carried away by the ring were cleaned of the excess yolk in the medium and the embryonic disk, thus free of the excess vitellin, were collected with a Pasteur pipette.
The duck embryos were placed in 50 ml_ tubes containing PBS 1X. The duck embryos were then mechanically dissociated, washed with PBS, and seeded on an inactivated layer of feeder STO cells into complete culture medium at 390C, 7,5 % CO2. The feeder cells were seeded in 6 well plates or dishes at around 2,7 x104 cell/cm2. The complete culture medium is composed of serum free medium DMEM-Ham F12 supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 μg/ml and yeastolate 1X. Rapidly at the passage 4, the mixture of antibiotics is no longer added to the medium.
The duck ES cells were cultured in the DMEM-Ham F12 medium up to passage 4. After passage 4, the base medium is modified and DMEM-Ham F12 complete medium is replaced by the SFM GTM-3 medium supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, at a final concentration of 1 ng/ml, with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM and yeastolate 1X. The duck ES cells were further cultured during 14 passages in this new medium of culture, then growth factors deprivation was performed at passage 18. IGF1 and CNTF were simultaneously removed from the medium, thus from passage 19 to passage 24, the medium of culture was GTM-3 medium supplemented with 10 % FBS, with 1 % non- essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM and yeastolate 1X.
When the duck ES cells from Peking duck embryos are passaged from a culture dish to another, the seeding of culture dish was performed with around between 7 x 104/cm2 to 12 x 104/cm2of duck ES cells in the complete culture medium.
Then, after passage 24, depletion of feeder cells were performed by a progressive decrease of feeder cells concentration over several passages. The dishes were originally seeded with around 2,7 x104 feeder cells/cm2, then around 1 ,8 x 104 feeder cells/cm2 between passage 25 and 31 , then around 1 ,4 x104 cells/cm2 between passage 32 and 35, then around 1 x 104 feeder cells/cm2 between passage 36 and 41 , then around 0,7 x 104 feeder cells/cm2 between passage 42 and 44, and finally from passage 45 dishes were seeded only with avian cells and without feeder cells. At the end of the feeder depletion, the dishes are seeded with 9 x 104 avian cells/cm2 to 12.7 x 104 avian cells/cm2. The depletion of feeder cells started at passage 25 and ended at passage 45. During the depletion of feeder cells, the duck ES cells are seeded in culture dishes at a higher concentration than in step a), about around 9 x 104 cell/cm2 to 12.7 x 104 cell/cm2.
After several passages without feeder cells, growth parameters (Population Doubling Time (PDT) and Density) are studied to confirm cell stability and robustness and to initiate the deprivation of amino acids, vitamins, beta mercaptoethanol, sodium pyruvate and yeastolate. Cells are considered as enough robust to be submitted to such deprivation if, PDT is lower than around 40 hours and cell density higher than around 26x104 cells/cm2.
In the case of the present duck EBx® cells development, named EB66, deprivation of vitamins, sodium pyruvate, non essential amino acids and beta mercaptoethanol were initiated at passage 52. All those additives were removed simultaneously from the medium. Thus, between passage 52 and passage 59, the medium of culture is SFM GTM-3 supplemented with glutamine, yeastolate and FBS. Following a short period of adaptation to the new conditions of culture, temperature decreasing was initiated. This decrease was performed progressively between passage 60 and passage 67. After passage 67 cells were able to grow at 370C. After passage 67, the base medium GTM-3 was replaced by a new SFM base medium called Excell 65788. So, after passage 67 the culture medium was Excell 65788 supplemented with 10 % FBS, 2,5 mM glutamine and 1X yeastolate. At passage 80, 4x106 cells were transferred in a Ultra Low Attachment (ULA) dish maintained under constant agitation to initiate anchorage- independent cells growth. To promote the growth as suspension, the base medium was modified and percentage of serum was decreased from 10 % to 5 % for the seeding in the ULA dish. Thus from passage 80 to passage 85 the medium of culture was SFM GTM-3 supplemented with 5 % FBS, 2.5mM glutamine and 1X yeastolate. Slow decrease of FBS was initiated on EB66 cell suspension after passage 85. Serum depletion was performed by a progressive decreasing starting from 2.5 % serum, then 1 ,5 % of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 86 and ended at passage 94. At the end of serum depletion, anchorage independent dEB66 cells were able to grow at 370C in absence of grow factors, in absence of feeder cells, in serum free medium.
After the obtaining of EB66 duck cells that are able to grow at 370C in the SFM GTM-3 supplemented by 2,5 mM glutamine, some further adaptation to SFM media were made by dilution or progressive adaptation in new SFM formulations as Excell 63066, Excell 66444, Excell CHO ACF for example.
The subcloning of suspension duck EB66 cell could also realized in presence or absence of yeastolate EXAMPLE 4: Duck EBx cell line EB26
4.1 - RAW MATERIAL
Duck Eggs, Feeder cells, additives, Buffers and Fixators, Cryopreservative agents, Fetal Calf Serum & dissociating agents (Idem as Example 3).
Duck eggs from Peking strains GL30 were used. Medium
Medium EX-CELL 65319, 63066 and 66444 (SAFC, customized medium)
Medium GTM-3 (Sigma, Cat n0 G9916) DMEM (Cambrex, Cat n0 BE 12-614F) Factors Six different recombinant factors were used:
□ Recombinant Human Ciliary Neurotrophic Factor (CNTF) (Peprotech Inc, Cat n0 450-13)
□ Recombinant Human Insulin Like Factor I (IGF1 ) (Peprotech Inc, Cat n0 100-11 ) π Recombinant Human lnterleukin 6 (IL6) (Peprotech Inc, Cat n0 200-06)
□ Recombinant Human soluble lnterleukin 6 receptor (slL6r) (Peprotech Inc, Cat n0 200-06 R)
□ Recombinant Human Stem Cell Factor (SCF) (Peprotech Inc, Cat n0 300-07)
□ Recombinant Human basic Fibroblast Growth Factor (bFGF) (Peprotech Inc, Cat n0 100- 18B) All those factors, excepted IL6r, are produced in E. CoIi bacteria. Soluble IL6r is expressed in transfected HEK293 cells.
4.2 - PROCESS OF ESTABLISHMENT OF DUCK EBx CELL LINE EB26
The duck embryos were collected as previously described with EB66. The duck embryos were placed in 50 mL tubes containing PBS 1X. The duck embryos were then mechanically dissociated, washed in PBS, and seeded on an inactivated layer of feeder STO cells into complete culture medium at 390C, 7,5 % CO2. The feeder cells were seeded in 6 well plates or dishes at around 2,7 x104 cell/cm2. The complete culture medium is composed of serum free medium GTM-3 supplemented with 5 % fetal bovine serum, with IGF1 , CNTF, II-6, II-6R, SCF and FGF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 μg/ml and yeastolate 1X. Rapidly after the first passages of the cells, the mixture of antibiotics is no longer added to the medium. The expression rapidly is understood to mean after the first 3 to 9 passages in general. The duck ES cells were cultured in the complete medium up to passage 9. After passage 9, the complete medium is partially depleted in factors. Thus, between passage 10 and 13, SCF, IL6, IL6r and bFGF were removed for the medium and only recombinant IGF1 and CNTF were maintained at a concentration of 1 ng/mL. A simultaneous decease of concentration of IGF1 and CNTF is secondly performed between passage 13 and 16 to finally obtain cells able to grow without recombinant factors at passage 17. The factor depletion were made by a progressive adaptation to lower concentrations of factors. When the duck ES cells from Pekin duck embryos were passaged from a culture dish to another, the seeding of culture dish was performed with around between 7 x 104/cm2 to 12 x 104/cm2 of duck ES cells in the complete culture medium. Preferably, the seeding is made with around 7.3 x 104/cm2 (4 x 106 cells/55cm2 or 4 x 106 cells/100 mm dish). After depletion of recombinant factors, a decrease of yeastolate were performed at passage 23 reaching the final concentration at 0,5X. Then, after passage 31 , depletion of feeder cells were performed by a progressive decrease of feeder cells concentration over several passages.. The dishes were originally seeded with around 2,7 x104 feeder cells/cm2, then around 1 ,8 x 104 feeder cells/cm2 between passage 32 and 38, then around 1 ,4 x104 cells/cm2 between passage 39 and 44, then around 1 x 104 feeder cells/cm2 between passage 45 and 47, then around 0,7 x 104 feeder cells/cm2 between passage 48 and 50, and finally from passage 51 dishes were seeded only with avian cells and without feeder cells,. At the end of the feeder depletion, the dishes are seeded with 9 x 104 avian cells/cm2 to 12,7 x 104 avian cells/cm2. The depletion of feeder cells started at passage 32 and ended at passage 51. During the depletion of feeder cells, the duck ES cells are seeded in culture dishes at a higher concentration than in step a), about around 9 x 104 cell/cm2 to 12,7 x 104 cell/cm2. After several passages without feeder cells, growth parameters (Population Doubling Time (PDT) and Density) were studied to confirm cell stability and robustness and to initiate the cell growth as suspension. Cells are considered as enough robust to be submitted to a culture in suspension if, PDT is lower than around 40 hours and cell density higher than around 26x104 cells/cm2 . Moreover, cells morphology should be: round, refringent, very small and the cells shall not attached to the plastic dish too much.
In the case of the EB26 cell development, culture in suspension were initiated at passage 53. 7 x106 cells were transferred in a Ultra Low attachment dish and maintained under constant agitation at around 50 to 70 rpm. For the next passages, cells were seeded in T175 flasks (Sarsted, ref 831812502) at a concentration comprise between 0,4 to 0,5x106 cells/mL. Following a short period of adaptation to the new conditions of culture, cells PDT decreased from around 160 H to 40 hours. Regarding this good evolution, at passage 59, a new set of deprivation was performed. Thus vitamins, sodium pyruvate, beta-mercaptoethanol and non essential amino acids were removed. Thus after passage 59, the culture medium was supplemented with 5 % FBS, 0,5 X yeastolate and 2,5 mM glutamine only. The serum depletion is performed on cell suspensions already depleted in growth factor, feeder cells, vitamins, non essential amino acids, sodium pyruvate and beta-mercaptoethanol. Serum depletion was performed by a progressive decreasing starting from 5 % serum, then 2.5 %, then 1 ,5 %,of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 61 and ended at passage 79. At the end of serum depletion, anchorage independent duck EB26 cells were able to grow at 390C in absence of grow factors, in absence of feeder cells, in serum free medium. EB26 cells were then adapted to growth in absence of 0.5X yeastolate at 370C, by decreasing cell culture temperature at passage 80.
After the obtaining of EB26 cells that are able to grow at 370C in the SFM GTM-3 supplemented by 2,5 mM glutamine, some further adaptation were made by dilution or progressive adaptation on new SFM formulations as Excell 63066, Excell 66444, Excell CHO ACF. The subcloning of suspension duck EB26 cell could also realized in presence or absence of yeastolate.
EXAMPLE 5: Duck EBx cell line EB24
5.1 - RAW MATERIAL
Duck Eggs, Feeder cells, additives, Buffers and Fixators, Cryopreservative agents, Fetal Calf Serum & dissociating agents (Idem as Example 3). Duck eggs from Peking strains GL30 were used. Medium
Medium EX-CELL ™ 65319, 63066 and 66444 (SAFC, customized medium)
Medium GTM-3 (Sigma, Cat n° G9916)
DMEM F12 (Cambrex, Cat n° BE04-687) DMEM (Cambrex, Cat n° BE 12-614F) Factors Six different recombinant factors were used:
□ Recombinant Human Ciliary Neurotrophic Factor (CNTF) (Peprotech Inc, Cat n0 450-13)
□ Recombinant Human Insulin Like Factor I (IGF1 ) (Peprotech Inc, Cat n0 100-11 ) π Recombinant Human lnterleukin 6 (IL6) (Peprotech Inc, Cat n0 200-06)
□ Recombinant Human soluble lnterleukin 6 receptor (slL6r) (Peprotech Inc, Cat n0 200-06 R)
□ Recombinant Human Stem Cell Factor (SCF) (Peprotech Inc, Cat n0 300-07)
□ Recombinant Human basic Fibroblast Growth Factor (bFGF) (Peprotech Inc, Cat n0 100- 18B) All those factors, excepted IL6r, are produced in E. CoIi bacteria. Soluble IL6r is expressed in transfected HEK293 cells.
5.2 - PROCESS OF ESTABLISHMENT OF DUCK EBx® CELL LINE EB24
The duck embryos were collected as previously described with EB66. The duck embryos were placed in 50 mL tubes containing PBS IX.The duck embryos are then mechanically dissociated and seeded on an inactivated layer of feeder STO cells into complete culture medium at 390C, 7,5 % CO2. The feeder cells were seeded in 6 well plates or dishes at around 2,7 x104 cell/cm2. The complete culture medium is composed of serum free medium DMEM-Ham F12 supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, II-6, II-6R, SCF and FGF at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 μg/ml and 1X yeastolate. Rapidly after the first passages of the cells, the mixture of antibiotics is no longer added to the medium. The expression rapidly is understood to mean after the first 3 to 9 passages in general.
The duck ES cells are cultured in the DMEM-Ham F12 complete medium up to passage 7. After passage 7, the base medium is modified and DMEM-Ham F12 complete medium is replaced by the GTM-3 complete medium supplemented with 10 % fetal bovine serum, with IGF1 , CNTF, II- 6, II-6R, SCF and FGF at a final concentration of 1 ng/ml, with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 μg/ml and yeastolate 1X. Thus, at passage 11 , the serum concentration is decreased at 5 % and SCF, IL6, IL6r and bFGF are removed for the medium. So, from passage 11 , the medium is composed of 5 % FBS, with IGF1 and CNTF at a final concentration of 1 ng/ml_ with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 μg/ml and yeastolate 1X. A simultaneous withdrawal of IGF1 and CNTF is performed at passage 22. No recombinant factors are present in the GTM-3 culture medium after passage 22. Duck cells were maintained in a such medium between passage 23 and passage 28. When the duck ES cells from Pekin duck embryos are passaged from a culture dish to another, the seeding of culture dish was performed with around between 7 x 104/cm2 to 12 x 104/cm2 of duck ES cells in the complete culture medium. Preferably, the seeding is made with around 7.3 x 104/cm2 (4 x 106 cells/55cm2 or 4 x 106 cells/100 mm dish). Then, after passage 28, depletion of feeder cells is performed by a progressive decrease of feeder cells concentration over several passages. The dishes were originally seeded with around 2,7 x104 feeder cells/cm2, then around 1 ,8 x 104 feeder cells/cm2 between passage 29 and 33, then around 1 ,4 x104 cells/cm2 between passage 34 and 37, then around 1 x 104 feeder cells/cm2 between passage 38 and 42, then around 0,7 x 104 feeder cells/cm2 between passage 43 and 46, and finally from passage 47 dishes were seeded only with avian cells and without feeder cells,. At the end of the feeder depletion, the dishes are seeded with 9 x 104 avian cells/cm2 to 12,7 x 104 avian cells/cm2. The depletion of feeder cells started at passage 29 and ended at passage 47. During the depletion of feeder cells, the duck ES cells are seeded in culture dishes at a higher concentration than in step a), about around 9 x 104 cell/cm2 to 12,7 x 104 cell/cm2. After several passages without feeder cells, growth parameters (Population Doubling Time (PDT) and Density) were studied to confirm cell stability and robustness and to initiate the cell growth as suspension. Cells are considered as enough robust to be submitted to a culture in suspension if, PDT is lower than around 40 hours and cell density higher than around 26 x 104 cells/cm2. Moreover, cells morphology should be: round, refringent, very small and the cells shall not attached to the plastic dish too much. In the case of the EB24 cell development, culture in suspension is initiated at passage 48. 8 x106 cells were transferred in a Ultra Low attachment dish and maintained under constant agitation at around 50 to 70 rpm. For the next passages, cells were seeded in T175 flasks (Sarsted, ref 831812502) at a concentration comprise between 0,4 to 0,5x106 cells/mL. Following a short period of adaptation to the new conditions of culture, cell PDT decreased from around 248 H to 128 hours and the next step of deprivation is then performed. Thus at passage 52, vitamines, non essential amino acids, sodium pyruvate and beta mercaptethanol are removed. Regarding the good evolution of the PDT reaching 44 hours, at passage 56, from passage 57, the serum deprivation was initiated. Thus from passage 57, the culture medium GTM-3 was supplemented with 5 % FBS, 1X yeastolate and 2,5 mM glutamine only. The serum depletion is performed on cell suspensions already depleted in growth factors, feeder cells, vitamins, non essential amino acids, sodium pyruvate and beta- mercaptoethanol. Serum depletion was performed by a progressive decreasing starting from 5 % serum, then 2.5 %, then 2 %, then 1.5 % of serum concentration in SFM cell culture medium to finally reach 0 % serum in SFM cell culture medium. Serum depletion started at passage 57 and ended at passage 77. During this serum depletion, adaptation to growth at 370C was also performed. Thus at passage 65, cells growing in the culture medium supplemented with 2,5 % FBS were transferred at 370C avoiding a progressive temperature shift. At the end of serum depletion, anchorage independent duck EB24 cells were able to grow at 370C in absence of grow factors, in absence of feeder cells, in serum free medium.
After the obtaining of duck EB24 cells able to grow at 370C in the SFM GTM-3 supplemented by 2,5 mM glutamine, some further adaptation were made by dilution or progressive adaptation in new SFM formulations as Excell 63066, Excell 66444, Excell CHO ACF. The subcloning of suspension duck EB24 were performed, an duck EB24-12 subclone were selected because of its good performance to efficiently replicate viruses.
EXAMPLE 6: SPF Duck Muscovy EBx cell line
6.1 - RAW MATERIAL Duck Eggs:
Duck SPF eggs from Muscovy strains were obtained from Le Couvoir de Cerveloup (France). Those SPF duck eggs, are produced from a flock tested intensively to various poultry pathogens. Disease tested include: Salmonella gallinarum-pullorum, Mycoplasma synoviae, Mycoplasma meleagridis, Mycoplasma galliepticum, Marek's disease virus, Avian Influenza, Type 2 Paramyxovirus, Type 3 Paramyxovirus, Newcastle disease, Type 3 Adenovirus (EDS), Gumboro disease, Avian reovirus, Reticuloendotheliosis virus, Avian encephalomyelitis, infectious rhinotracheitis virus and Chlamydiosis. Muscovy duck eggs were only submitted to a disinfection with the decontaminant to avoid any risk of contamination linked to the manipulation of eggs during the transport. Feeder cells (see previous examples) Media
Medium EX-CELL ™ 66444 (SAFC, customized medium) Medium GTM-3 (Sigma, Cat n° G9916)
DMEM- HamF12 (Cambrex, Cat n0 BE04-687) Additives
Glutamine (Cambrex, Cat n0 BE17-605E)
Pencillin/streptomycin (Cambrex, Cat n0 BE17-602E)) Non essential Amino Acids (Cambrex, Cat n0 BE13-114E)
Sodium pyruvate (Cambrex, Cat n°BE13-115 )
Vitamines (Cambrex, Cat n0 13-607C)
Beta Mercapto Ethanol (Sigma, Cat n0 M7522)
Yeastolate (SAFC, Cat n0 58902C) Buffer and fixators:
PBS 1X (Cambrex, Cat n0 BE17-516F) Cryoprotective agent
Dimethyl Sulfoxyde (DMSO) (Sigma, Cat n0 D2650)
Factors
Two different recombinant factors were used:
□ Recombinant Human Ciliary Neurotrophic Factor (CNTF) (Peprotech Inc, Cat n0 450-13)
□ Recombinant Human Insulin Like Factor I (IGF1 ) (Peprotech Inc, Cat n0 100-11 ) Those 2 factors are produced in E. CoIi bacteria. Fetal Bovine Serum
Non irradiated Fetal Bovin Serum (FBS) (JRH, Cat n° 12003)
The non irradiated serum used in the program was collected and produced in Australia. Animals used for collection were USDA inspected and acceptable for slaughter. It was added in the medium during avian stem cells culture. This batch was not submitted to irradiation to avoid the destruction of critical proteins or components identified as essential for the maintenance of stem cells in culture.
Irradiated serum (JRH, Cat n0 12007)
The irradiated batch used in this program was collected in Australia. This irradiated batch was added as supplement in the DMEM medium used for the culture of STO cells (feeder cells). Those cells do not require as stem cells a specific quality of serum for growth and maintenance in culture. To minimize high concentration of serum in the medium we have adapted the STO cells to grow in presence of 4 % of FBS only. Dissociating agents: • Pronase (Roche, Cat n° 165 921) • Trypzean (Sigma, cat n° T3449)
6.2 - PROCESS OF ESTABLISHMENT OF MUSCOVY DUCK EBx CELL LINE
Embryos from 20 fertilized SPF eggs from Muscovy ducks were collected according to the process described in Example 3. The duck embryos were placed in 50 ml_ tubes containing
PBS 1X. The duck embryos were then mechanically dissociated, washed with PBS, and seeded in a well of a 12 well plate coated with an inactivated layer of feeder STO cells. Duck
Embryonic cells were seeded into complete culture medium and transferred at 390C, 7,5%5 %
CO2. The feeder cells were seeded at around 2,7 x104 cell/cm2. The complete culture medium used is composed of DMEM-Ham F12 supplemented with 10 % fetal bovine serum, with IGF1 ,
CNTF, at a final concentration of 1 ng/ml, and with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of
0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM, penicillin at a final concentration of 100 U/ml, streptomycin at a final concentration of 100 μg/ml and yeastolate 1X. At passage 2, the DMEM-HamF12 base medium is replaced by GTM-3 base medium. The mixture of antibiotics is no longer added to the medium after passage 4.
The duck ES cells were cultured in the complete GTM-3 medium up to passage 8. After passage 8, concentration of IGF1 and CNTF are reduced to 0,5 ng/mL.The duck ES cells were further cultured during 2 passages in this new medium of culture, then growth factor deprivation was performed at passage 10. IGF1 and CNTF were simultaneously removed from the medium.
Thus from passage 10 to passage 37, the medium of culture was GTM-3 medium supplemented with 10 % FBS, with 1 % non-essential amino acids, with 1 % of mixture of vitamins of commercial origin, with sodium pyruvate at a final concentration of 0,1 mM, with beta-mercapto-ethanol at a final concentration of 0.5 mM, glutamine at a final concentration of 2,1 mM and yeastolate 1X.
When the duck ES cells isolated from Muscovy duck embryos are passaged from a culture dish to another, the seeding was performed with around 12 x 104/cm2 of duck ES cells in the culture medium. Some conditionated medium can be occasionaly used for cell seeding to improve cell recovery post dissociation. Then, after passage 37, depletion of feeder cells was performed by a progressive decreasing of feeder cells concentration over several passages following the step by step process previously described.
During this phase of feeder deprivation, some cells able to grow in suspension were isolated and adaptated to grow without additives and serum (Figure 4C). Anchorage-independent Muscovy duck EBx cells express ES cells markers, such as telomerase, SSEA-1 and EMEA-1 (data not shown).
EXAMPLE 7: EBx Cell Lines Characterization 7.1 - CHICKEN VALO EBv13 CELLS CHARACTERIZATION
7.1.1 - Telomerase activity
Telomerase detection is achieved by using the TeIo TAGGG Telomerase PCR ELISA developed by Roche Applied Science (Telomeric Repeat Amplification Protocol (TRAP) - Cat. No. 1 1 854 666 910 ) according to the supplier protocol. The TeIo TAGGG Telomerase PCR ELISA allows amplification of Telomerase-mediated elongation products combined with non radioactive detection following an ELISA protocol. The assay is valid if absorbance value of the negative control is less than or equal to 0.25 A450Hm - A690nm and if absorbance value of the positive control is higher than or equal to 1.5 A450Hm - A690nm when using 1 x 103 cell equivalents in the assay. Samples are regarded as telomerase positive if the difference in absorbance is higher than 0,2 A450Hm - A690nm units Two controls were used: the negative control is murine fibroblasts (FED cells) and the positive controls are FGB8 cells (Embryonic Stem cells established by Vivalis from 129 SV mouse embryos) and chicken EB14-O74 cells previously established in WO 03/076601. Results obtained are summarized on the figure N°2 . EBv13 cells do express high level of telomerase. At passage p193 and 195, the telomerase activity is equivalent to the one of chicken EB14-074 cells.
7.1.2 - ES cells biological markers
Embryonic stem cells are characterized by the expression of biological markers expressed on the cell membrane. The expression of EMA-1 (Epithelial Membrane Antigen-1 ) and SSEA-1
(Stage Specific Embryonic Antigen-1 ) on EBv 13 cells were evaluated by FACS analysis. After
10 minutes of fixation with PFA 4 % (Para-formaldehyde), cell samples and controls are rinsed and pre-incubated with monoclonal antibodies specific of EMA-1 or SSEA-1. A second antibody conjugated to FITC is used for detection of cells expressing the 2 biological markers selected. Samples were analyzed by flow cytometry using a FACS (Flow Activated Cell Sorter) from
Coulter.
FACS analysis was done on mouse fibroblasts cells (FED cells) as a negative control, murine ES FGB8 cells as a positive control, chicken EB14-O74 cells as a positive control EBx cells and EBv 13 cells. As expected FED cells do not express biological markers whereas FGB8 and EB14-O74 cells present an important staining, respectively of, 60,13 % and 78,7 for EMA-1 and 94,45 % and 95 % for SSEA-1 (data not shown). Chicken valo EBv 13 cells population do not present any staining for EMA1 (2 %) and a very light one for SSEA-1 (22 %).
7.1.3 - Karyotype
Karyotype analysis was performed to check the cell diploidy and the avian origin of EBv13 cells. Cells in the exponential phase of growth were harvested and treated 2 hours by colcemid (0,02μg/ml_). After washing and centrifugation, an hypotonic choc is performed on cells with KCI (0,56 %) during 20 minutes. Subsequently, EBv13 cells were fixed in methanol/acetic acid (3/1 ) and stored overnight at -2O0C. The day after, metaphasis were spotted on glass, stained by a wright/giemsa solution and observed under microscope. Several series of metaphases were observed confirming the chicken origin of EBv13 cells. No evidence of polyploidy is observed.
7.1.4 - Influence of cell culture medium composition on the clumps size of EBv13 cells The inventors have found that the concentration of Calcium and Magnesium in the serum-free medium used for the EBx cells culture and infection have an impact on the clumps size. Figure 10 shows the decrease in clumps size when EBv13 cells are passed from a medium with a high to a low Ca2+ and Mg2+ concentration.
7.2 - Duck EBx CELL LINES CHARACTERIZATION
7.2.1 - Duck EBx cells morphology
Transmission Electronic Microscopy analysis of dEBx® cells were performed by Dr. A Rivoire (Lyon, France). Duck EBx® cells display a typical embryonic stem cells morphology (i.e high nucleo-cytoplasmic ratio) that resemble the phenotype of murine embryonic stem cells and VIVALIS EB14 cells described in WO2006/108846. Duck EBx® cells are small round cells (diameter ~ 10 μm) with a large nucleus and nucleolus, with short pseudopodia extending from the plasma membrane (Figure 4). They are highly metabolic active with a ribosome and mitochondria rich cytoplasm. They contain numerous intracellular vacuoles, a very developed Golgi system and a granulous reticulum endoplasmic.
7.2.2 - Telomerase expression of duck EBx® cells
Telomerase expression during different stages of establishment of in duck EBx® cells was investigated by using Roche telomerase detection kit (Telomerase OCR ELISA). Telomerase is found to be highly expressed in adherent duck EBx® cells, as well as during feeder deprivation, during the process of adapting duck EBx® cells to suspension and during feeder deprivation.
Figure 5 shows that duck EB24 and EB26 express high level of telomerase, just like chicken EB14 cells. Duck EB66 also express high level of telomerase all along cell passages. This high telomerase activity is stable in EB66 cells after adaptation in different SFM (Figure 15). 7.2.3 - Duck EBx® cells display no endogenous reverse transcriptase activity
Endogenous reverse transcriptase expression was investigated by direct F-PERT analysis (Lovatt et al., 1999, J. Virol. Methods, 82:185-200) in Clean Cells (FRANCE). Duck EBx® cell lines, EB24 (data not shown), EB66 (data not shown), EB26 and EB51 , display no endogenous Reverse Transcriptase (RT) activity (Figure 6A). RT activity were detected in chicken EB14 cells culture as well as, to a lesser extend, in chicken Embryonic fibroblast derived from Specific Pathogen Free (SPF) chicken strain.
The presence of endogenous retroviral particles, either replicative or non-replicative, in the cell culture supernatant of duck and chicken EBx® cells were investigated by an ELISA assay detecting the avian leukosis major capsid antigen P27 (Figure 6B). All Duck EBx® cell lines (EB26, EB51 , EB24, EB66...), as well as chicken EBv13 do not secrete ALV p27 antigen. In the opposite, chicken EB14 cells do express ALV P27 antigen.
7.2.4 - Duck EBx cells do not secrete replicative avian leucosis virus (ALV) Co-cultivation assay of duck EBx cells with quail QT6 cell line, known to be sensitive to endogenous and exogenous ALVs, were performed to detect the presence of endogenous replicative duck viruses. Figure 7A described the principle of QT6 co-culture. The presence of replicative virus is detected by an ELISA assay detecting the avian leucosis major capsid antigen P27. The assay demonstrates that none of duck EBx cells tested secrete replicative (i.e replication competent) ALV (Figure 7B).
7.2.5 - Duck EBx cells express avian and human influenza virus receptors
The detection of receptors to avian (Siaα2-3Gal) and human (Siaα2-6Gal) influenza viruses on duck EBx cells were performed by fluorescent cell sorter analysis by using digoxygenin labelled lectins (Boehringer):
Q Sambuca nigra (SNA) agglutinin lectin specifically binds to Siaα2-6Gal;
Q Maackia amurensis (MAA) agglutinin lectin specifically binds to Siaα2-3Gal.
Chicken EB14 and duck EBx cells were washed in 1 OmM HEPES, 15OmM NaCI pH7.5 and resuspended in the same buffer at a 5.106 final concentration. Cells were incubated 30 min on ice, then for an additional 15 to 30 minutes in presence of SNA or MAA. Lectin treated cells were washed in 1OmM HEPES, 15OmM NaCI pH7.5, prior to incubation on ice during 15 to 30 minutes with FITC-labelled anti-digoxygenin antibody. Then cells are washed in NaCI 0.9 % and
FACS analyzed.
Chicken EB14 and duck EBx cells express cell surface receptors comprising oligosaccharides with Siaα2-6Gal and Siaα2-3Gal residues (Figure 8).
7.2.6 - Karyotype
Karyotype analysis was performed to check the cell diploidy and the avian origin of duck EB24 and EB66 cells. Cells in the exponential phase of growth were harvested and treated 3 to 6 hours by colcemid (0,6 mg/mL). After washing and centrifugation, an hypotonic choc is performed on cells with KCI (0,56 %) during 20 minutes. Subsequently, duck EB24 and EB66 cells were fixed in methanol/acetic acid (3/1 ) and stored overnight at -2O0C. The day after, metaphasis were spotted on glass, stained by a wright/giemsa solution and observed under microscope.
Several series of metaphases were observed confirming the duck origin of EBx cells. No evidence of polyploidy were observed. Figure 16 shows diploid karyotype of duck EBx66 cells (Figure 16).
EXAMPLE 6: Poxyirus Replication in Chicken EBv13 cell line
Susceptibility of EBv13 cells to infection with poxvirus was investigated using a recombinant Modified Vaccinia Ankara (MVA) encoding a GFP gene (Green Fluorescent Protein).
The following protocol were used: Three days before infection, 0.4X106 EBv13 cells (passage 188)/ml_ are seeded in T175 flasks under 40 mL of SFM Excell 65319 (SAFC) supplemented with 4 mM Glutamine. The infection is performed at a multiplicity of infection of 10~2 TCID50/cell (MVA-GFP stock is at 10e9.7 TCID/ml). One hour post infection, 60 ml of fresh medium is added to the flask. The culture and the infection were performed at 370C, 7.5 % CO2 and agitated at 60 rpm. Each day post infection an aliquot of the cell suspension is collected and frozen. At the end of the kinetic, an evaluation of the productivity is performed following the TCID50 method. Briefly, the titration of infectious MVA-GFP viruses was performed on DF-1 cells. Cells were seeded in 96 flat-bottom well plates at a density of 15 x103 cells/well in DMEM medium (Biowhittaker) supplemented with 5 % foetal calf serum (FCS) (SAFC) and 2 mM L- glutamine (Biowhittaker). Twenty-four hours later, cells were infected with ten fold serially diluted samples in DMEM and incubated for one week at 370C, 5 % CO2 in a humidified atmosphere. Virus infectivity was measured through microscopic observation of global cytopathic effect (CPE) and UV-exposed infected cells. Then, TCID50 titers were calculated according the Reed and Muench method (1938, A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-97). All along the experiment cell proliferation and viability are monitored. Chicken VaIo EBv13 cells appear to be highly sensitive to MVA-GFP infection (Figures 3A-3B).
EXAMPLE 8: Poxyirus Replication in duck EBx cell lines
Susceptibility of duck EBx cells to infection with poxvirus was investigated using a recombinant Modified Vaccinia Ankara encoding a GFP. The virus titration was performed as previously described for chicken EBv13 cells.
8.1 - Cell culture Method
Duck EBx cells were stored in cryovials in liquid nitrogen at -1960C (20x106 cells/vial). The cryovial is directly thawed into a +37 0C pre-warmed water bath. The cell suspension is put into a 50 ml sterile tube with 30 ml pre-warmed culture medium. After centrifugation (5 min at 300 ±20 g, at room temperature), 15 ml of fresh culture medium is added on the pellet and gently homogenised. The sample is numbered using Trypan blue. Numeration has to be > 20 x106 cells and viability has to be > 70 % to guarantee a good culture.
The cell suspension is plated into a T75 cm2 flask and incubate at + 37 0C under an 7.5 % CO2 atmosphere on an orbital shaker at 50 rpm. Fresh medium is then added daily. The cells are then passaged to increase cells biomass to seed a 3L-bioreactor. 320.106 cells are needed to inoculate a 3L-bioreactor. A sample is taken after gently mixing to perform a numeration using trypan blue to determine cell density. A 150 ml_ cell mix is prepared in order to obtain a cell concentration of 0.4x106 cells. ml"1 into the 800 ml final culture volume in the bioreactor. Prior to seed cells, the pH is set in the vessel to 7.2 (because pH will be decrease by CO2 surface injection). The pθ2 is set to 50 % O2 saturation (the mass flow controller is adjusted to 100 % which correspond to a maximum sparger flow rate to 50 ml. min'1). At the beginning of the process, the pH is maintained by CO2 surface injection, later, it is controlled by addition of 7.5 % NaHCO3. The surface aeration is started with air at a flow rate of 0.3 ml. min'1. Cell numeration is performed on a routine basis.
After 3 days of culture, cell density should be higher than 4-5 x 106 cells. ml"1. If the expected cell density is reached, the virus infection is performed at a MOI of 10~4. The vessel temperature is set to 330C. The virus strain is thawed on ice. The infection mix is prepared in 10 ml of production medium. After inoculation of the infection mix into the bioreactor, viral adsorption is performed during 1 hour. The final production medium is prepared: in 1.5 L of production medium, trypsin is added in order to obtain a final concentration in the vessel of 0.3 U. ml"1 (2.3 L on the whole). The pre-warmed final production medium is then added. Every day a sample of approximatively 15 ml is collected from the bioreactor to perform cell numeration, cell morphology analysis and to observe CPE. The metabolites such as glutamate, glutamine, lactate and glucose are analyzed all along the culture with the BioProfile Basic software. Concentration of the metabolites is adjusted if necessary. For example, glutamine concentration is adjusted to 2 mM if necessary. The glucose concentration is adjusted to 2 g.L"1 if necessary.
Virus titration is carried-out at the end of the experiment using all collected samples.
8.2 - Results
8.2.1 - Cell growth kinetics of duck EBx® cells in a 3L fedbatch bioreactor Duck EBx® cells are routinely cultured in stirred-tank bioreactor. Duck EBx®-derived biomass is allowed to accumulate at 370C in a cell growth medium until a cell density of 5-6.106 cells/mL was reached. Then the mixture is diluted from around 3 to 10 fold, and cell growth kinetic is followed-up over a 10 days period. In such conditions, cell density of 12 to 20 million cells/ml is routinely reached around day 5 to 8. Thus Duck EBx® cells display a range of splitting ratio that goes at least up to 10 to 15 fold.
8.2.2 - Influence of cell culture medium composition on the clumps size during MVA-GFP virus infection of duck EBx cells The inventors have found that the concentration of Calcium and Magnesium in the serum-free medium used for the EBx cells culture and infection may have an impact on the clumps size. The presence of small clumps of duck EBx cells improves virus infection and propagation, leading to high MVA virus titers (Figure 9A).
8.2.3 - MVA virus production in 3L-bioreactor
Duck EBx® -derived biomass was allowed to accumulate during cell proliferation phase in Excell 66444 growth medium. Cells were then infected with 10~2 TCID50/cell of MVA-GFP virus and the mixture was diluted in Excell 66444 production medium. Following addition of fresh Excell medium, cell density dropped down on day 2, and at day 4, the cell density of infected cells increased and reached 12 million cell/ml. In such conditions, the MVA-GFP productivity is high. Since at day 4 post-infection, the MVA-GFP titer is around 108 TCID50/ml (Figure 9B). A MVA-GFP yield of 205 TCID50/cell was obtained in duck EBx® cells.
EXAMPLE 9: Production of Influenza Virus in duck EBx cell lines 9.1 - Materials & Methods
9.1.1 - Influenza virus infectivity assay (TCID50)
Titration of infectious influenza viruses was performed on MDCK cells. In brief, cells were seeded in 96 flat-bottom well plates at a density of 3x103 cells/well in UltraMDCK medium supplemented with 2.5 mM L-glutamin. Twenty-four hours later, cells were infected with ten fold serially diluted samples in UltraMDCK containing 6μg.ml_~1 trypsin-EDTA and incubated for one week at 330C, 5 % CO2 in a humidified atmosphere. Virus replication was then tested in an HA assay using chicken red blood cells and TCID50 titers were calculated according the Reed and Muench method (1938)*._*Reed L, Muench H, 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-97.
9.1.2 - Single radial immuno-diffusion assay (SRID)
The concentration of haemagglutinin in samples derived from influenza virus infected-EB14 cells, was determined as described by Wood and colleagues*. Briefly, glass plates were coated with an agarose gel containing anti-Influenza serum (recommended concentration provided by NIBSC). After the gel has set, 10 μL of appropriate dilutions of the reference and the samples were loaded in 3mm 0 punched wells. Following a 18-24h incubation in a moist chamber at room temperature, plates were soaked in 0.9 % NaCI and washed in distilled water. The gel was then pressed and dried. The plates were stained on Coomassie Brillant Blue solution for 15 min and destained twice in a mixture of methanol and acetic acid until clearly defined stained zones became visible. After drying the plates, the diameter of the stained zones surrounding antigen wells were measured in two directions at right angles. Dose-response curves of antigen dilutions against the surface were constructed and the results were calculated according to standard slope-ratio assay methods. *Wood JM. Et al. "An improved single-radial- immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines" (J. Biol. Stand., 1977, 5(3):237-47).
9.1.3 - Western blot analysis of influenza hemagglutinin protein SDS-PAGE was performed as described by Laemmli UK (1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 259:680-685) in 10 % polyacrylamide gel. Denaturated proteins (1 % SDS, 7OmM β-mercaptoethanol) were transferred to polyvinylidene difluoride membrane (hybond P, Amersham) by a semidry blotting procedure (Kyhse-Andersen J (1984) Electroblotting of multiple gels : a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose (J Biochem Biophys Methods 10:203-209). Blots were blocked for 1 h at room temperature with a mixture composed of 5 % fat dry milkpowder in TBST suplemented with 1 % FCS (SAFC). Then, the blots were incubated overnight in blocking solution supplemented with specific polyclonal anti- HA sheep serum (1 :500 (NIBSC). The blots were washed 6 times with TBST and incubated for 1 h at room temperature with a hrp-conjugated rabbit anti-sheep IgG polyclonal antibody (1 :5000 (Rockland) in blocking solution. After 6 washes with TBST, the protein-conjugate complex was finally revealed using chemiluminescence (ECL kit, Amersham) and films (Hyperfilm, Amersham).
9.2 - Influenza virus infection of duck EBx® cells in 3L-Bioreactor 9.2.1 - Materials and equipment
Cell thawing material o T75 cm2 flasks (Sarstedt, Cat# 831813502) o Culture medium (serum free medium) o L-Glutamine 20OmM (Biowhittaker, Cat# BE17-605E) o Orbital agitator IKA KS260 (Fisher Bioblock, Cat# F35044) Cell amplification material o T175 cm2 flasks (Sarstedt, Cat# 831812502) o Culture medium (serum free medium) : Excell 65319 (JRH, Cat# 65319- 1000M1687) added with 2.5mM glutamine o L-Glutamin 20OmM (Biowhittaker, Cat# BE17-605E) o D (+) Glucose (45 %) (Sigma, Cat# G8769) Production material o Production medium (serum free medium) : Excell 65629 (JRH, Cat# 65629) supplemented with 2.5mM glutamine o L-Glutamin 20OmM (Biowhittaker, Cat# BE17-605E) o D (+) Glucose (45 %) (Sigma, Cat# G8769) o Trypzean "IX (Sigma, Cat# T3449) o 7.5 % bicarbonate sodium solution (Sigma, Cat# 205-633-8) o Influenza virus strain (frozen at -8O0C)
9.2.2- Cell culture Method (Idem as for MVA replication - Example 7.1 )
Virus titration, haemmaglutinin assays (HAU) and HA antigen quantifications (western blot, SRID) are carry out at the end of the experiment using all collected samples.
9.3- Results The inventors demonstrate that duck EBx cells are a reliable and efficient cell substrate for the replication of various strains A and B of influenza virus. Influenza virus production can be performed in various vessels, such as flasks and spinner (data not shown) and bioreactors. Reproducible and efficient fedbatch process of production of influenza virus in 3L and 3OL stirred tank bioreactors were obtained by the inventors. Viral yield above 15 mg/l and up to 50 mg/l of haemagglutinin are routinely obtained in flasks and in bioreactors with strains A and B of influenza virus (Figures 11 and 12).
EXAMPLE 10: Newcastle Disease Virus Replication in duck EBx cell lines
Susceptibility of duck EBx cells to infection with Newcastle Disease virus was investigated using a NDV La Sota strain.
10.1 - Methods
Duck EBx® cells were grown in Excell medium (SFAC) in T175 flasks at 37 0C under 7.5 % CO2 atmosphere on an orbital shaker at 60 rpm. At day 0, cells are seeded at 0.4x106 cells/mL in 40 ml fresh medium. Cell culture was incubated at 370C, 7.5 % CO2 under shaking (60 rpm). Cell growth kinetics were followed until cell density has reached a concentration between 4x106 to 6x106 cells/ml (usually at day 3 post seeding). At that point, cells are inoculated with NDV La Sota strain at two different MOI (103and 10~4 TCID50/cells) and incubated for one additional hour at 370C, 7.5 % CO2 under shaking (60 RPM). Then the cell culture was diluted with the addition of 60 mL fresh viral production medium and the incubation pursued at 370C and 7.5 %CO2 under shaking (60 rpm). The cell growth and virus production kinetics were performed over 7 days. As a source of protease, recombinant trypsin (SAFC) was added every day in the culture medium; two concentration of trypsin (0.4 and 0.75 USP/mL) were tested. Daily aliquots were removed for cell numeration, virus titration and Western blotting analysis.
The samples were separated using 10 % SDS-PAGE and blotted onto PDVF membrane (Amersham) by the semi-dry technique. Immunodetection was performed using chicken polyclonal antiserum against NDV (1 :2000, CHARLES RIVER laboratories), followed by Alkaline phosphatase-conjugated rabbit anti-chicken (1 :5000, SIGMA). Bound secondary antibody was detected using the ECL-Chemiluminescence detection system kit (ROCHE).
10.2 - Results Duck and chicken EBx cells are sensitive to and replicate NDV La Sota strain. Titers (in TCID50/ml) of NDV produced in duck EBx® cells increase from day 0 to day 2 pi to reach an average of 106 83 τciD5o/mL (Figure 13 left panel).
Western blot analysis (Figure 13 right Panel) showed NDV viral proteins (HN, Fo/F, NP & M) expression. The viral proteins composition of NDV virus produced in duck EBx® cells are similar to the one obtained with NDV virus produced in chicken EBx® cells. In addition, the kinetic of release for viruses produced in chicken and Duck EBx cells are similar.
EXAMPLE 11 : Measles Virus Replication in duck EB66 cells
Susceptibility of duck EB66 cells to infection with measles virus was investigated using a recombinant measles virus expressing green fluorescent protein.
11.1 - Methods
EB66 cells were grown in Excell medium in T175 flasks at 37 0C under 7.5 % CO2 atmosphere on an orbital shaker at 60 rpm. At day 0, cells are seeded at 0.4x106 cells/mL in 40 ml fresh medium. Cell culture was incubated at 370C, 7.5 % CO2 under shaking (60 rpm). Cell growth kinetics were followed until cell density has reached a concentration between 4x106 to 6x106 cells/ml (usually at day 3 post seeding). At that point, cells are inoculated with recombinant measles virus at two different MOI (10"1and 10~2 TCID50/cells) and incubated for one additional hour at 370C, 7.5 % CO2 under shaking (60 RPM). Then the cell culture was diluted with the addition of 60 mL fresh viral production medium and the incubation pursued at 370C and 7.5 %CO2 under shaking (60 rpm). The cell growth and virus production kinetics were performed over 7 days. Daily aliquots were removed for cell numeration and virus titration.
11.2 - Results EB66 cells are sensitive to and replicate measles virus. In non optimised conditions, titers (in TCID50/ml) of measles produced in EB66 cells reach an average of 107 TCID50/mL (Figure 14).

Claims

1. A Process for obtaining continuous diploid avian cell lines, named EBx®, derived from avian embryonic stem cells (ES), wherein said avian cell lines do not produce replication- competent endogenous retrovirus particles, and said process comprising the steps of: a) isolating bird embryo(s) at a developmental stage around oviposition, wherein the genome of said bird does not contain endogenous proviral sequences susceptible to produce replication competent endogenous retroviral particles; b) suspending avian embryonic stem (ES) cells obtained by dissociating embryo(s) of step a) in a basal culture medium supplemented with:
- insulin Growth factor 1 (IGF-1 ) and Ciliary Neurotrophic factor (CNTF);
- animal serum; and
- optionally, growth factors selected in the group comprising interleukin 6 (IL-6), interleukin 6 receptor (IL-6R), Stem cell Factor (SCF) and Fibroblast Growth Factor (FGF); c) seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ES cells for at least one passage; d) optionally withdrawing all the growth factors selected from the group comprising IL- 6, IL-6R, SCF, FGF from the culture medium and further culturing the ES cells for at least one passage; e) withdrawing IGF-1 and CNTF from the culture medium, and further culturing the cells for at least one passage; f) progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, and further culturing the cells; g) optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages and: h) obtaining adherent avian EBx® cell lines derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; i) optionally, further adapting adherent avian EBx® cell lines to suspension culture conditions.
2. The process according to claim 1 wherein said bird is selected in the Order of Anseriformes.
3. The process according to claim 2 wherein said bird is a duck, preferably a Pekin duck.
4. The process according to claim 1 wherein said bird is selected in the Order of Galliformes.
5. The process according to claim 4 wherein said bird is an ev-0 domestic Chicken.
6. Continuous diploid avian cell lines obtainable by the process according to claims 1 to 5 wherein cells of said avian cell lines have at least one of the following characteristics: a high nucleo-cytoplasmic ratio, an endogenous telomerase activity, a diameter of around 10 μm; a population doubling time of around 30 hours or less at 370C; - and optionally, said cells may express one or more additional markers selected in the group comprising alkaline phosphatase, SSEA-1 , EMA-1 , ENS-1 , and wherein said cells do not produce replication-competent endogenous retrovirus particles.
7. A process of replicating a virus in the continuous diploid avian cells of claim 6 or obtainable by the process according to one of claims 1 to 5, comprising the steps of: a) infecting said avian cells with a virus of interest; b) culture of said infected avian cells in order to replicate said virus; c) harvest the virus in cell culture supernatant and/or inside said cells.
8. The process according to claim 7, wherein said virus is selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnavriruses and retroviruses.
9. The process according to claim 8 wherein the virus is a poxvirus or a recombinant poxvirus selected among the group comprising Modified Vaccinia Ankara (MVA) virus, Lister- Elstree vaccinia virus, LC16m8 vaccinia virus, CVI78 vaccinia virus, Fowl pox virus, canary pox virus (i.e ALVAC), NYVAC, juncopox virus, mynah pox virus, pigeonpox virus, psittacine pox virus, quail pox virus, sparrow poxvirus, starling pox virus, turkey pox virus.
10. The process according to claim 7 wherein the virus is a paramyxovirus or a recombinant paramyxovirus preferably selected among the group comprising measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human para- influenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, duck para-influenza virus.
11. The process according to claim 7 wherein the virus is an orthomyxovirus, a recombinant orthomyxovirus or a reassorted orthomyxovirus selected among human influenza virus, avian influenza virus, swine influenza virus, equine influenza virus, feline influenza virus.
12. The process according to claim 7 wherein the virus is a togavirus preferably selected among Sinbis virus, Semliki forest virus, O'nyong'nyong virus, Chikungunya virus, Mayaro virus, Ross river virus, Eastern equine encephalitis virus, Western Equine encephalitis virus, Venezuelan Equine encephalitis virus, or a recombinant togavirus thereof.
13. The process according to claim 7 wherein the virus is a retrovirus selected among reticulo-endotheliosis virus, duck infectious anemia virus, suck spleen necrosis virus, or a recombinant retrovirus thereof.
14. The process according to claim 7 wherein the virus is a parvovirus preferably a duck parvovirus or a recombinant parvovirus thereof.
15. The process according to claim 7 wherein the virus is an adenovirus preferably selected among fowl adenovirus, goose adenovirus, duck adenovirus and pigeon adenovirus or a recombinant adenovirus thereof.
16. The process according to claim 7 wherein the virus is a birnavirus preferably Infectious Bursal Disease virus.
17. The process according to claim 7 wherein the virus is a flavivirus preferably selected among Dengue virus, Japanese encephalitis virus and West Nile virus.
18. A virus obtained by a process as claimed in one of claims 7 to 17.
19. A vaccine containing virus as claimed in claim 18, if appropriate in combination with pharmaceutically acceptable substances which increase the immune response.
20. The vaccine according to claim 19 wherein the virus is selected in the group comprising the virus present as an intact virus particles and the virus present as a disintegrated virus particles.
21. A vaccine containing at least one viral antigenic protein obtained from a virus as claimed in claim 18, if appropriate in combination with pharmaceutically acceptable substances which increase the immune response.
22. A vaccine comprising avian cells derived from avian cell lines as claimed in claim 6 or obtainable by the process according to one of claims 1 to 5, and infected with a virus.
23. A process of production of recombinant proteins and peptides, comprising the steps of: a) genetically modifying the continuous diploid avian cell lines obtainable by the process according to one of the claims 1 to 5, or according to claim 6, by transient or stable transfection of an expression vector; b) optionally, selecting said modified continuous diploid avian cell lines expressing said recombinant proteins or peptides; and c) purifying the recombinant peptides or proteins expressed by said genetically modified continuous diploid avian cell lines.
PCT/EP2008/054912 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines WO2008129058A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CN200880013257.3A CN101668539B (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
AU2008240708A AU2008240708B2 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
PL08736491T PL2150275T3 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
NZ581321A NZ581321A (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
EA200970996A EA021064B1 (en) 2007-04-24 2008-04-23 Continuous diploid avian cell lines derived from embryons, process for obtaining same and use thereof for the production of viral vaccines, recombinant proteins and peptides
CA2684845A CA2684845C (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
ES08736491.5T ES2442009T3 (en) 2007-04-24 2008-04-23 Stem cell lines derived from duck embryos for the production of viral vaccines
EP08736491.5A EP2150275B1 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
US12/597,486 US20100062489A1 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
BRPI0809842A BRPI0809842B8 (en) 2007-04-24 2008-04-23 process for obtaining continuous diploid avian cell lines, process of replicating a virus in a continuous diploid avian cell line, and process for producing recombinant peptides and proteins
SI200831121T SI2150275T1 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
KR1020157005296A KR20150036788A (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
MX2009011505A MX343247B (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines.
DK08736491.5T DK2150275T3 (en) 2007-04-24 2008-04-23 ANT-EMBRYONIC DERIVATIVE STEM CELL LINES FOR THE PREPARATION OF VIRAL VACCINES
JP2010504672A JP5539185B2 (en) 2007-04-24 2008-04-23 Duck embryo-derived stem cell line for the production of viral vaccines
IL201679A IL201679A (en) 2007-04-24 2009-10-22 Continuous genetically stable avian cell lines, process for obtaining the same, process for replicating viruses therein and vaccines containing said viruses
HK10107529.3A HK1140964A1 (en) 2007-04-24 2010-08-06 Duck embryonic derived stem cell lines for the production of viral vaccines
US14/069,423 US9260694B2 (en) 2007-04-24 2013-11-01 Generation of duck cell lines
HRP20131203AT HRP20131203T1 (en) 2007-04-24 2013-12-17 Duck embryonic derived stem cell lines for the production of viral vaccines
US15/013,079 US9822345B2 (en) 2007-04-24 2016-02-02 Method of making a virus using duck embryonic derived stem cell lines
US15/785,530 US20180135026A1 (en) 2007-04-24 2017-10-17 Duck embryonic derived stem cell lines for the production of viral vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07300979A EP1985305A1 (en) 2007-04-24 2007-04-24 Duck embryonic derived stem cell lines for the production of viral vaccines
EP07300979.7 2007-04-24

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/597,486 A-371-Of-International US7700133B2 (en) 2004-02-18 2005-02-17 Antimicrobial formulations and methods of using the same
EP12187538.9A Previously-Filed-Application EP2572727B1 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
US12/597,486 A-371-Of-International US20100062489A1 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines
US14/069,423 Division US9260694B2 (en) 2007-04-24 2013-11-01 Generation of duck cell lines

Publications (1)

Publication Number Publication Date
WO2008129058A1 true WO2008129058A1 (en) 2008-10-30

Family

ID=38521810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/054912 WO2008129058A1 (en) 2007-04-24 2008-04-23 Duck embryonic derived stem cell lines for the production of viral vaccines

Country Status (23)

Country Link
US (4) US20100062489A1 (en)
EP (4) EP1985305A1 (en)
JP (1) JP5539185B2 (en)
KR (2) KR20150036788A (en)
CN (1) CN101668539B (en)
AU (1) AU2008240708B2 (en)
BR (1) BRPI0809842B8 (en)
CA (1) CA2684845C (en)
CY (1) CY1114736T1 (en)
DK (1) DK2150275T3 (en)
EA (1) EA021064B1 (en)
ES (2) ES2574827T3 (en)
HK (1) HK1140964A1 (en)
HR (1) HRP20131203T1 (en)
IL (1) IL201679A (en)
MX (1) MX343247B (en)
MY (1) MY151119A (en)
NZ (1) NZ581321A (en)
PL (1) PL2150275T3 (en)
PT (1) PT2150275E (en)
SI (1) SI2150275T1 (en)
WO (1) WO2008129058A1 (en)
ZA (1) ZA200908152B (en)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052214A3 (en) * 2008-11-05 2010-07-22 Glaxosmithkline Biologicals S.A. Novel method
WO2010081890A1 (en) 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies
WO2010089339A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
WO2010130756A1 (en) * 2009-05-12 2010-11-18 Transgene Sa Immortalized avian cell lines and use thereof
JP2011512800A (en) * 2008-02-25 2011-04-28 バクスター・インターナショナル・インコーポレイテッド Generation of continuous cell lines
WO2011051445A1 (en) 2009-10-30 2011-05-05 Glaxosmithkline Biologicals S.A. Process for preparing an influenza seed virus for vaccine manufacture
WO2011051235A1 (en) 2009-10-27 2011-05-05 Glaxosmithkline Biologicals, Niederlassung Der Smithkline Beecham Pharma Gmbh & Co. Kg Process for producing influenza vaccine
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011098615A1 (en) 2010-02-15 2011-08-18 Universite Claude Bernard Lyon 1 Cells modified for virus production by inhibition of the hipk2 gene
WO2011138229A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
WO2012004323A1 (en) 2010-07-08 2012-01-12 Glaxosmithkline Biologicals S.A. Process for removing adventitious agents during the production of a virus in cell culture
WO2012021934A1 (en) 2010-08-17 2012-02-23 Csl Limited Humanized anti-interleukin 3 receptor alpha chain antibodies
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
JP2012525830A (en) * 2009-05-08 2012-10-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method for producing virus from cell culture including homogenization
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
WO2013059886A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
US20130115234A1 (en) * 2010-03-26 2013-05-09 Emergent Product Development Gaithersburg,Inc. Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
US8524249B2 (en) 2009-12-15 2013-09-03 University Of Saskatchewan Vaccines for inclusion body hepatitis
US8962311B2 (en) 2006-08-09 2015-02-24 Valneva Method of obtaining chicken embryonic stem cells
WO2015028546A1 (en) 2013-08-30 2015-03-05 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
US9260694B2 (en) 2007-04-24 2016-02-16 Valneva Generation of duck cell lines
US9382513B2 (en) 2002-03-08 2016-07-05 Valneva Method of making an avian cell line
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US10144917B2 (en) 2014-08-29 2018-12-04 Calixar Method for preparing a vaccine antigen, resulting vaccine antigen and uses
WO2018227016A1 (en) 2017-06-07 2018-12-13 Wild Type, Inc. Ex vivo meat production
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa Oncolytic viruses expressing agents targeting metabolic immune modulators
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
EP3552615A1 (en) 2014-07-16 2019-10-16 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
WO2019219649A1 (en) 2018-05-14 2019-11-21 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
WO2020012037A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
US10584175B2 (en) 2014-10-23 2020-03-10 La Trobe University FN14-binding proteins and uses thereof
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020049001A1 (en) 2018-09-03 2020-03-12 Bioinvent International Ab Novel antibodies and nucleotide sequences, and uses thereof
WO2020074690A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
WO2020094693A1 (en) 2018-11-07 2020-05-14 Vivet Therapeutics Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
WO2020104650A1 (en) 2018-11-23 2020-05-28 Valneva Se Food products comprising avian stem cells
WO2020123876A1 (en) 2018-12-12 2020-06-18 Wild Type, Inc. Synthetic food compositions
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
EP3744351A1 (en) 2014-12-17 2020-12-02 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
WO2021001377A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada cPLA2e INDUCING AGENTS AND USES THEREOF
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
EP3799889A1 (en) 2014-12-17 2021-04-07 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease and other conditions
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2022029322A2 (en) 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
WO2022033983A1 (en) 2020-08-10 2022-02-17 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
WO2022074105A1 (en) 2020-10-09 2022-04-14 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023046777A1 (en) 2021-09-22 2023-03-30 Bioinvent International Ab Novel combinations of antibodies and uses thereof
WO2023073071A1 (en) 2021-10-28 2023-05-04 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
US11654189B2 (en) 2016-09-28 2023-05-23 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
EP4219552A2 (en) 2013-02-07 2023-08-02 CSL Ltd. Il-11r binding proteins and uses thereof
EP4257155A2 (en) 2018-11-16 2023-10-11 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
US12083188B2 (en) 2017-12-01 2024-09-10 Encoded Therapeutics, Inc. Engineered DNA binding proteins

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102120983B (en) * 2010-01-07 2013-04-03 中国农业科学院北京畜牧兽医研究所 Separation and culture method of epidermal stem cells of Beijing ducks
WO2012050229A1 (en) * 2010-10-15 2012-04-19 財団法人東京都医学総合研究所 Recombinant vaccinia virus having hemagglutinin protein genes derived from novel influenza viruses
FR2967072B1 (en) 2010-11-05 2013-03-29 Univ Dundee PROCESS FOR IMPROVING INFLUENZA PRODUCTION OF VACCINE AND SEEDS
CN103157107A (en) * 2011-12-14 2013-06-19 普莱柯生物工程股份有限公司 Chicken Marek's disease vaccine produced by using continuous passage cell line and production method
AR089231A1 (en) * 2011-12-15 2014-08-06 Amgen Inc FLOCULATION METHOD
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
SG11201503854UA (en) * 2012-11-22 2015-06-29 Asahi Kasei Medical Co Ltd Method for producing parvovirus having high infectivity titer
PT2951208T (en) 2013-02-01 2019-12-30 Univ California Anti-cd83 antibodies and use thereof
FR3008992A1 (en) * 2013-07-25 2015-01-30 Agronomique Inst Nat Rech METHOD FOR SELECTING A PERMISSIVE CELL LINE FOR THE REPLICATION OF AVIAN VIRUSES
CN105177176A (en) * 2014-06-13 2015-12-23 亚宝药业太原制药有限公司 Adenovirus titer detection method
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
CN107137704B (en) * 2016-08-20 2020-02-21 山东信得科技股份有限公司 Duck type 2 adenovirus inactivated vaccine
CN106692964A (en) * 2016-12-05 2017-05-24 扬州大学 Serum type 4 fowl adenovirus inactivated vaccine and preparation method thereof
CN107058243A (en) * 2017-03-23 2017-08-18 华南农业大学 A kind of suspension culture method of MDV
CN107794248A (en) * 2017-10-24 2018-03-13 广州齐志生物工程设备有限公司 A kind of method with microcarrier suspension culture CDV
KR102121042B1 (en) * 2017-12-06 2020-06-09 이정복 Medium composition for cell proliferation, skin regeneration and wrinkle improvement comprising conditioned medium of pluripotent stem cells, neural stem cells and embryonic fibroblasts isolated from an egg of a bird
CN108220227A (en) * 2017-12-27 2018-06-29 华农（肇庆）生物产业技术研究院有限公司 A kind of method for the culture newcastle disease virus that suspended by the continuous cell line that suspends entirely
CN108159412A (en) * 2018-01-12 2018-06-15 华农（肇庆）生物产业技术研究院有限公司 It is a kind of to produce cell source newcastle disease, method of bird flu bivalent inactivated vaccine and products thereof
CN108261543B (en) * 2018-02-08 2019-03-08 华农（肇庆）生物产业技术研究院有限公司 The preparation method and applications of subculture cell source ND, IB, AI triple inactivated vaccine
CN108187039A (en) * 2018-03-29 2018-06-22 山东信得动物疫苗有限公司 A kind of inactivated avian influenza vaccine production technology and product
CN108977554B (en) * 2018-09-05 2021-08-31 湖北省农业科学院畜牧兽医研究所 Egg duck circular RNA circ _13034 and detection reagent, method and application thereof
WO2020108735A1 (en) 2018-11-26 2020-06-04 Blink Biomedical Sas Antibodies to cytomegalovirus interleukin-10
CN113423815A (en) * 2018-12-06 2021-09-21 创赏有限公司 Bacterial growth on non-animal derived media
CN109593729A (en) * 2018-12-29 2019-04-09 肇庆大华农生物药品有限公司 A kind of fowl Egg Drop syndrome virus cultural method and its application in vaccine
MX2021006115A (en) * 2019-01-17 2021-07-07 Boehringer Ingelheim Animal Health Usa Inc Serum-free medium for avian vaccine production and uses thereof.
JP7212588B2 (en) 2019-06-20 2023-01-25 オルガノ株式会社 water treatment equipment
CN112094819B (en) * 2020-08-13 2022-10-14 浙江美保龙生物技术有限公司 Full suspension culture method of chicken infectious bursal disease virus
CN112442486B (en) * 2020-11-05 2023-02-10 上海奥浦迈生物科技股份有限公司 Culture medium for maintaining late-stage viability of CHO DG44 cells cultured in vitro and application thereof
CN113699119A (en) * 2020-12-10 2021-11-26 华农（肇庆）生物产业技术研究院有限公司 Serum-free full-suspension culture preparation method of newcastle disease virus and vaccine
CN113278595B (en) * 2021-04-28 2023-05-09 重庆永健生物技术有限责任公司 Duck adenovirus type 3 strain, duck adenovirus egg yolk antibody, and preparation methods and application thereof
CN115449502B (en) * 2022-08-15 2023-10-20 广东省华晟生物技术有限公司 Serum-free full-suspension culture type BHK-21-C cell strain and construction method and application thereof
WO2024188801A1 (en) * 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076601A1 (en) * 2002-03-08 2003-09-18 Vivalis Avian cell lines for the production of useful substances
WO2005007840A1 (en) * 2003-07-22 2005-01-27 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
WO2007135133A1 (en) * 2006-05-19 2007-11-29 Vivalis Avian cell lines derived from primordial germ cells useful for the production of substances of interest

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534740A (en) * 1895-02-26 Indicating door-bell
CA1341469C (en) 1988-08-04 2004-12-28 Robert Lindsay Williams In vitro propagation of embryonic stem cells
US5162215A (en) 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
JPH05227947A (en) 1992-01-14 1993-09-07 Rikagaku Kenkyusho Method for separating avian primordial germ cell
AU3597093A (en) 1992-01-27 1993-09-01 Embrex Inc. Gene transfer in poultry by introduction of embryo cells (in ovo)
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
WO1994003585A1 (en) 1992-08-04 1994-02-17 Commonwealth Scientific And Industrial Research Organisation A method for maintaining embryonic stem cells and avian factor useful for same
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
JPH0924997A (en) 1995-07-11 1997-01-28 Tokico Ltd Shipping apparatus
WO1998015614A1 (en) 1996-10-10 1998-04-16 Life Technologies, Inc. Animal cell culture media comprising plant-derived nutrients
DE69729839T2 (en) 1996-11-12 2005-07-21 Pfizer Inc. Attenuated live Neospora vaccine
EP1616943A1 (en) 1997-08-04 2006-01-18 University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, Avian primordial germ cell (PGC) cell line and a method for long term culturing thereof
ATE312167T1 (en) 1997-08-04 2005-12-15 Univ Massachusetts PRODUCTION OF EMBRYONIC BIRD GERM CELL LINES BY PROLONGED CULTIVATION OF PGCS, USING THE SAME FOR CLONING AND CHIMERIZATION
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
CN100386429C (en) 1999-02-11 2008-05-07 韩在容 Avian pluripotent embryonic germ cell line
DE19947407C2 (en) 1999-10-01 2002-08-01 Bayerische Motoren Werke Ag Data bus system for motor vehicles
ES2398706T3 (en) * 2002-07-09 2013-03-21 Baxter International Inc. Animal protein free medium for cell culture
EP1500699A1 (en) * 2003-07-22 2005-01-26 Vivalis Production of vaccinia virus with adherent or non adherent avian cell lines
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (en) 2005-04-11 2010-11-05 Vivalis USE OF EBX AVIATION STEM CELL LINES FOR THE PRODUCTION OF INFLUENZA VACCINE
CN102268413A (en) * 2006-01-05 2011-12-07 特兰斯吉恩股份有限公司 avian telomerase reverse transcriptase
MX2009001477A (en) 2006-08-09 2009-02-18 Vivalis Method of production of transgenic avian using embryonic stem cells.
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076601A1 (en) * 2002-03-08 2003-09-18 Vivalis Avian cell lines for the production of useful substances
WO2005007840A1 (en) * 2003-07-22 2005-01-27 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
WO2007135133A1 (en) * 2006-05-19 2007-11-29 Vivalis Avian cell lines derived from primordial germ cells useful for the production of substances of interest

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUSSAIN ALTHAF I ET AL: "Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: Investigation of transmission to vaccine recipients.", JOURNAL OF VIROLOGY, vol. 77, no. 2, January 2003 (2003-01-01), pages 1105 - 1111, XP002453377, ISSN: 0022-538X *
JOHNSON J A ET AL: "Characterization of endogenous avian leukosis viruses in chicken embryonic fibroblast substrates used in production of measles and mumps vaccines.", JOURNAL OF VIROLOGY APR 2001, vol. 75, no. 8, April 2001 (2001-04-01), pages 3605 - 3612, XP002453378, ISSN: 0022-538X *
KEMBLE G ET AL: "Novel generations of influenza vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 16, 1 May 2003 (2003-05-01), pages 1789 - 1795, XP004418059, ISSN: 0264-410X *
PAIN B ET AL: "Long-term in vitro culture and characterisation of avian embryonic stem cells with multiple morphogenetic potentialities", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE,, GB, vol. 122, no. 8, 1996, pages 2339 - 2348, XP002164729, ISSN: 0950-1991 *

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382513B2 (en) 2002-03-08 2016-07-05 Valneva Method of making an avian cell line
US8962311B2 (en) 2006-08-09 2015-02-24 Valneva Method of obtaining chicken embryonic stem cells
US9260694B2 (en) 2007-04-24 2016-02-16 Valneva Generation of duck cell lines
US9822345B2 (en) 2007-04-24 2017-11-21 Valneva Method of making a virus using duck embryonic derived stem cell lines
JP2011512800A (en) * 2008-02-25 2011-04-28 バクスター・インターナショナル・インコーポレイテッド Generation of continuous cell lines
US8865450B2 (en) 2008-02-25 2014-10-21 Baxter International Inc. Method for producing continuous cell lines
US9388380B2 (en) 2008-02-25 2016-07-12 Nanotherapeutics, Inc. Method for producing continuous cell lines
US20140315277A1 (en) * 2008-11-05 2014-10-23 Glaxosmithkline Biologicals S. A. Novel method
WO2010052214A3 (en) * 2008-11-05 2010-07-22 Glaxosmithkline Biologicals S.A. Novel method
WO2010081890A1 (en) 2009-01-19 2010-07-22 Innate Pharma Anti-kir3d antibodies
WO2010089339A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
JP2012525830A (en) * 2009-05-08 2012-10-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method for producing virus from cell culture including homogenization
WO2010130756A1 (en) * 2009-05-12 2010-11-18 Transgene Sa Immortalized avian cell lines and use thereof
CN103547285A (en) * 2009-05-12 2014-01-29 特兰斯吉恩股份有限公司 Immortalized avian cell lines and use thereof
JP2012526532A (en) * 2009-05-12 2012-11-01 トランジェーヌ、ソシエテ、アノニム Immortalized avian cell lines and their uses
WO2011051235A1 (en) 2009-10-27 2011-05-05 Glaxosmithkline Biologicals, Niederlassung Der Smithkline Beecham Pharma Gmbh & Co. Kg Process for producing influenza vaccine
US9636394B2 (en) 2009-10-27 2017-05-02 Glaxosmithkline Biologicals Sa Process for producing influenza vaccine
US10398771B2 (en) 2009-10-27 2019-09-03 Glaxosmithkline Biological S.A. Process for producing influenza vaccine
US20120207785A1 (en) * 2009-10-30 2012-08-16 Luc Gilbert Fabry Process for preparing an influenza seed virus for vaccine manufacture
JP2013509167A (en) * 2009-10-30 2013-03-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method for preparing influenza seed virus for vaccine production
WO2011051445A1 (en) 2009-10-30 2011-05-05 Glaxosmithkline Biologicals S.A. Process for preparing an influenza seed virus for vaccine manufacture
US9333253B2 (en) 2009-12-15 2016-05-10 University Of Saskatchewan Vaccines for inclusion body hepatitis
US8524249B2 (en) 2009-12-15 2013-09-03 University Of Saskatchewan Vaccines for inclusion body hepatitis
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011098615A1 (en) 2010-02-15 2011-08-18 Universite Claude Bernard Lyon 1 Cells modified for virus production by inhibition of the hipk2 gene
US20130115234A1 (en) * 2010-03-26 2013-05-09 Emergent Product Development Gaithersburg,Inc. Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
JP2013523096A (en) * 2010-03-26 2013-06-17 エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド Influenza matrix 2 protein ectodomain, expression system and uses thereof
EP2566958B1 (en) 2010-05-03 2015-12-30 GlaxoSmithKline Biologicals S.A. Method for inactivating influenza virus
JP2013529897A (en) * 2010-05-03 2013-07-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム New method
WO2011138229A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
WO2012004323A1 (en) 2010-07-08 2012-01-12 Glaxosmithkline Biologicals S.A. Process for removing adventitious agents during the production of a virus in cell culture
EP2778175A1 (en) 2010-08-17 2014-09-17 CSL Limited Humanized anti-interleukin 3 receptor alpha chain antibodies for use in treating acute myeloid leukemia (AML)
WO2012021934A1 (en) 2010-08-17 2012-02-23 Csl Limited Humanized anti-interleukin 3 receptor alpha chain antibodies
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
WO2013059886A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
EP4219552A2 (en) 2013-02-07 2023-08-02 CSL Ltd. Il-11r binding proteins and uses thereof
WO2015028546A1 (en) 2013-08-30 2015-03-05 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
EP3552615A1 (en) 2014-07-16 2019-10-16 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
US10144917B2 (en) 2014-08-29 2018-12-04 Calixar Method for preparing a vaccine antigen, resulting vaccine antigen and uses
US10584175B2 (en) 2014-10-23 2020-03-10 La Trobe University FN14-binding proteins and uses thereof
EP3799889A1 (en) 2014-12-17 2021-04-07 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease and other conditions
EP3744351A1 (en) 2014-12-17 2020-12-02 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US11643461B2 (en) 2016-01-11 2023-05-09 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US12060423B2 (en) 2016-01-11 2024-08-13 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11654189B2 (en) 2016-09-28 2023-05-23 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2018122088A1 (en) 2016-12-28 2018-07-05 Transgene Sa Oncolytic viruses and therapeutic molecules
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018227016A1 (en) 2017-06-07 2018-12-13 Wild Type, Inc. Ex vivo meat production
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa Oncolytic viruses expressing agents targeting metabolic immune modulators
US12083188B2 (en) 2017-12-01 2024-09-10 Encoded Therapeutics, Inc. Engineered DNA binding proteins
WO2019219649A1 (en) 2018-05-14 2019-11-21 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
WO2020012037A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
US12053518B2 (en) 2018-07-13 2024-08-06 Valneva Se Method for rescuing and producing a virus in avian cells
WO2020049001A1 (en) 2018-09-03 2020-03-12 Bioinvent International Ab Novel antibodies and nucleotide sequences, and uses thereof
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
EP4223320A2 (en) 2018-10-12 2023-08-09 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
WO2020074690A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
WO2020094693A1 (en) 2018-11-07 2020-05-14 Vivet Therapeutics Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
EP4257155A2 (en) 2018-11-16 2023-10-11 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
US20220017859A1 (en) * 2018-11-23 2022-01-20 Valneva Se Food Products Comprising Avian Stem Cells
WO2020104650A1 (en) 2018-11-23 2020-05-28 Valneva Se Food products comprising avian stem cells
WO2020123876A1 (en) 2018-12-12 2020-06-18 Wild Type, Inc. Synthetic food compositions
KR20210110838A (en) 2018-12-28 2021-09-09 트랜스진 에스.에이. M2 defective poxvirus
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
WO2021001377A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada cPLA2e INDUCING AGENTS AND USES THEREOF
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
KR20230038496A (en) 2020-07-13 2023-03-20 트랜스진 treatment of immunosuppression
WO2022029322A2 (en) 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
WO2022033983A1 (en) 2020-08-10 2022-02-17 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
WO2022074105A1 (en) 2020-10-09 2022-04-14 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023046777A1 (en) 2021-09-22 2023-03-30 Bioinvent International Ab Novel combinations of antibodies and uses thereof
WO2023073071A1 (en) 2021-10-28 2023-05-04 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Also Published As

Publication number Publication date
US20100062489A1 (en) 2010-03-11
PT2150275E (en) 2014-01-10
CA2684845C (en) 2017-12-05
EP2572728A1 (en) 2013-03-27
EA021064B1 (en) 2015-03-31
US9822345B2 (en) 2017-11-21
JP5539185B2 (en) 2014-07-02
HK1140964A1 (en) 2010-10-29
EA200970996A1 (en) 2010-04-30
MX2009011505A (en) 2009-11-09
NZ581321A (en) 2012-05-25
KR101624678B1 (en) 2016-05-26
HRP20131203T1 (en) 2014-02-14
BRPI0809842B8 (en) 2021-05-25
CA2684845A1 (en) 2008-10-30
EP2572727B1 (en) 2016-05-18
CN101668539B (en) 2014-02-19
BRPI0809842B1 (en) 2019-09-10
JP2010524482A (en) 2010-07-22
SI2150275T1 (en) 2014-04-30
AU2008240708A1 (en) 2008-10-30
US20160257940A1 (en) 2016-09-08
BRPI0809842A8 (en) 2019-07-16
AU2008240708B2 (en) 2013-04-18
IL201679A (en) 2013-11-28
ZA200908152B (en) 2010-04-28
IL201679A0 (en) 2010-05-31
ES2442009T3 (en) 2014-02-07
US20140154741A1 (en) 2014-06-05
MY151119A (en) 2014-04-15
ES2574827T3 (en) 2016-06-22
CN101668539A (en) 2010-03-10
EP2150275B1 (en) 2013-11-13
EP2572727A1 (en) 2013-03-27
PL2150275T3 (en) 2014-03-31
US20180135026A1 (en) 2018-05-17
KR20150036788A (en) 2015-04-07
DK2150275T3 (en) 2014-01-13
BRPI0809842A2 (en) 2014-09-23
EP1985305A1 (en) 2008-10-29
CY1114736T1 (en) 2016-12-14
KR20100017340A (en) 2010-02-16
MX343247B (en) 2016-10-31
US9260694B2 (en) 2016-02-16
EP2150275A1 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
US9822345B2 (en) Method of making a virus using duck embryonic derived stem cell lines
RU2457253C2 (en) Method for virus replication in avian embryo stem cells
AU2011253998B2 (en) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008736491

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200880013257.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08736491

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2684845

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 201679

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12597486

Country of ref document: US

Ref document number: 2010504672

Country of ref document: JP

Ref document number: MX/A/2009/011505

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7290/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008240708

Country of ref document: AU

Ref document number: 581321

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200970996

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20097024511

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008240708

Country of ref document: AU

Date of ref document: 20080423

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0809842

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091023